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General introduction
G liom as
Tumors of the central nervous system (CNS) constitute about 9% of all human 
cancers, and gliomas account fo r 40-50% of these CNS tumors[1,2]. Most 
intracrania l gliomas occur in patients o lde r than 45 years and the majority of 
these patients have a grim prognosis (survival often less than one yea r after 
surgery)[1,2]. According to the resemblance of tum or cells with cells of normal 
glia, they are classified as astrocytic tumors (As), pure o ligodendrog lia l tumors 
(Os), o r ependymal tumors (Es). Furthermore, some gliomas, the so-called mixed 
gliomas, show a combination of astrocytic, o ligodendroglia l, and/o r ependymal 
differentiation. Oligo-astrocytic tumors (OAs) are the most frequently recognized 
mixed gliomas. Based on sim ilarities in clinical features and genetic aberrations, 
these O As are often grouped together with pure O s as o ligodendrog lia l tumors 
(OTs). Furthermore, a malignancy grade is assigned to the gliomas based on the 
presence of histopathological criteria including nuclear atypia, mitotic activity, 
high cellularity, necrosis, and florid m icrovascular proliferation. These 
histopathological characteristics have been used in different grading schemes 
over the years, of which the W H O -2000  classification3  is now used as the 
worldw ide standard. G liom as may focally show more malignant regions and 
grading is based on the areas showing the highest degree of malignancy, in the 
assumption that the tum or cell population in these areas eventually determines 
the course of the disease. Unfortunately, the assessment of the histopathological 
criteria fo r grade of malignancy is to a certain degree subjective. A lthough 
glioblastoma multiforme (GBM) is generally considered as an astrocytic tum or of 
the highest malignancy g rade[4], some GBMs focally show o ligodendroglia l o r 
ependymal characteristics, which may suggest that they progressed from 
o ligodendroglia l, ependymal o r mixed precursor lesions. Apart from the 
biological behavio r of the tumor, patient survival is also dependent on a variety 
of clinical parameters, e.g. age and condition of the patient, tum or location, and 
treatment, e.g. extent of surgery, radiotherapy, and chemotherapy. M a lignan t 
gliomas usually present with progressive neuro logical deficit, whereas low-grade 
tumors most often cause epileptic seizures[3].
A  summary of histopathological, clinical and molecular genetic aspects of As, 
Os, OAs and Es is given below (based on[1,3,5-10] and references therein). A  
selection of relevant genetic information was made from the literature ava ilab le 
at the time we started the studies described in this thesis (1996). M ore  recent 
genetic aspects w ill be discussed in the fo llow ing chapters.
A stro c yt ic  tu m o r s  : A s
Chapter 1 -----------------------
Histopathology
Astrocytic tumors are the most common glioma type (figure 1-1). The majority 
of As are diffusely infiltrating neoplasms and can be subdivided into low-grade 
astrocytoma (lg-As; W H O  grade II), anaplastic astrocytoma (a-As; W H O  grade 
III), and glioblastoma (GBM; W H O  grade IV)[3]. Additionally, more circumscribed 
variants of astrocytic tumors exist of which the pilocytic astrocytoma (W H O  grade 
I) is the most common. These more circumscribed As show a different age 
distribution, localization and biological behavior, and should therefore not be 
grouped together with diffuse As.
The diffuse As are composed of astrocyte-like neoplastic cells; the nucleus is 
oval o r more irregular, and the amount and the shape of the eosinophilic 
cytoplasm varies considerably. The tumorcells can de star shaped with 
eosinophilic cell processes. The presence of high cellularity, nuclear atypia and 
marked mitotic activity reflect progression to an a-A, whereas necrosis and florid 
m icrovascular proliferation reflect progression to a GBM.
Figure 1-1. Histopathological features of astrocytic tumors. A  pilocytic astrocytoma, B low- 
grade astrocytoma, C anaplastic astrocytoma, D glioblastoma multiforme. Arrows indicate 
rosenthal fibers (A), mitoses (C) and necrosis (D).
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Clinical features
Diffusely infiltrating As preferentia lly arise in the cerebral hemispheres, the 
frontal and temporal lobe being most frequently affected. The lg-As primarily 
affect young adults at a mean age of 34 years and with a mean post-operative 
survival in the range of 6-8 years. The a-As may arise from a lg-A but are also 
diagnosed at first biopsy w ithout evidence fo r a less malignant precursor lesion. 
The mean age of patients with an a-A is approximately 41 years and the mean 
post-operative survival is 2-5 years. Both lg-As and a-As have an intrinsic 
tendency for malignant progression to a GBM. GBMs are the most frequent 
primary brain tumor, accounting fo r approximately 12-15% of all intracranial 
neoplasms and 50-60% of the As. GBMs preferentia lly affect adults, the mean 
age being 53 years and the mean survival less than 1 year. Based on clinical 
and histopathological exam ination, GBMs can be subdivided in de novo /  
primary GBMs (no evidence of a less malignant precursor lesion) and secondary 
GBMs (with evidence fo r a less m alignant precursor lesion). The majority of the 
GBMs is of the primary type. O n  average, patients with a secondary G B M  are 
younger and show a longer survival compared to patients with a primary GBM.
Molecular genetics
M o lecu la r genetic analysis of gliomas frequently focussed on the most 
common type, the As. An overview  of different genes known to be involved in the 
oncogenesis of As was incorporated in the publication of the W H O -2000  
classification3 . There is increasing evidence that the progression of lg-As to a-As 
and GBMs is associated with a cumulative acquisition of genetic alterations. 
TP53 mutations (chromosomal location of the P53 gene: 1 7p13), loss of 
heterozygosity fo r chromosome 17p (LOH 17p), and overexpression of PDGFR 
(platelet derived growth factor receptor) are frequently detected in lg-As. The 
a-As show aberrations affecting cell cycle regulation involving p16, RB1, and 
CDK4 (gene location at 9p21 (the p16 protein is encoded by the C D K N 2A  
gene), 13q14, and 12q14, respectively). Sim ilarly, LOH 9p and LOH  13q and 
an amplification including 12q14 are frequently detected in a-As. Because these 
aberrations are detected in a-As in addition to the ones detected in lg-As, it is 
assumed that they are involved in the progression of lg-As to a-As. Subsequently, 
LOH  10 and amplification of the EGFR gene (epidermal growth factor receptor, 
located at 7p 12), are frequently detected in GBMs and may therefore be 
involved in the progression to GBMs.
It has been reported that GBMs can be subdivided in at least two distinct 
m olecular entities (including approximately 60% of all GBM s)[5,7,11,12]: Type-1 
GBMs containing LOH 17p and TP53 mutations, whereas type-2 GBMs harbor 
an amplification of the EGFR gene. O vera ll, patients with type-1 GBMs are 
younger and show a better prognosis compared to type-2 GBMs. W hether this 
better prognosis is related to younger age o r the genetic background is not yet 
clear.
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Pure o l ig o d e n d r o g l ia l  tu m o r s  : O s 
H istopathology
According to the W H O -2000  classification O s can be divided in low-grade 
oligodendrogliom as (lg-Os; W H O  grade II) and malignant o r anaplastic 
o ligodendrogliom as (hg-Os; W H O  grade III) (figure 1-2). A  diagnostic problem 
exists in the distinction of O s from O As as unequivocal criteria are lacking, and 
since some astrocytic features can be accepted in anaplastic oligodendrogliomas 
w ithout classifying the tum or as an O A [13]. The O s  are predom inately composed 
of monotonous cells with small round nuclei surrounded by c lear perinuclear 
halos and an associated "chickenwire" o r "honeycomb" pattern of delicate 
capilla ry blood vessels. M icrocalcifications may be present but are not specific 
fo r Os. To detect malignant progression in Os, special attention is paid to the 
presence of high cellularity, nuclear pleomorphism, brisk mitotic activity, necrosis 
and florid m icrovascular p ro liferation3 . In this thesis, tumors had to show at least 
three of these characteristics (brisk mitotic activity being defined as >  10 mitoses 
per 2mm2) to be classified as a hg-O. Distinction between G B M  with (major) 
o ligodendrog lia l differentiation and hg-O is also subject to the preference of the 
individual neuropathologist.
Figure 1-2. Histopathological features of pure oligodendroglia l tumors. A  low-grade 
oligodendroglioma, B anaplastic oligodendroglioma (synonym: malignant 
oligodendroglioma). Arrows indicate calcification.
Clinical features
O s preferentia lly arise in the cerebral hemispheres, with a predilection fo r the 
frontal lobe, followed by the temporal lobe. For patients with a lg-O, a long 
preoperative history (5 years o r more) is not uncommon. The neurological 
symptoms, most frequently consist of progressive epileptic seizures. S im ilar to 
o ther anaplastic gliomas, the preoperative history of patients with a hg-O is often
14
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short and long-standing signs suggest a low-grade precursor lesion. The mean 
age at operation is 43  years fo r lg-Os and 49 years fo r hg-Os. Survival of 
patients with O s is genera lly better than fo r patients with As, the mean survival 
time being 10 years fo r lg-Os and 4 years fo r hg-Os. Furthermore, malignant 
progression of a recurrent tum or is less common for O s than fo r As. Interestingly, 
approximately two-thirds of anaplastic oligodendrogliomas respond to 
chemotherapy with Procarbazine-Lomustine-Vincristine (PCV), whereas As such 
as GBMs respond only occasionally to chemotherapeutic treatment[14-16]. For this 
reason, accurate discrim ination between Os, OAs and As is now of significant 
clinical importance.
Molecular genetics
Although relatively little was known about the genetic background of O s  at the 
beginning of ou r studies in 1996, it was clear that genetic alterations in O s  differ 
from those commonly found in As. LOH  analysis revealed that LOH 1p, LOH 
19q, and of both 1p and 19q were frequently detected, in up to 100%, 88%, 
and 88% of the tumors, respectively[17-25]. The wide range in the frequencies 
reported is probably caused by the significant interobserver variation and related 
to the vague definitions and subjective interpretation in the histopathological 
diagnosis of OTs. A lthough m inimal regions of overlap have been identified on 
1p and 19q, the actual tum or suppressor genes involved in the oncogenesis of 
O s have not yet been identified. Aberrations reported to be involved in the 
oncogenesis of As, such as LOH  10, LOH  9, LOH  17p, and TP53 mutations, 
were only occasionally detected in O s [21,26].
M ixed o l ig o -astro c yt ic  tu m o r s  : O A s 
H istopathology
Oligo-astrocytic tumors (figure 1 -3) are the most common type of mixed 
gliomas. A lthough O As are considered to be a distinctive tum or category in the 
current W H O  classification[27,28], unequivocal criteria for identification and 
grading of these tumors are lacking[13,29]. Thus, a significant diagnostic problem 
exists in the delineation of O As from pure astrocytic tumors (As) on the one hand 
and pure o ligodendroglia l tumors (Os) on the other, resulting in a high 
interobserver va ria bil ity[29]. According to the W H O -2000  classification, two 
different grades of malignancy can be identified, the low-grade oligo- 
astrocytoma (lg-OA; W H O  grade II) and the anaplastic o r m alignant oligo- 
astrocytoma (hg-OA; W H O  grade III). In ou r studies, OAs were designated as 
hg-OA when three o r more of the fo llow ing five criteria were present: high 
cellularity; nuclear pleomorphism; brisk mitotic activity ( >  1 0 /2 mm2); florid 
m icrovascular proliferation; necrosis.
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Clinical features
Localization preferences are as reported for Os, and clinical symptoms and 
signs are sim ila r to those reported for As o r Os. Because of the high 
interobserver variab ility due to the subjective interpretation of histopathological 
criteria fo r the classification and grading of OAs, incidence, mean age, and 
mean post-operative survival may vary and should be interpreted with caution. 
O ve ra ll, the mean age at surgery is comparable to that reported for Os, 35 to 
45 years fo r lg-OAs and 45 years fo r hg-OAs. The mean post-operative survival 
is 6.3 years for lg-OAs and 2.8 to 4.2 years for hg-OAs. The prognosis of 
patients with hg-OAs is poor compared to hg-Os (4 years), but still considerably 
better than for patients with GBMs (less than 1 year). S im ilarly to Os, part of the 
O As is considered to be chemosensitive to PCV.
Figure 1 -3. Histopathological features of mixed oligo-astrocytoma. A  low-grade oligo- 
astrocytoma, B anaplastic oligo-astrocytoma (synonym: malignant oligo-astrocytoma). Open 
and closed arrows indicate astrocytic and oligodendroglia l features, respectively. 
M icrovascular proliferation is indicated by an asterisk (B).
Molecular genetics
In several studies, sim ilarities have been described between O As and Os: 
molecular genetic studies using LOH analysis revealed LOH  1p and LOH 19q to 
be the most frequently detected aberrations in both tumors[5,18,21]. M u ltip le  LOH 
studies analyzing chromosome 1p and 19q in O As have been performed[17- 
22,30,31], in these studies the frequency of LOH 1p ranged from 19%[21] to 
100% [20], whereas LOH 19q ranged from 14%[30] to 75%[18'22]. O n  average, 
LOH  1p and 19q were detected in approximately half of the tumors. A lthough 
the presence of both o ligodendrog lia l and astrocytic features w ithin a tum or 
might suggest development from different precursor cells, genetic analysis 
revealed that sim ila r aberrations are present in both components, indicating that 
O As are clonal tumors o rig inating from a single cell[18]. Additionally, genetic 
heterogeneity of O As was reported [11,22] and at least 2 different genetic 
pathways fo r O As were proposed: 1) OAs presumed to be genetically related to
16
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O s and characterized by LOH  1p and 19q (50% OAs), and 2) O As presumed to 
be genetically related to As and characterized by LOH 17p o r TP53 mutations 
(25% O As)[11,22]. Tumors containing a combination of these alterations were 
infrequently detected[22,32].
Ependym al tu m o r s  : Es
Histopathology
Based on histopathological findings Es are classified as myxopapillary 
ependymoma (myxo-E; W H O  grade I), low-grade ependymoma (lg-E; W H O  
grade II), anaplastic ependymoma (a-E; W H O  grade III), o r incidentally as 
subependymoma (W H O  grade I) (figure 1-4). Key histologic features fo r Es are 
perivascular pseudorosettes and true (ependymal) rosettes. Perivascular 
pseudorosettes are formed by tum or cells more o r less radially arranged around 
blood vessels, the zone immediately surrounding the blood vessel wall containing 
neuropil w ithout tum or cell nuclei. Ependymal rosettes (and ependymal canals) 
are composed of tum or cells arranged around a lumen. The lg-Es may be further 
subtyped as cellular, c lear cell, papillary o r tanycytic ependymoma. For the 
diagnosis of a-E special attention is paid to the presence of high cellularity, 
marked nuclear polymorphism, brisk mitotic activity, and florid m icrovascular 
proliferation. In o u r study on Es, tumors had to contain three of these four 
features to be diagnosed as a-E. Additionally, the most m alignant g lia l tumor, 
i.e. G B M  (W H O  grade IV), sometimes shows focal formation of perivascular 
pseudorosettes. It remains to be seen if this phenomenon indeed indicates a 
special subtype of G B M  (GBM-E). The myxo-Es show a papillary growth pattern, 
the papillae being covered by ependymal cells, and the stroma of these papillae 
showing myxoid change.
Clinical features
Es are considered to arise from the ependymal o r subependymal cells 
surround ing the ventricles in the brain and of the central canal in the spinal cord, 
as well as from ependymal clusters of the filum term inale. A lthough Es occur in 
all age groups, it is well established that tum or localization and age of the 
patient are interrelated: patients with spinal Es are on average 40  years, whereas 
infratentorial Es predominate in children (mean age 6.4 years)[3]. Supratentorial 
Es affect pediatric as well as adult patients. Infratentorial tumors are most 
frequently located around the fourth ventricle, sometimes extending into the 
foramen of Luschka. C lin ica l studies revealed that post-operative survival 
depends on age of onset, tum or localization, and extent of tum or resection; 
adult patients fare better than pediatric patients and spinal Es have a more 
favorable prognosis than intracranial Es[3].
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Figure 1-4. Histopathological features of ependymal tumors. A  myxo-papillary ependymoma, 
B low-grade ependymoma, C anaplastic ependymoma (synonym: malignant ependymoma), D 
glioblastoma multiforme with focal ependymal features. Open arrows indicate myxoid stroma 
(A) or perivascular pseudorosettes (B, C, and D). Closed arrows indicate true rosettes (B) or 
florid microvascular proliferation (C).
Molecular genetics
At the molecular genetic level Es appear clearly distinct from As and OTs 
(including both O s and OAs) as LOH  22q and mutations in the 
neurofibromatosis type-2 gene (NF-2; located at 22q12) are most frequently 
detected. Interestingly, NF-2 and LOH 22q appear not to be present in myxo-Es. 
C lin ica l data suggest that distinct tum or entities exist among Es, which may be 
age o r localization related. Indeed, age related genetic pathways are suggested 
by LOH analysis, reporting LOH 22q to be a common finding in adult Es that is 
only rarely present in a pediatric popu la tion[33]. Localization dependent genetic 
pathways are suggested by the observation that NF-2 patients especially develop 
spinal Es, and that sporadic spinal Es are characterized by a high incidence of 
loss of 22q and NF-2 mutations[3,34].
18
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A im  a n d  o u tl in e  o f  this thesis
Genetic changes characteristic of human gliomas have been studied 
extensively over the last few years (for review see references[1,5'10]). However, the 
vast majority of published studies focussed prim arily on the most common 
glioma type, the As, and relatively few data were ava ilab le on OTs (Os and 
OAs) and Es. Additionally, most previous studies used LOH  analysis on only a 
few chromosomes w ithout evaluating chromosomal imbalances of the entire 
tum or genome. The goal of ou r studies was to characterize chromosomal 
imbalances involved in the oncogenesis of the less common gliomas, i.e. the 
OTs and the Es. As comparative genom ic hybridization (CGH) is a molecular 
cytogenetic technique that allows screening of chromosomal imbalances 
th roughout the entire tum or genome in a single experiment^5, 36], we chose to use 
C G H  for this purpose. Additionally, some other molecular genetic techniques, 
single stranded conformation polymorphism (SSCP) analysis, sequencing, 
southern blotting, and representational difference analysis (RDA) were used to 
further analyze tumors characterized by CGH.
In chapter 2 the protocol used for C G H  as performed in o u r studies is 
described, and the different optim ization experiments and pitfalls are discussed. 
In chapter 3 this technique is used to create an overview of chromosomal 
imbalances involved in the oncogenesis of Os. Chap ter 4 describes the 
involvement of the PTEN gene in the two genetic subtypes of OTs as identified in 
the previous chapter and in GBMs. In chapter 5 chromosomal imbalances in 
O As are characterized by CG H . Add itiona lly the influence of a "strict" and a 
more "relaxed" approach fo r the classification of O As on the frequency of the 
different genetic subtypes is analyzed. Chap ter 6 describes chromosomal 
imbalances identified in primary OTs and the ir recurrences, thereby providing 
some information on chromosomal regions involved in the genetic progression 
of OTs. In chapter 7 the prognostic and therapeutic implications of the genetic 
subtyping of OTs is analyzed. Since xenografted tumors are used as models to 
study different aspects of gliomas, we analyzed in chapter 8 whether xenografted 
GBMs are valid models from a genetic point of view. In chapter 9, the 
xenografted G B M  showing genetic characteristics of OTs (loss of 1p and 19q), 
was investigated by RDA to identify homozygously deleted regions involved in O T  
oncogenesis. In chapter 10 chromosomal imbalances in Es are identified and a 
correlation between specific aberrations and histopathological grading, patient 
age and tum or localization is investigated. A  general discussion and some future 
perspectives are provided in chapter 1 1 . Finally, a summary of the studies 
incorporated in this thesis is presented in chapter 12.
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A bstract
Com parative genom ic hybridization (CGH) is a technique to identify copy 
number changes th roughout a genome. Until now, hundreds of C G H  studies 
have been published reporting chromosomal imbalances in a large variety of 
human neoplasms. Additionally, technical improvements of specific steps in a 
C G H  experiment and reviews on the technique have appeared. Full C G H  
protocols, however, are only occasionally published. In this paper a review of 
C G H  is presented, including the technique, pitfalls and difficulties. O u r  own 
protocol is fully described and discussed, including the different optim ization 
experiments used to establish this protocol, and points requiring special 
attention. A lthough this protocol results in re liable and sensitive C G H  
experiments in ou r hands, readers should keep in mind that other laboratories 
may prefer other protocols. Testing different options, among others as discussed 
in the current paper, generates the most appropriate protocol. This paper shows 
the complexity of the C G H  technique and may serve as a guideline for starting 
C G H  o r as a trouble-shooting guide fo r those who perform CGH.
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INTRODUCTION 
Comparative Genomic Hybridization: CGH
In 1992 Kallioniem i et a l.[35] described a new technique called comparative 
genom ic hybridization (CGH) (figure 2-1). C G H  is based on the comparison of 
two genomic D N A  populations; one derived from the tissue to be analyzed and 
one from a karyotypic normal reference. Test and reference D N A  is differentially 
labeled (e.g. reference in red and test in green) with fluorochromes (direct 
labeling), o r haptens (indirect labeling) which are later visualized by 
fluorescence. Both DNAs are mixed in a 1:1 ratio in the presence of repetitive 
D N A  (COT-1 DNA) and are in situ hybridized onto normal human metaphase 
chromosomes. During this co-hybridization, tum or and reference D N A  compete 
fo r the same targets on the metaphase chromosomes. The relative amount of 
tum or and reference D N A  bound to a given chromosomal region is dependent 
on the relative abundance of these sequences in both D N A  samples. Therefore, 
intensity differences in the fluorescent hybridization patterns of test (green) and 
reference (red) D N A  can be interpreted as copy number differences between 
both genomes (e.g. gains w ill show in green, losses w ill show in red whereas 
regions that are normally present w ill show in yellow). The presence and 
localization of chromosomal imbalances can be detected and quantitated by 
analyzing the ratio of test-fluorescence to reference-fluorescence (green /  red) 
along the target chromosome using digital image analysis. These ratios show 
which chromosomal regions in the test genome are over- o r under-represented 
relative to the reference genome. As ratio profiles are calculated along all 
chromosomes in the normal metaphase, an overview  of the chromosomal 
imbalances th roughout the entire genome is created.
Advantages of CGH compared with other molecular and 
cytogenetic techniques
The m ajor advantage of C G H  is that it does not require pre-knowledge about 
the genetic constitution of the tum or (test-sample) and that the entire genome is 
analyzed in a single experiment. This is in contrast to other molecular genetic 
techniques which are highly focused, only analyzing one specific gene o r 
chromosomal region of interest. C G H  can be applied to most samples from 
which D N A  can be isolated. In contrast to classical karyotyping, no short-term 
tum or cultures are necessary which is notoriously difficult for solid tumors and 
can induce culture artifacts and clonal selection. Additionally, karyograms may 
contain chromosomal fragments of unknown orig in i.e. marker chromosomes, 
chromosomal gains showing as double minutes (dmin) o r homogeneously 
staining regions (hsrs).
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DNA isolation and 
differential labeling
Probe preparation : 
mix labeled DNA 1:1 
excess COT-1-DNA
Simultaneous denaturation 
probe and chromosomes
Hybridization of probe 
to chromosomes
Differential fluorescent 
detection both DNAs
CGH-Analysis :
Karyotype chromosomes
Ratio: tumor / reference
Schematic overview of 
chromosomal imbalances
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Figure 2-1. A  schematic overview of the comparative genomic hybridization (CGH) technique 
as described in the text (red is represented in light-gray and green is represented in dark-gray). 
For a color figure providing a schematic overview of C G H  see page 184 or the original 
publication.
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A  high concordance between C G H  and classical karyotyping and molecular 
genetic analysis has been reported'37'. Studies combining LOH and C G H  on the 
same set of tumors reported a concordance of up to 92%'38,39'. Discrepancies 
between LOH  and C G H  may be explained by: 1) aberrations detectable by LOH 
which are too small to be detected by C G H , 2) uniparenta l disomy, an allelic 
imbalance not resulting in a copy number change 3) mitotic recombination, 
resulting in an imbalance between both alleles as detected by LOH and in a net 
gain of this chromosomal region as detected by CG H . These situations illustrate 
that complementary information can be generated by combining C G H  with 
LOH. W h ile  LOH  is often interpreted as loss of one allele, the latter two 
situations underline that LOH  should be interpreted as an alle lic imbalance 
ra ther than as a loss of one allele.
Limitations and sensitivity of CGH
C G H  is reported to detect aberrations present in the majority of cells (>50%) 
and therefore the presence of non-neoplastic cells in a tum or sample decreases 
the C G H  sensitivity'40'. A  study using pooled D N A  of different tumors reported 
that some of the aberrations which were present in 25% of the individual tumors 
were detected'41'. However, because the hybridization efficiency in a C G H  
experiment using D N A  isolated from paraffin embedded tissue is usually less 
compared to experiments using D N A  isolated from frozen tissue, and in the latter 
study samples from frozen and paraffin embedded tissue were pooled in equal 
amounts, this percentage might be inaccurate. Additionally, this study reports 
that high copy number gains present in only a small percentage of the individual 
tumors could also be detected (ratio >1.2) using pooled DNA'41'. Application of 
microdissection can be used to reduce the number of non-neoplastic cells o r 
separate different populations in a heterogenic tumor, in o rder to elucidate the 
true genetic nature of tumors o r the diverse genetic background of 
heterogeneous tumors. Because C G H  only reveals information about copy 
number changes relative to the reference DNA, balanced translocations, 
rearrangements and ploidy changes are not detected.
The major disadvantage of C G H  is that small aberrations are not detected 
because normal metaphase chromosomes (consisting of condensed DNA) are 
used fo r the identification and localization of chromosomal imbalances. Since 
the first reports on C G H , the sensitivity has been improved and further 
established during optim ization of the technique. In the initial paper, Kallioniem i 
et al. reported that losses were detected which were estimated to span about 10 
and 20  Mb'35'. Furthermore, a more than 50-fold amplification of a 300-kb 
region could be detected, and it was suggested that detection of an amplification 
depends on the amount of amplified D N A  (the size of the amplicon times the 
number of copies) rather than on the size of the amplicon'35'. As losses can either 
be heterozygous o r occasionally homozygous, the size of the aberration is 
critical. In 1994 it was estimated that fo r detection by C G H  theoretically the 
amount of gained D N A  has to be at least 2 M b  whereas the size of a loss has to
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be 3 to 5 Mb'40,42'. In 1998 and 1999 two papers were published on the 
m inimal size of losses detectable by C G H  using the same set of tumors'43,44'. A  
loss of 3 M b  present in 82% of the cells was clearly visible in the ratio profile. 
This aberration was not detected using fixed thresholds (as is commonly the case) 
because the ratio did not cross the threshold 0.8 set to detect losses'43'. However, 
using standard reference intervals to detect chromosomal imbalances (based on 
the 99.5% confidence interval), this aberration was detectable by C G H '44'. The 
advantages and disadvantages of the use of data-driven analysis such as 
performed using standard reference intervals, and of fixed threshold to detect 
chromosomal imbalances are discussed later on. To o u r knowledge, the only 
paper addressing the detection lim it of C G H  for an amplification reports that the 
lowest amount of amplified D N A  detectable using a threshold of 1.3 is 15 Mb 
(consisting of 5 copies of 3 M b o r 10 copies of 1.5 M b  in contrast to 2 copies in 
the reference DNA)'45'. A lthough the sensitivity has been subject of research, it 
w ill largely depend on the (constant) quality of C G H  experiments in the different 
laboratories, the percentage of cells containing the aberration and criteria used 
fo r the detection of imbalances.
Application of CGH
C G H  has been successfully used to identify chromosomal regions involved in 
the oncogenesis of a diverse spectrum of tumors (for reviews see'46-50') and 
served as a starting point fo r the search of novel genes implicated in cancer. 
Subsequently, o ther molecular techniques, such as FISH, LOH, and sequencing, 
may be used to narrow  down the chromosomal regions of interest identified by 
C G H  and pinpoint the actual genes involved in cancer development. A lthough it 
is most likely that genes located in an aberrant region are also deleted o r 
amplified, C G H  does not generate information at the gene level. A  new 
application of C G H  is the so-called A rray-CGH o r matrix-CGH. For this 
technique, test and reference D N A  are differentially labeled and competitively 
hybridized onto a glass-slide containing multiple D N A  fragments. Thereby Array- 
C G H  provides information on gains o r deletions of the genes present on this 
micro-array. Expression of genes may be fu rther analyzed using expression-arrays 
fo r which two RNA samples are differentially labeled and competitively hybridized 
to an array-slide.
Until now, hundreds of studies have been published using C G H  to obtain 
copy number karyotypes fo r a large variety of human neoplasms (for reviews 
see'46-50'). Prognostic and/or therapeutic implications fo r imbalances detected by 
C G H  have been proposed and a role fo r C G H  in tum or pathology has been 
suggested'49,51,52'. In gliomas, for example, two genetic subtypes were identified 
in oligodendrogliom as of which one may predict longer survival and 
chemosensitivity'53', and a correlation between radiosensitivity and imbalances 
detected by C G H  was reported'54'. Additionally, C G H  has been applied to 
clinical samples, among others in pre- and postnatal screening'55,56'.
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The majority of published C G H  papers describe chromosomal imbalances 
and possible implications in a specific tumor-type. Additionally, technical 
improvements of specific steps in C G H  (among others:'57-62') and reviews on the 
technique (among others:'35,40'49'51'63'65') have appeared. A lthough some of these 
latter papers discuss C G H  steps that require special attention, they do not 
describe the complete C G H  protocols, whereas papers on specific tum or types 
generally contain a short version of the protocol used. This paper presents a 
short review of the C G H  technique and a detailed protocol fo r perform ing CGH. 
Furthermore, the different optim ization experiments used to establish this 
protocol, and points requiring special attention are discussed. A lthough this 
protocol results in re liab le and sensitive C G H  experiments in ou r hands, readers 
should keep in mind that different laboratories may find other protocols working 
best. This paper shows the complexity of the C G H  technique and may serve as a 
guideline fo r starting C G H  o r as a trouble-shooting guide.
M aterials a n d  M ethods  
DNA isolation
Reference D N A  is extracted from peripheral blood lymphocytes of a donor 
showing a normal karyogram, and tum or D N A  is extracted from frozen or 
paraffin embedded tum or tissue, by a salting out procedure as described 
elsewhere with m inor modifications'66'. Briefly, to extract reference DNA, a 4x 
excess of erythrocyte lysisbuffer (155 mM N H 4Cl, 10 mM K H C O 3, 1 mM EDTA, 
pH 7.4) is added to whole blood and incubated on ice fo r 15-30 minutes. After 
centrifugation, the cell pellet is rinsed in the same buffer until it is c lear and 
white. The cells are incubated overnight in lysisbuffer (500 mM Tris-HCl, 25  mM 
EDTA, 100 mM NaC l) supplemented with SDS (1%) and pronase (600 mg /  ml) 
at 37 °C  (we use 1 ml lysisbuffer per 2 ml whole blood). The suspension is 
adjusted to room temperature and one-third vo lum e of 6 M  N aC l is added. After 
vigorously shaking, the precipitated proteins are removed through centrifugation. 
V igorously shaking and centrifugation are repeated till the supernatant is clear. 
By adding 2 volumes of ethanol absolute and gently stirring, high molecular 
weight D N A  is removed with a sterile loop needle. The air-dried D N A  is 
dissolved in water (we use 500  ml fo r D N A  orig inating from 8-ml whole blood).
For D N A  isolation of frozen tum or tissue, approximately 20  mm3 tum or tissue 
sliced in sections of 40  mm is collected in a 15-ml tube. Lysisbuffer supplemented 
with SDS (1%) and Proteinase K (150 mg /  ml) is added to the frozen tissue and 
incubated overnight at 37°C . Proteins are removed and D N A  is precipitated as 
described above. If no o r only a small amount of D N A  can be removed using a 
loop needle, the precipitation is extended at -20°C (overnight) and after 
centrifugation and a wash with 70% ethanol to remove co-precipitated salt, the 
air-dried D N A  is dissolved in water.
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D N A  is isolated from paraffin embedded tissue (100 mm3 tum or tissue sliced 
in sections of 40  mm) after deparaffinizing the sections with xylol (2 washes of 10 
minutes each). The tissue is washed in 100% ethanol (three times) and air-dried 
after which it is dissolved in 1 M  sodium thiocyanate and incubated fo r 1 hour at 
80°C. After rinsing the tissue in water it is resuspended in lysisbuffer and D N A  is 
isolated as described fo r frozen tissue.
D N A  concentration and quality are estimated after electrophoreses on a 1% 
agarose gel including a molecular weight and a mass marker. If RNA is present 
this can be removed by treatment with RNase I (RNase steps can be standardly 
included, e.g. after the overnight incubation in lysisbuffer).
Universal amplification of small amounts of DNA
Small amounts of D N A  can be amplified by DOP-PCR (degenerate 
o ligonucleotide prim er PCR), however, in o rder to avoid artifacts, we prefer not 
to use this for o u r C G H  experiments. A lthough we tested DOP-PCR for C G H , we 
refer to recent papers on improving DOP-PCR for C G H  for exact protocols'57,58'.
Differential labeling of DNAs
In a nick-translation reaction 1 mg of D N A  is labeled in 50 ml labeling-mix 
(0.4 mM dATP, dCTP, dGTP, and labeled dUTP (biotin-16-dUTP o r digoxigenin- 
11-dUTP (ROCHE Diagnostics, Almere, The Netherlands)), 0.03 units of DNase 
(ROCHE Diagnostics, Almere, The Netherlands), 10 units of D N A  polymerase I 
(G ibco BRL Life Technologies, Breda, The Netherlands), 50 mM Tris-HCl, 5 mM 
M g C l2, 10mg/ml BSA, and 10 mM ß-mercaptoethanol) at 16°C  fo r 1 hour. 
Samples are put on ice and EDTA is added to 10 ml of the mix which is used for 
electrophoreses to inhibit enzyme activity (30 mM). If the D N A  fragments are still 
too long nick-translation is continued at 16 °C  whereas EDTA is added to the rest 
of the sample if the appropriate fragment length is generated.
For the labeling of degraded DNA, unsuitable fo r nick-translation, a universal 
linkage system (ULS)(Kreatech, Amsterdam, The Netherlands) is used. O ne  mg of 
D N A  (without contam ination of RNA o r proteins) is labeled in a volume of 20ml 
in the presence of 1 unit ULS fo r 30  minutes at 85°C . The labeled D N A  is 
purified using a spin column according to the manufacturers protocol to reduce 
back-ground staining and stored at -20°C.
Preparation of the CGH probe
The C G H  probe is prepared by an ethanol precipitation (overnight at -20°C) 
of d ifferentially labeled tum or and reference DNA, each 350  to 400  ng, in the 
presence of an 100x excess of human COT-1-DNA and a 50x excess of herring 
sperm D N A  as a carrier. The air-dried pellet is dissolved in hybridization buffer 
(50% formamide, 10% dextran sulphate, 2xSSC, pH 7.0)(approximately 25 ng 
tum or D N A  and 25 ng reference D N A  per ml). Probes are prepared on the day 
of the C G H  experiment and never stored fo r later. In o rder to detect 
chromosomal imbalances of the X chromosome, C G H  is performed using tum or
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and reference D N A  of the same gender.
Metaphase chromosomes
Target metaphase spreads are prepared from phytohaematoglutinine- 
stimulated peripheral blood lymphocyte cultures of a karyotypic normal donor. 
Cells are arrested in mitosis by colcemid and treated with hypotonic KCl 
(0.075M), rinsed to remove cytoplasm after which they are fixed in 
methanol/acetic acid (3:1). Chromosome slides (uncoated) are prepared from a 
fresh suspension. Small amounts of slides are sealed with silica gel in a plastic 
conta iner and stored at -80°C.
Slides fo r C G H  are adjusted to room temperature before opening the sealed 
containers and are used the same day. Metaphase chromosomes are treated 
with RNase A  (0,5 mg/ml fo r approximately 30 minutes at 37°C), pepsin (400 
U/ml 0.01 M  HCl fo r 10 min at 37°C) (Sigma-Aldrich Chem ie, Zwijndrecht, The 
Netherlands), sequentially postfixed with formaldehyde (1% in PBS for 5 min) 
(Merck, Amsterdam, The Netherlands) dehydrated and air-dried.
Denaturation, hybridization, and post-hybridization
The CGH-probe is applied to the air-dried metaphase slides. A  coverslip is 
added and the hybridization area is sealed with rubber cement. The slides are 
put in the Om niS lide Thermal Cyc ler (Thermo-Hybaid, Breda, The Netherlands) 
and the water is adjusted fo r hum idity during hybridization. A  cycle of 5 minutes 
at 37°C , 3 minutes at 74 °C  fo r denaturation, and a hold on 37 °C  for 
hybridization, is performed. Hybrid ization is performed fo r 3 days. Post­
hybridization washes are performed twice fo r 1 minute in 0.4xSSC-Tween at 
68 °C  in the accompanying wash units (Thermo-Hybaid, Breda, The 
Netherlands).
A lternatively, slides can be put in a metal box with a thin film of water between 
the slides and the metal. Denaturation is performed by floating the box fo r 3 
minutes in a waterbath of 75°C. For hybridization the slides are then stored in a 
plastic box containing wet paper tissues in a 37 °C  stove. Post-hybridization 
washes are performed in a waterbath using a slides-container with 50% 
formam ide in 2xSSC (pH 7.0) (3x 5 minutes at 42°C), with 2xSSC (5 minutes at 
42°C), and with 0.1xSSC (3x 5 minutes at 60°C).
If the D N A  is indirectly labeled, biotin and digoxigenin are detected using 
(strept)avidin-FITC and sheep-anti-digoxigenin-TRITC (ROCHE Diagnostics, 
Almere, The Netherlands), respectively (dilution 1/100 in 4xSSC-T-M), after 
blocking the slides with non-fat m ilk in 4xSSC-Tween (4SSC-T-M). Finally, the 
chromosomes are counterstained with DAPI (4,6'-diamino-2-phenylindole- 
dihydrochloride) in 2xSSC (10 ng /  ml) fo r 10 minutes. After washing, the slides 
are dehydrated, a ir dried and mounted in the antifading F luoroGuard™  which is 
diluted in buffer (1:1) as suggested by the manufacturer (Biorad, Veenendaal, 
The Netherlands).
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Microscopy and image analysis
Image acquisition and analysis are performed as described by du M ano ir et 
al.'67,68'. An epifluorescence microscope (DMRBE; Leica, Rijswijk, The 
Netherlands) is used equipped with DAPI, FITC, and TRITC bandpass filters, a 
100x plan apochromatic lens, and a HBO  100 watt bulb. D igital gray-scale 
images of FITC, TRITC and DAPI are captured using IPLab software (Synal 
Analytics, Arlington, VA, USA) with a cooled C C D  camera (Quantix/KAF 1400 
camera; Photometrics, Tucson AZ, USA) mounted on the microscope.
For analysis of chromosomal gains and losses the C G H  QU IPS software is 
used (produced by Vysis, Downers G rove, IL, USA and now ava ilab le by Applied 
Imaging, United Kingdom). Detection thresholds fo r losses and gains of 
chromosomal regions'35,36' are set at 0.8 and 1.2 respectively. Aberrations with a 
ratio of 0.6 o r 1.4 are called c lear copy number changes and a ratio la rger then 
1.6 is called high copy number gains.
Quality control of CGH analysis
To test the quality of the C G H  hybridizations, a negative control experiment 
(using male and female reference DNA) and a positive control experiment (we 
use tum or D N A  of a xenografted tum or which harbors many low-level am pli­
fications and deletions) are included in each series of C G H  hybridizations'53'.
DISCUSSION o f  the C G H  PROTOCOL 
Starting CGH
For adequate C G H  experiments, D N A  and normal metaphase spreads of high 
quality are of paramount importance. Xenografted tumors o r tum or cell-lines are 
most suitable for optim izing the different steps in C G H  because of the ample 
ava ilab ility of this material and the absence of contam inating non-neoplastic 
(human) cells. Furthermore, the microscope and image analysis systems have to 
be optimally adjusted.
DNA isolation
For D N A  isolation different protocols are available. W hen we started to 
perform C G H  in ou r lab, we first tested which method yielded the highest 
amount of high-molecular weight D N A  using snap-frozen tum or tissue. The tissue 
first has to be fragmented to make it accessible fo r the proteinase and the SDS 
supplemented to the lysisbuffer. For this purpose we use frozen 40  mm sections 
rather than tissue that is cut in small pieces after defrosting the tissue. Reduction 
of the thickness of the slides increases the relative amount of partial nuclei and 
appeared to be less efficient. Furthermore, in ou r hands removing proteins by a 
salting-out procedure'66' gave better results than the commonly used phenol-
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chloroform  extraction. Moreover, no residual salt is present which interferes with 
other molecular genetic techniques such as southern blotting, PCR, SSCP, LOH 
analysis and sequencing'69'. Using ou r protocol, apart from high-molecular 
weight DNA, RNA can also be isolated. The characteristic ribosomal RNA bands 
(16s and 28s) are not visible if the RNA is fragmented. Especially from formalin 
fixed and paraffin embedded tissue, high amounts of fragmented RNA were 
often co-isolated. Caution should be taken as RNA might result in an 
overestimation of D N A  concentration using photospectometry. Additionally, RNA 
is labeled by ULS (see below) which can have a negative effect on the C G H  
experiment.
D N A  isolated from formalin fixed and paraffin embedded tissue is less suitable 
fo r C G H  compared to D N A  isolated from frozen tissue because it is degraded 
and cross-linked during fixation. D N A  quality is dependent on the pH of the 
fixative, the time of fixation, and the time between removal of the sample and 
fixation. Different protocols fo r D N A  isolation from formalin fixed and paraffin 
embedded tissue are used by different laboratories analyzing different tissues. 
Testing different lysisbuffers we noticed a difference in the amount of high 
molecular weight DNA. Furthermore an incubation step with sodium thiocyanate 
was included to decrease the cross-links within the D N A  making it ava ilab le for 
hybridization. A lthough the total amount of D N A  might increase as the Prot K 
incubation is extended up to 72 hours (fresh Prot K is added every 24 hours) as 
described in many articles'65', we noticed that the amount of high-molecular 
weight D N A  did not increase and even became less, probably due to 
fragmentation. Sim ilarly, an increase of incubation temperature was not efficient 
in o u r hands. As o u r goal was to develop a protocol with a high amount of high- 
molecular weight DNA, we choose to incubate the deparafinized glioma tissue 
overn ight at 37°C. Different tissues and fixation protocols may require individual 
adaptation of the protocol for the isolation of D N A  from paraffin embedded 
tissue; e.g. it was reported that use of multiple thin paraffin sections instead of a 
few thick sections and a prolonged digestion of proteins resulted in an increased 
amount of high molecular weight D N A  isolated from paraffin embedded breast 
cancers'70'. For C G H  using paraffin embedded tissue, reference D N A  may also 
be isolated from paraffin embedded tissue. However, as we did not detect 
differences using reference D N A  isolated from either paraffin embedded tissue or 
blood lymphocytes, we use the latter because of the accessibility.
Frequently several samples of a tum or are available. W e consult a pathologist 
to identify the best sample fo r C G H  (representative tum or areas and as little non­
neoplastic areas as possible). If warranted micro- o r macro-dissection can be 
performed.
Universal amplification of small amounts of DNA
In some cases only a very limited amount of D N A  can be isolated from 
tumors; e.g. when the biopsy specimens are small o r when micro-dissection is 
performed in o rder to elim inate non-neoplastic cells o r to study specific tum or 
regions. DOP-PCR (degenerate o ligonucleotide prim er PCR) can be used to
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scale up the amount of DNA. DOP-PCR products can be labeled either during 
PCR by the incorporation of labeled nucleotides, o r afterwards by a universal 
labeling system (ULS) o r by nick-translation. During DOP-PCR artifacts may be 
introduced and the appropriate reference sample should be carefully selected. 
Genera lly, C G H  results are more reliable when both test and reference D N A  are 
amplified since false negative and false positive aberrations may be obtained 
using amplified tum or D N A  versus non-amplified reference DNA. Additionally, if 
formalin-fixed and paraffin embedded tissue is used, DOP-PCR on reference 
D N A  also isolated from formalin fixed paraffin-embedded tissue can be the most 
appropriate. Testing the quality of C G H  using DOP-PCR should be performed 
on samples of which abundant D N A  is ava ilab le so all test CG H s can be 
performed using the same D N A  thereby preventing differences depending on 
DNA-samples rather than experimental conditions.
The prim er used in DOP-PCR contains a stretch of -N N NN NN - (in which N is 
either A, C, G , o r T), therefore different batches of prim er may differ in actual 
prim er composition and show differences in efficiency. Furthermore, when 
histologically stained slides are used fo r micro- o r macrodissection one should 
realize that some stainings can hamper DOP-PCR more than others'57'. O vera ll, 
DOP-PCR has been proven to be useful in combination with C G H '57-59', but 
C G H  w ithout DOP-PCR is still preferable.
Differential labeling of DNAs
For C G H , test (e.g. tumor) and reference (e.g. blood) D N A  is differentially 
labeled. Different techniques and labels may be used depending on the DNA  
quality and the preferences of the researchers. D N A  may be labeled indirectly by 
haptens such as biotin o r d igoxigenin (which are later detected by fluorescent 
green o r fluorescent red) o r directly with green and red fluorescent labels. W e 
prefer indirect labeling of ou r samples because it results in brighter fluorescence 
intensities. A lthough it has been suggested that using direct labeling reduces 
background, in ou r experience background problems are correlated with the 
quality of the metaphase chromosomes and can be avoided using a batch of 
high-quality metaphase spreads. The labeling technique used is dependent on 
the fragment length of the test DNA, because the quality of a C G H  experiment 
is, among others, dependent on the fragment size of the D N A  after labeling'40,71'. 
Labeled D N A  should approximately range from 500-2500 bp; smaller fragments 
can result in non-specific hybridization, whereas longer fragments can result in 
halos around the chromosomes and an increased background.
Nick-translation is most frequently used fo r labeling of D N A  because optimally 
sized fragments of labeled D N A  can be acquired by an optimal ratio of DNase I 
and D N A  polymerase I. Different nick-translation kits are commercially available, 
some especially designed fo r CG H . Using commercially ava ilab le kits, it should 
be checked if both kits used to label reference and test D N A  show a comparable 
labeling efficiency. After testing several of these commercial kits, in our 
experience creating o u r own "kit" (as described above) gave the best results. 
Differences in protocols fo r nick-translation encompass: the amount of DNase I
32
Comparative genomic hybridization
and Polymerase 1 and the ratio between both enzymes, the concentration of 
dNTPs (0.2 o r 0.4 mM), the presence of unlabeled dTTP in addition to labeled 
dUTP, incubation temperature and time, use of a cooling block o r a polystyrene 
box with water, and the amount of D N A  per labeling. After nick-translation, 
fragment length is checked by gel electrophoresis and labeling efficiency can be 
tested using spot blotting. In o u r experience, labeling efficiency is dependent on 
the labeled dUTPs, enzymes, o r DNA.
The ULS (universal linkage system) is used fo r the labeling of fragmented D NA  
unsuitable fo r nick-translation because the latter decreases the fragment size 
even further resulting in non-specific hybridization. The ULS-system is developed 
by Kreatech but is also commercially ava ilab le by M o lecu la r Probes. Alers et 
al.'60' reported that this labeling is preferable over nick-translation fo r samples of 
which the bulk fragment size is smaller than 1 kb. ULS on la rger fragments can 
result in a high background staining of a so-called starry-sky appearance, 
hampering C G H  analysis'60'. Before ULS labeling, D N A  may be adjusted to the 
right fragment size by a DNase treatment. However, as this is difficult to 
reproduce because of m inimal amount of DNase, they suggest boiling the D NA  
(30 minutes at 95 °C  in 10 mM TRIS, pH 8.0) which results in a reproducible 
decreased fragment size. W e noticed that next to a decreased fragment length, 
the D N A  concentration also decreases due to degradation. Alternatively, 
sonification can be used. Furthermore Alers et al. report that nick-translated 
reference D N A  may be used in combination with ULS labeled test D N A  without 
introducing false positive C G H  results'60'. However, as shown in the ir results, 
caution should be taken fo r the interpretation of chromosomes 1p, 9p, and 19. 
A lthough the threshold sets fo r gains and losses are not crossed (exception for 
19p which is gained), the ratios in these regions deviate from the normal ratio of 
1.0, underlin ing the importance of control experiments. It should be tested if the 
artifacts in these regions decrease using ULS labeled reference DNA. Using ULS 
it is important to realize that high concentrations of, among others, EDTA 
(> 5 mM), Tris-HCl (> 4 0  mM), and NaC l ( > 1 0 0  mM), have a rate limiting 
effect. Furthermore, the ratio between ULS-mix and D N A  is crucial, and 
contam ination of RNA and proteins in the D N A  samples w ill reduce the D NA  
labeling efficiency because ULS can also label proteins and RNA. In C G H  
experiments, labeled RNA o r proteins may show as spots in nuclei, a weak C G H  
signal, and halos surround ing the chromosomes. RNase and proteinase 
treatment of the D N A  sample and/o r metaphase slides p rio r to labeling and 
hybridization improve C G H  results. Next to purification of the D N A  sample, the 
labeling efficiency may be improved by increasing the amount of units ULS used 
per labeling (1 to 2 units per mg DNA). Different incubation protocols are 
described fo r ULS containing different labels, e.g. biotin-ULS: 30 minutes at 
85 °C  and Rhodamine-ULS: 15 minutes at 65°C. Currently we use the 
rhodamine-ULS kit from Kreatech with an incubation of 30 minutes at 85°C. 
Testing the different kits and protocols in a C G H  should identify the most suitable 
combination.
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Preparation of the CGH probe
The use of 200  ng labeled D N A  has been described in different C G H  
protocols but although all aberrations can be detected using 200  ng of each 
labeled DNA, we prefer to use a h igher amount of labeled D N A  (350-400 ng) 
as this results in brighter C G H  signals. For C G H  using D N A  isolated from 
formalin fixed and paraffin embedded tissue several protocols describe the use of 
twice as much test D N A  as reference D N A  (e.g. 200  ng reference and 400  ng 
test DNA). The reason fo r this is that during fixation of the tissue, D N A  is cross­
linked resulting in a D N A  sample of which only part of the D N A  is ava ilab le for 
hybridization. W e included sodium thiocyanate treatment in the D N A  isolation 
protocol fo r paraffin embedded tissue in o rder to reduce these cross-links. In our 
experience such an uneven ratio between test and reference D N A  does not result 
in better C G H  results.
COT-1-DNA contains repetitive D N A  and is added to prevent non-specific 
binding of labeled D N A  to repetitive sequences present in the centromeres and 
heterochromatic regions. Because COT-1-DNA is enriched in repetitive 
sequences, different batches may show different blocking capacities. For each 
new batch the blocking capacity is established by using 50x, 100x, and 150x 
excess of COT-1-DNA in a C G H  experiment. To minimize these tests, we order 
large quantities of one batch of COT-1-DNA. Insufficiently blocking batches are 
returned to the manufacturer because the use of such batches in an excess of 
150x o r more results in decreased signal intensities, probably due to the 
presence of non-repetitive sequences which compete with the labeled DNAs for 
hybridization on the metaphase chromosomes o r which bind the labeled DNA  
itself. A lthough it has been reported that a h igher amount of COT-1-DNA is 
needed during simultaneous denaturation of probe and metaphase DNA  
compared to separate denaturation, the amount of COT-1-DNA used by us in 
combination with simultaneous denaturation is not h igher than described by 
others using separate denaturation.
The amount of formam ide in the hybridization buffer may be increased (50%, 
62%, o r 75%) depending on the batch of metaphase spreads (described below).
Metaphase chromosomes
The quality of the metaphase chromosomes highly affects the quality of the 
C G H  experiment. It should be emphasized that slides, which are adequate for 
FISH experiments, are not necessarily useful fo r CG H . A lthough we were able to 
prepare chromosome spreads suitable fo r C G H  ourselves, the quality of our 
C G H  experiments improved since we acquire ou r metaphase slides from the 
Department of Human Genetics, where a lot of expertise in this field is present. 
In o u r experience, the costs of commercially ava ilab le slides are high and the 
slides are of variab le quality, some of them being inadequate fo r CGH. 
Requirements of the spreads are discussed by Karhu et al.'61'. In short, attention 
should be paid to the amount of cytoplasm surrounding the nuclei and 
chromosomes (cytoplasm results in decreased C G H  signals, increased
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background staining and false positive and negative results), spreading of the 
chromosomes (overlapping chromosomes can not be included in C G H  analysis), 
size of the chromosomes (CGH  sensitivity decreases when shorter chromosomes 
are used and karyotyping of the chromosomes becomes more difficult when 
longer chromosomes are used), the number of metaphase spreads compared to 
the number of nuclei (labeled D N A  binding to nuclei is wasted fo r C G H  
analysis), and the number of spreads and nuclei in a hybridization field (a high 
number of nuclei and spreads in a hybridization field can decrease the signal 
intensity and more probe D N A  might be necessary to obtain bright C G H  
signals). These features and hybridization efficiency can differ between 
individuals and therefore several blood donors may be tested.
Next to the quality of the batch of metaphase spreads, the type of slides used, 
the storage, age and defrosting of the slides is very important. W e use uncoated 
slides which are cleaned in ethanol as in o u r hands the background was h igher 
using coated slides. A lthough it seems to be common practice in many 
cytogenetic laboratories to store the slides at room temperature, usually in a 
dessicator'72', in ou r experience the metaphase spreads are better preserved if the 
slides are sealed with silica gel and stored at -80°C. Alternatively, slides are 
reported to be stored in 100% ethanol o r sealed with silicagel in -20°C'65,72'. 
Furthermore, we use a new batch every 2 to 3 months as over time the back­
ground increases, the ratio-profile of the X-chromosome in a male to female 
C G H  slightly decreases, and the banding pattern of the chromosomes used for 
karyotyping becomes less clear. In o rder to reduce the number of slides used, 
two C G H  experiments are performed on one slide. Each new batch of 
chromosomes is tested using ou r positive control D N A  (described below) to 
establish the denaturation conditions (% formam ide in the hybridization buffer, 
denaturation temperature, and time). Slides treated with RNase, pepsin and 
formaline as described in the Materia ls and Methods require stronger 
denaturation compared to untreated slides. Occasionally, a batch is not suitable 
for C G H  and is replaced by a new one rather than to adjust the C G H  protocol.
Denaturation, hybridization, and post-hybridization
Several C G H  protocols describe denaturation of the probe and chromosomes 
separately, and pre-annealing of the COT-1-DNA to the labeled D N A  p rio r to 
hybridization. However, o u r C G H  improved by perform ing a simultaneous 
denaturation of probe and chromosomes. Denaturation, hybridization, and post­
hybridization washes were in itia lly performed in a waterbath and a stove as 
described above. In this situation, denaturation temperature and time are 
dependent on the thickness of the metal box. O verdenatura tion w ill result in 
chromosomes with a swollen appearance and a vague banding pattern but 
generally showing bright fluorescent intensities. Additionally, bright signals can 
be present between closely neighboring chromosomes. Insufficient denaturation 
w ill result in chromosomes with a very nice banding pattern but little signal o r 
signal intensity changes along the chromosomes fo llow ing the banding pattern.
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The post-hybridization washes with (toxic) formam ide at 4 2 °C  should be 
performed with caution, and use of a waterbath in a fume-hood is necessary.
In o u r experience the use of the Om niS lide Thermal Cyc ler with the 
accompanying wash-units resulted in a better standardization of the 
denaturation, hybridization and post-hybridization washes. Furthermore, it 
improved and facilitated ou r C G H  experiments; signals are brighter, and post­
hybridization washes do not require formam ide anymore and are less time 
consuming. A lthough two days of hybridization is sufficient in most cases, we 
perform an over weekend hybridization (3 days) as this results in brighter 
fluorescent intensities and the Om niS lide is ava ilab le fo r other purposes during 
the week.
The chromosomes are counterstained with DAPI to focus the microscope and 
localize the spreads. Additionally, the inverse of the DAPI image results in a 
banding pattern, which is used to karyotype the normal metaphase 
chromosomes during analysis. Com bin ing DAPI in the antifading solution is 
frequently described. However, as this results in a transient weak blue fluorescent 
background, we prefer to stain the chromosomes by DAPI diluted in 2xSSC and 
mount them in an anti-fading solution after rinsing and dehydration of the slides. 
Some antifading solutions may decrease the intensity of specific fluorochromes, 
e.g. in ou r hands the antifading Vectashield (described to be useful fo r FITC 
signals) decreased the intensity of FITC which became evident after replacing the 
antifading by glycerol (true intensity of the fluorescent signal is visible for only a 
short time). W e prefer to use FluoroGuard™ , which is diluted in a 1:1 ratio as 
described by the manufacturer to decrease the transient weak blue fluorescent 
background when using DAPI filter. The combination of fluorescence and the 
filters used may determine which antifading solution is the most appropriate and 
can therefore differ among laboratories. Furthermore, fluorescent signals should 
show as a non-granular and bright co lor
Microscopy and image analysis
In o rder of recommendability, mercury bulbs of 100 watt, mercury bulbs of 50 
watt o r xenon bulbs can be used fo r CG H . As the ratio between the intensity of 
reference and tum or D N A  is indicative for chromosomal gains and losses it is 
crucial that the bulb is optimally aligned fo r uniform illum ination. Inadequate 
alignm ent may result in spreads in which both homologue chromosomes show a 
different ratio profile. W e check the position of the lamp by focussing the camera 
on a spread o r nucleus and capturing a b lank image fo r 5 o r 10 seconds for 
both the green (FITC) and red (TRITC) filter. After merging these images, a 
homogenous co lo r should be present. A lthough mercury bulbs of 100 watt can 
be used fo r FISH for approximately 300  hours, we noticed that after 
approximately 100 hours differences appear between both ratio profiles of both 
homologue chromosomes if they are located at the opposite ends of the image 
captured, which results in a large standard deviation and an underestimation of 
the aberrations. Instable bulbs are replaced immediately. Furthermore, the 
usefulness of the filters fo r C G H  should be checked. Bandpass filters fo r green
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and red are recommendable. Longpass filters fo r red may be used, but longpass 
filters fo r green are not useful as it w ill result in the red signal being captured in 
the green image and false ratio profiles (false negative results causing 
underestimation of the imbalances present in the tumor). Lateral shift may be 
detected between red, green o r blue fluorescent using a manual filter wheel. 
Furthermore, objective lenses (plan-apochromatic, 63x o r 100x, no 
autofluorescence, transmit UV excitation) and camera should be appropriate and 
apochromatic w ithout autofluorescence'67'.
For the identification of chromosomal gains and losses it is essential that the 
chromosomes are correctly classified. If this is difficult due to poor banding, the 
chromosomes might be overdenaturated and a new batch of chromosomes, less 
formam ide in the hybridization buffer, o r lower temperatures for denaturation 
might be tested. Additionally, special options in the C G H  analysis software o r 
other graphic software packages (e.g. Adobe Photoshop) may be used to 
improve the banding patterns. For each tumor, the results of analysis of multiple 
metaphase spreads are averaged, we prefer to analyze 10-15 examples of each 
chromosome fo r definite interpretation.
Interpretations can be performed using fixed thresholds o r statistical 
thresholds'68'. Theoretically, aberrations fo r the X-chromosome in a male to 
female C G H  experiment should be 0.5 o r 1.5, however, they usually show as 
1.2 and 0.8 o r 1.25 and 0.75'35'. Fixed threshold are most w idely used and 
range from 1.25 and 0.75 to 1.1 and 0.9. As previously described we use the 
fixed thresholds of 0.8 fo r a loss and 1.2 for a gain'35,36', furthermore we 
discrim inate between clear-copy number changes (crossing 0.6 and 1.4) and 
high copy amplifications (crossing 1.6). Using high quality D N A  isolated from 
snap-frozen tum or tissue in o u r optimized C G H  experiments, the standard 
deviation is very small and more narrow thresholds (1.1 and 0.9) could be used. 
However, in o u r case this would not result in a h igher frequency of aberrations 
as almost all aberrations are also detected using 1.2 and 0.8. Based on the 
standard deviation of the experiment and the ratio profile of the negative control 
experiment, thresholds might be adjusted. Statistical thresholds are based on 
standard reference intervals and/or confidence intervals (95%, 99% or 
99.5%)'44,73,74'. Aberrations are detected if no overlap exists between the 
matched standard reference intervals and the corresponding confidence interval 
of the tum or ratio profile'44,73'. A lternatively, aberrations are detected if the 
confidence interval does not include a ratio of 1.0 ('74' and references therein). 
A lthough with these so called data-driven analysis more aberrations might be 
detected, the use of fixed thresholds is recommended because less false positive 
imbalances are detected ('74' and reference therein).
Because COT-1-DNA is used to block repetitive sequences present in 
pericentromeric and heterochromatic regions, these regions can not be reliably 
evaluated by CGH. Furthermore, interpretation of telomeric regions should be 
performed with caution. At the telomeres the fluorescent intensities gradually 
decrease and when the absolute intensities start to approach the background 
fluorescence, unreliab le ratio changes may occur'40'.
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During the eva luation of the profiles, close attention should be paid to the 
analysis of individual metaphase spreads because; 1) a small shift of the actual 
location of an aberration may occur during graphical depiction (a specific 
chromosome may vary in size in different spreads and therefore the ratio is 
scaled and depicted along the ideogram  of the chromosome). This can result in 
inadequate identification of the regions affected e.g. an aberration which is 
clearly visible below the centromere on the individual co lo r images may be 
depicted as a peak in the centromeric region of the ideogram and therefore be 
mistaken as centromere artifact rather than as a true aberration. Additionally, 
small aberrations may be better localized combining both the co lo r images 
showing the aberration and the corresponding DAPI banding pattern. 2) small 
aberrations may be less c lear in the average ratio profile than in the individual 
profiles (in the average ratio profile the actual ratio of a small aberrations may 
be diluted by the neighboring normal ratios due to the shift mentioned above) 
e.g. a loss of a small specific chromosomal region may show a ratio of 0.8 on 
the individual chromosomes and be clearly present in the co lo r image whereas in 
the average ratio profile a la rger region may show a ratio of e.g. 0.9 not 
crossing the threshold set for losses.
Quality control of CGH analysis
Sim ilarly to other molecular genetic techniques, the proper controls should be 
included. Unfortunately, most C G H  papers do not mention control experiments. 
In o rder to detect chromosomal imbalances of the X chromosome in the 
analyzed samples, C G H  was performed using tum or and control D N A  of the 
same gender. Using control D N A  of the o ther sex has been described as an 
internal control of C G H  but is less desirable because it is not clear if the X- 
chromosome is normally present in the test DNA. W e used the quantitative 
criteria of Karhu'61' to assure the quality of C G H  experiments. W e noticed that, 
although all these criteria were met, not all aberrations were detected in ou r 
positive control experiment. Since the introduction of a positive control 
experiment, repeated experiments (performed on all tumors) gave the same 
results indicating the re liab ility of o u r C G H  control experiments. In the control 
experiments special attention should be paid to the G-C rich regions on 1p, 9p, 
16, 19, and 22 which have been described as problem areas because they can 
show aberrations in a negative control experiment (false positives) and indicate 
suboptimal CGH. Additionally, it was suggested that labeling both A-T and G-C 
sequences by using both dCTP and dUTP during labeling results in a more 
uniform hybridization with fewer hybridization artifacts'62'.
Critical inspection of the C G H  experiments before image capturing and 
analysis might save a lot of time, which w ill otherwise be wasted on image 
acquisition and analysis. In o u r experience, green and red signals should be 
visible using the smallest objective lens (10x) in the microscope and the 
hybridization signal should clearly extent the overa ll background intensity. The 
signals should be smooth, because a g ranu la r signal results in large standard 
deviations after interpretation. Varieties in signal intensity in a banding like
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pattern probably result from inadequate denaturation and are therefore not 
useful. Background should be low and homogenous. Furthermore all aberrations 
should be detected in the positive control experiment whereas no aberrations 
except fo r X may be detected in the negative control experiment.
In  c o n c l u s io n
C G H  has been applied successfully to identify chromosomal imbalances 
involved in the oncogenesis of different tum or types. Because different genetic 
subtypes o r specific imbalances were reported to have prognostic o r therapeutic 
implications, C G H  has been proposed as a diagnostic tool. As pointed out 
above, C G H  is a complex technique encompassing different steps which need 
special attention in o rder to be able to successfully perform C G H  experiments.
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A bstract
In contrast to astrocytic tumors, approximately two-thirds of anaplastic 
o ligodendrogliom as are reported to be chemosensitive. Relatively little is known 
about the genetic aberrations in o ligodendroglia l tumors (OTs), including both 
pure o ligodendrog lia l tumors (Os) and mixed oligo-astrocytic tumors (OAs). In 
o rder to elucidate the o ligodendrog lia l oncogenesis and to find specific genetic 
aberrations which may have prognostic and therapeutic implications, we 
performed comparative genomic hybridization (CGH) to detect chromosomal 
copy number changes in 17 low-grade O s (lg-Os) and 12 high-grade Os 
(hg-Os) lacking a prom inent astrocytic component. Loss of chromosome 1 p 
(79%) and 19q (76%) were most frequently detected by C G H : all lg-Os and 50% 
of the hg-Os contained -1p (including 1p36-32), -19q (including 19q13.3), o r 
both, the rest of the hg-Os showed + 7 ,  -10, o r both. Since losses of 1p36-32 
and 19q 1 3.3 were mutually exclusive with + 7  o r -10, the hg-Os could be 
divided in "-1p/-19q" and " +  7/-10" tumors. W h ile  the "-1p/-19q" tumors can be 
considered as pure anaplastic oligodendrogliomas, the " +  7/-10" tumors may 
rather be glioblastomas with prom inent o ligodendrog lia l differentiation. W e 
conclude that C G H  is a powerful tool to assist in the identification of two major 
subgroups of hg-Os with prognostic and possibly therapeutic relevance.
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INTRODUCTION
According to conventional histopathological classification, o ligodendroglia l 
tumors (OTs), including both pure o ligodendrog lia l tumors (Os) and mixed 
oligo-astrocytic tumors (OAs), account fo r 5 to 33% of all gliomas'75,76'. Because 
of vague definitions and subjective interpretation, the histopathological diagnosis 
of OTs is subject to significant interobserver variation that w ill adversely impact 
the evaluation of therapeutic protocols and the interpretation of molecular 
m arker studies related to tum or progression and biology'29,75'. The distinction 
between pure astrocytic tumors (As), mixed OAs, and pure O s  was previously of 
rather limited importance because there were no therapeutic implications. 
However, because it has been reported that approximately two-thirds of ana­
plastic oligodendrogliomas respond to chemotherapy with Procarbazine- 
Lomustine-Vincristine (PCV), whereas As such as glioblastoma multiforme (GBM) 
respond only occasionally to chemotherapeutic treatment'14-16', accurate 
discrim ination between OTs and As has now become of even greater 
importance. Non-chemoresponsive anaplastic oligodendrogliom as may either be 
misclassified tumors o r may represent a distinct subtype.
Genetic changes characteristic of human gliomas have been studied 
extensively over the last few years (for review see references'1,5-10'). However, the 
majority of published studies focussed prim arily on As and only few data are 
ava ilab le on OTs. Additionally, previous studies on genetic aberrations in OTs 
were largely limited to loss of heterozygosity (LOH) analysis on only a few 
chromosomes, and did not evaluate chromosomal imbalances of the entire 
tum or genome'17-20,77'. Com parative genom ic hybridization (CGH) is a molecular 
cytogenetic method that allows screening of chromosomal imbalances th roug­
hout the genome in a single experiment'35,36'. A lthough C G H  analysis has been 
performed on gliomas before'78-84', in these studies only 5 of the reported tumors 
were anaplastic oligodendrogliomas'83'. The aim of the present study is to 
characterize sets of genetic aberrations typifying O s and thereby gain better 
insight into the ir oncogenesis. W e performed C G H  to screen fo r chromosomal 
imbalances in a series of 17 low-grade O s (lg-Os) and 12 high-grade O s 
(hg-Os). OTs with a prom inent astrocytic component (i.e., OAs) were excluded.
M aterials a n d  M ethods
Surgical specimens of 29 O s w ithout a prom inent astrocytic component (17 
lg-Os and 12 hg-Os) were obtained from patients treated at the Department of 
Neurosurgery at the University Medica l Center St Radboud in N ijmegen, the St. 
Elizabeth Hospital of Tilburg, and the University Hospital Bonn (B-numbers) (table
3-1). During surgery a portion of the tum or was snap-frozen in liquid nitrogen 
and stored at -80°C. Each tum or was diagnosed by at least two independent 
neuropathologists according to the revised W H O  classification. A t diagnosis, the
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lg-Os were classified as oligodendrogliomas, and the hg-Os as anaplastic 
oligodendrogliomas. For the latter diagnosis, the tum or had to show three o r 
more of the fo llow ing characteristics: high cellularity, nuclear pleomorphism, 
brisk mitotic activity (>10 /2m m 2), necrosis and florid m icrovascular 
proliferation'28'. As suggested by Burger and Scheithauer'13', some astrocytic 
features were accepted in anaplastic oligodendrogliom as w ithout classifying the 
tum or as an OA. In table 3-2 histological features and clinical data of the hg-Os 
are summarized.
Com parative genomic hybridization was performed as described in chapter 2.
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Figure 3-1 . Histology and the corresponding ratio profiles of two pure high-grade 
oligodendroglia l tumors, N46 and N12. Mitoses (^) and blood vessels (BV) are indicated in 
the hematoxylin and eosin staining. Corresponding ratio profiles of chromosome 1, 7, 10, 
and 19 are shown. The mean ratio (heavy line) with thresholds (thin lines, 0.8 and 1.2) are 
shown. Losses and gains are indicated respectively by bars on the left and the right of the 
chromosome ideogram. The number of analyzed chromosomes (n) is indicated under the ratio 
profile. For corresponding color images of representative CG H  experiments see page 185.
Results
C G H  was performed on 17 lg-Os and 12 hg-Os. Figure 3-1 shows ra tio­
profiles of chromosome 1, 7, 10, and 19 and the histopathological features of 
two hg-Os, N 46  and N12. Table 3-1 and figure 3-2 summarize the genetic 
aberrations as detected by CGH. Recurrent aberrations in ou r group of O s were 
loss of chromosome arm 1p and 19q. Twenty-three tumors (79%) harbored a 
complete (69%) o r partial (10%) loss of chromosome 1p. Partial losses of 1p
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involved 1 p 1 3-31 and 1p31-pter. Chromosome 1 9q was lost in twenty-two 
tumors (76%). Two of these (7%) had a partial loss involving 19q13-qter. All 
tumors with a complete 1p loss also had a complete loss of 19q. Partial loss of 
1p co-occurred with either partial loss of 19q o r with a normal chromosome 19. 
In the g roup of hg-Os, gains involving chromosomes 1p o r 19q were 
occasionally detected. O the r chromosomes frequently involved in chromosomal 
imbalances (present in 4 cases o r more) were gain of 7, 8q, and X, and loss of 
4, 9p, 10, 14q, 15q, 16q, 22, and Xp. C lea r copy number gains involved 
chromosome 2pter, 11, and 17, whereas 8q23 was a high copy gain. The mean 
number of genetic aberrations was not significantly h igher in hg-Os than in 
lg-Os: 6.3 (75 aberrations in 12 tumors) (SD:4.0) versus 4.5 (77 aberrations in 
17 tumors) (SD:3.9), with a wide range in the number of detected genetic 
aberrations (2 to 18 fo r lg-Os and 2 to 19 fo r hg-Os).
In the group of lg-Os, all tumors lost 1p and/or 19q and no imbalances were 
detected on 7 and 10. In hg-Os, however, aberrations on all four chromosomes 
were detected. As -1p and -19q did not coincide with + 7  and -10 the tumors 
were subdivided according to these chromosomal aberrations (figure 3-3). 
Tum or N 132  (-1p13-31, + 7 , -10) was included in the "+7/-10" profile because 
the specific area indicated to be involved in O T  oncogenesis by a LOH  study 
(1p36-32)'19' was not lost in this tumor. Two tumors which had either + 7 q  
(N151) o r -10 (N40), were tentatively included in the "+7/-10" profile based on 
a normal constitution of 1p36-32 and 19q and the respective aberrations on 7q 
and 10. Six hg-Os (50%) showed a "-1p/-19q" profile, whereas the o ther 6 
showed a "+7/-10" profile. A  complete gain of 19 was detected in two "+7/-10" 
hg-Os.
The histological slides of the "-1p/-19q" and " +  7/-10" hg-Os were reviewed 
with special attention fo r the presence of o ligodendrog lia l and astrocytic 
differentiation, cellularity, nuclear polymorphism, mitoses, necrosis, florid 
m icrovascular proliferation, and calcification (table 3-2). Additionally, some 
clinical data are summarized in this table.
DISCUSSION
Chromosomal imbalances in Os
In ou r study, all lg-Os contained a loss on 1p (94%) o r 19q (94%), whereas a 
loss of both 1 p and 19q was detected in 88% of these tumors. This is in 
agreement with studies reporting LOH  1p, LOH 19q, and the combination of 
both in up to 100%, 88%, and 88% of lg-Os, respectively'17-25'. A  high 
concordance between LOH  and C G H  analysis (92%) was previously reported in 
a set of prostatic tumors'39' analyzed with both techniques. A lthough 1p o r 19q 
are frequently lost completely (figure 3-2), LOH studies detected a partial 
deletion in a m inority of the tumors, the commonly deleted region being 
1p36-32'19' and 19q13.3'23,85'. These regions most likely contain the putative
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tum or suppressor genes involved in o ligodendrog lia l oncogenesis. It has been 
proposed that LOH  19q precedes LOH  1p because some tumors only have LOH 
19q[18,21,22l. In o u r group of lg-Os, however, one tum or showed loss of 1p36-32 
w ithout loss of 19q13.3. Additionally o ther LOH studies also detected loss of 1p 
w ithout a LOH  19q in 4 out of 69 O s [20-22]. This does not support the proposed 
sequence of events. LOH  9p has been detected previously in hg-OTs, but not in 
lg-OTs[21]. Nevertheless, we detected loss of 9p in 3 out of 17 lg-Os. It remains 
to be seen if -9p in these lg-Os can be considered as an early marker of 
m alignant progression.
Table 3-1.
Chromosomal imbalances present in oligodendroglia l tumors as detected by CGH.
Tumor G rade CG H  losses CG H  gains
N7 lg-O p, 9 _Q
N13 lg-O p, 9 _Q
N36 lg-O 3p21-q21, 11p14-pter, 11q14- 8p22-qter, 9
q24, 12q21-23, 19q13, 22q13
N43 lg-O 1p, 9p, 19q
N47 lg-O 1p, 14q22-24, 19q
N105 lg-O 1p, 4, 9, 19q 11c, 17, 19p, 20
N148 lg-O p, 9 _Q
N134 lg-O p, 9 _Q 4p15-pter
N149 lg-O 1p, 13q, 19q 4p15-pter
N135 lg-O 1p31-pter, 4, 5q14-23, 6q11-22,
*
3p, 8q21-qter, 8q23 ,
11p15, 12q11-21, 15q, 18q, q 4­ 2 , 6, 7
19q13, 21, 22, Xp
N133 lg-O 1p, 19q X
N129 lg-O 1p, 19q, X
N131 lg-O 1p, 14q21-24, 19q
B218 lg-O 1p, 19q
B554 lg-O 1p, 19q Xp21-pter, Xq
B2578 lg-O 1p, 4, 5p, 9p, 16q, 18, 19q
B2930 lg-O 1p31-pter X
N41 hg-O 1p, 15q21, 19q
N46 hg-O 1p, 9p, 19q, 22, X
N107 hg-O 1p, 2q37, 15q, 18, 19q
N 130 hg-O 1p, 8p21-pter, 14q23-qter, 19q 8q22-qter
N152 hg-O 1p, 15q, 19q 8q21-qter
B550 hg-O p, 9 _Q
N12 hg-O 9p21-pter, 10, 15q13-21 7, 7p11-q11c, 12q14, 18, 19
N40 hg-O 2p21-qter, 4, 5, 8p23, 10, 12p, 1, 2p22-25c, 11q, 17c
12q15-21, 13q, 15q25, 16, 22
N132 hg-O 1p13-31, 6, 10, 14q, X 1q31-qter, 4p15-pter, 7, 8,
9q34, 19
N150 hg-O 9, 10, 11q14-qter, 16, 17, 22 5q, 7, 12q11-22, 13q, 15q
N151 hg-O 7q, X
N138 hg-O 6q15-qter, 9p, 10, 14q, 16q 7
lg-O: low-grade oligodendroglia l tumor; hg-O: high-grade oligodendroglia l tumor; c: clear 
copy number changes, ratio 1.4 or 0.6; *: high copy gain , ratio >1.6.
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Tabel 3-2.
Histological, clinical, and CGH  characteristics of high-grade oligodendroglia l tumors.
Tumor oligo-
features
astro- cellularity 
features
nuclear
polymorph
mitoses
ism
necrosis florid
MVP
calcifi­
cation
sex age therapy survival
"-1p/-19q" tumors 
N41 +  +  + + + + + + + + + + + M 42 > 2  yrs
N46 + + + ± + + + + + + + + ± + - F 48 - > 3  yrs
N107 + + + +  * + + + + + + + - + + + M 60 RT > 2  yrs
N130 + + + +  * + + + + + + + - + + + F 43 RT > 2  yrs
N152 + + + +  * + + + + + + + + + + + + + + F 50 RT > 2  yrs
B550#
" +  7/-10" tumors 
N12 +  + ± + + + + + + + + + + + + F 55 f  2 yrs
N40 + + ± + + + + + + + + + + + - - M 62 - f  1 mo
N132 + + + ± + + + + + + + + - + + - F 19 - >  5 yrs
N150 + + ± + + + + + + + + + + - + + M 45 - >  2 yrs
N151 + + + ± + + + + + + + + + + + - M 60 - f  3 mo
N138 + + + +  * + + + + + + +  + +  + M 60 - >  2 yrs
#  no data available. Cellu larity and nuclear polymorphism were scored in the area with the most severe abnormaliti es. Oligo-(dendrocytic) features[29]:
tum or cells showing a relatively monotonous, small, round nucleus, and a perinuclear halo or scant ring of cytoplasm; Astro-(cytic) features[29]: tumor 
cells with an elongated or more irregular nucleus and a variable amount of eosinophilic cytoplasm, often with cytoplasmic processes. O ligodendrocytic 
features and astrocytic features: - =  absent, ± =  dubious, +  =  some ( =  <5%), + +  =  marked, +  +  +  =  extensive; Cellularity: ± =  low, +  =  
moderate, + +  =  marked, +  +  +  =  high; Nuclear polymorphism: +  =  some, + +  =  marked, +  +  +  =  severe; Mitosis: - =  absent, +  =  <10\2mm2, 
+  +  =  >10\2mm2; Necrosis, florid MVP (microvascular proliferation), calcification: - =  absent, ± =dubious, +  =  sporadic, + +  =  dispersed, +  +  +  =  
wide spread; Sex: M =  male, F =  female; Age =  age at surgery; Therapy: - =  no previous treatment for braintumor, RT =  radiotherapy for braintumor 
prior to biopsy from which material was analyzed; Survival: >  =  still alive, yrs =  years, f  =  dead, mo =  months.
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Figure 3-2. Summary of all chromosomal imbalances detected by CGH  in pure low-grade 
(lg-) and high-grade (hg-) oligodendroglia l tumors (Os). Lines on the left and right of the 
chromosome indicate respectively losses and gains of these chromosomal regions. Genetic 
aberrations crossing the 0.8 or 1.2 threshold are indicated by a thin line, while clear copy 
number changes crossing the ratios 0.6 and 1.4 are indicated by a heavy line. High copy 
gains, indicated by a ratio larger than 1.6, are indicated by an additional spot on a bar.
In the present study, C G H  analysis of hg-Os most frequently detected -1p, 
+  7, -10, and -19q. Six tumors (50%) showed a genotype sim ila r to lg-Os, 
consisting of a combination of -1p and -19q (including 1p36-32 and 19q13.3), 
and the other six tumors showed + 7  and/o r -10. Since losses of 1p36-32 and 
19q13.3 were mutually exclusive with + 7  o r -10 in the tumors analyzed in this 
study, the hg-Os were subdivided in "-1p/-19q" tumors and "+7/-10" tumors 
(figure 3-3). The presence of + 7  and -10 appears to define a separate 
subgroup instead of being due to tum or progression.
" + 7/-10" tumors
The "+7/-10" and "-1p/-19q" tumors define two genetic subsets of hg-Os. In 
this group a sim ila r histopathological phenotype is apparently reached through 
different genetic pathways, as has been suggested fo r G B M s[5]. In light of the
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Figure 3-3. Summary of chromosomal imbalances in high-grade oligodendroglia l tumors. 
Tumors harbor either a loss of 1p and/or a loss of 19q ("-1p/-19q" hg-Os) or a gain of 7 
and/or a loss of 10 (" +  7/-10" hg-Os). Dotted lines represent tumors with either + 7  or -10. 
See also legends figure 3-2.
genetic aberrations in o u r group of lg-Os, the "—1p/-19q" hg-Os can be 
considered as pure anaplastic o ligodendrogliomas. The "+7/-10" genotype, 
however, is associated with As rather than Os; GBMs frequently show a gain of 7 
(in particular an amplification of the EGFR-gene located at 7p12) and a loss of 
10[5,10,78-84]. The "+7/-10" hg-Os may therefore be GBMs with major 
o ligodendrog lia l differentiation rather than pure anaplastic oligodendrogliomas.
The histological slides of the hg-Os were reviewed in o rder to find histological 
features related to the "+7/-10" o r the "—1p/-19q" genotype (table 3-2). 
Retrospectively, the " +  7/-10" hg-Os tended to show more necrosis. However, 
one "-1p/-19q" tum or (N152) also showed dispersed necrosis, and necrosis was 
absent in two " +  7/-10" tumors (N12 and N132). Additionally, in three of the six 
"+7/-10" tumors the o ligodendrog lia l phenotype was not as prom inent as in the 
other hg-Os. Unequivocal differentiation of the "—1p/-19q" hg-Os from the 
"+7/-10" tumors remained very difficult.
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Prognostic and therapeutic relevance of genetic subtyping
Cairncross et a l.[16] recently reported that in anaplastic oligodendrogliomas 
LOH  1p and a combination of LOH 1p with LOH 19q are strongly correlated 
with chemosensitivity and survival, while homozygous deletions of the C D K N 2A  
gene (located on chromosome 9p21) and ring enhancement on neuroimaging 
are associated with a significantly worse prognosis. The inverse relationship 
between C D K N 2A  gene deletions and LOH 1 p/19q suggested independent 
genetic subtypes of anaplastic oligodendrogliomas. Additionally, they described 
that 5 of the 8 anaplastic oligodendrogliomas harboring LOH 10q did respond 
to chemotherapy[16]. It is not c lear from this article if these tumors harboring LOH 
10q additiona lly have LOH 1p, LOH 19q, and/or amplification of chromosome 
7.
In ou r study, all patients with "-1p/-19q" hg-Os are alive fo r at least two years 
and currently doing well (table 3-2). The survival of patients in the "+7/-10" 
subgroup is variable: two patients died w ithin one year after operation (as can be 
expected fo r ord inary GBMs), one patient died after 2 years, whereas the other 
three patients are still a live and doing well for at least 2 years. The survival of the 
latter patients indicates that the "+7/-10" hg-Os are not just simply 
misdiagnosed GBMs. Interestingly, loss of 9p (including C D K N 2A  at 9p21) was 
detected by C G H  more frequently in o u r " +  7/-10" tumors (3/6) than in our 
"-1p/-19q" tumors (1/6). C lin ica l implications (chemosensitivity and prognosis) of 
genetic subtyping according to the proposed subtypes is the subject of o u r further 
investigation (chapter 7).
In c o n c l u s io n
C G H  analysis of 17 lg-Os and 12 hg-Os supports previous findings 
demonstrating that -1p and -19q is most frequently detected in Os. In ou r study 
all lg-Os and 50% of the hg-Os were characterized by -1 p and/o r -19q 
("-1p/-19q" Os). The other 50% of hg-Os harbored + 7  and/o r -10 w ithout a 
loss of 1p36-32 and w ithout a loss of 19q13.3 (" +  7/-10" Os). The latter tumors 
may be GBMs with a prom inent o ligodendrog lia l phenotype rather than 
anaplastic oligodendrogliomas. The molecular differences in the group of hg-Os 
are the result of the notoriously difficult problem to clearly distinguish these 
tumors on the basis of histopathological examination. Obviously, molecular 
genetics is a powerful tool to assist in subgrouping of tumors which may have 
prognostic va lue in predicting chemosensitivity and post-operative survival.
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A bstract
Recently we identified two genetic subtypes of pure high-grade 
o ligodendrog lia l tumors (hg-Os): "-1p/-19q" hg-Os are characterized by a loss 
of chromosome 1p32-36 and/o r a loss of 19q13.3 whereas "+7/-10" hg-Os 
harbor a gain of chromosome 7 (+7) and/o r a loss of 10 (-10) w ithout a loss of 
1p32-36 and w ithout a loss of 19q13.3. Because a + 7  and a -10 are most 
frequently detected in glioblastomas (GBMs), the genotype of "+7/-10" hg-Os 
suggests that these tumors are GBMs with a prom inent o ligodendroglia l 
phenotype rather than anaplastic o ligodendrogliomas. PTEN is a tum or 
suppressor gene, located at 10q23.3, which is involved in tum or progression of 
GBMs and other neoplasms. In this study we screened for PTEN mutations in six 
low-grade oligodendroglia l tumors (lg-Os), five "-1p/-19q" hg-Os, seven "+7/-10" 
hg-Os, and nine xenografted GBMs. PTEN mutations were detected in none of the 
lg-Os and "-1p/-19q" hg-Os, once in "+7/-10" hg-Os, and frequently in GBMs. 
As one of the " +  7/-10" hg-Os harbored a PTEN mutation this demonstrates that 
PTEN can be involved in the oncogenesis of this genetic subtype of hg-Os. The 
lower frequency of PTEN mutations in "+7/-10" hg-Os compared to GBMs 
suggests that these tumors are of a distinct tum or type rather than GBMs.
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INTRODUCTION
Pure o ligodendroglia l tumors (Os) account fo r 5% to 33% of all g liomas[75,76]. 
A lle lic deletions on chromosome 1p and 19q are detected in the majority of 
O Ts[21,22]. Recently, C G H  analysis of pure o ligodendroglia l tumors (Os) revealed 
two genetic subtypes w ithin the histopathological phenotype of high-grade (hg-) 
O s w ithout a prom inent astrocytic component: "-1p/-19q" hg-Os and "+7/-10" 
hg-Os[53] (chapter 3). The "-1p/-19q" hg-Os harbor a loss of 1p32-36 and/o r a 
loss of 19q13.3, genetic aberrations which were also present in all low-grade 
(lg-) O s  investigated by CG H . The "+7/-10" hg-Os contain a gain of 7 and/or a 
loss of 10 w ithout a loss of 1 p32-36 and w ithout a loss of 19q 13.3. The 
differences in the group of hg-Os might be the result of the problem of clearly 
distinguishing these tumors on the basis of histological exam ination[53]. Because 
a loss of chromosome 10 and a gain of chromosome 7 are most frequently 
detected in the most m alignant type of glioma, glioblastomas (GBMs)[5,10,86], the 
genotype of "+7/-10" hg-Os might suggest that these tumors are GBMs with a 
prom inent o ligodendrog lia l phenotype rather than anaplastic 
oligodendrogliomas.
The tum or suppressor gene PTEN[87] o r M M A C 1 [88] which is located at 
10q23.3, belongs to the most commonly mutated genes in human cancer. In a 
number of different types of tumors including melanomas and prostate cancer, 
PTEN is reported to be involved in tum or progression'89'91!. Germ-line mutations 
of the PTEN gene have been associated with Cowden disease and with two other 
distinct but related syndromes, Bannayan-Riley-Ruvalcaba syndrome and juvenile 
polyposis syndrome predisposing to multiple hamartomas'92-9^ . The PTEN gene 
encodes a dual specificity phosphatase that has been demonstrated to function 
in the regulation of cell growth, apoptosis, cell m igration and interactions with 
the extracellu lar matrix[97,98].
In gliomas, PTEN alterations are most frequently detected in GBMs and only 
occasionally in less m alignant gliomas indicating that PTEN alterations occur as 
a late event in glioma oncogenesis'89,99-10^ . A lthough PTEN mutation analysis 
has been performed on more than 800  gliomas, most frequently GBMs, hg-Os 
were included only occasionally (5 o r less hg-Os per study[89,102,103]) and no 
distinction was made between the different genetic subtypes[87'89,99'106]. The 
combination of a loss of chromosome 10 and PTEN mutations in GBMs raises 
the question whether PTEN is also involved in the oncogenesis of "+7/-10" 
hg-Os in contrast to "—1 p/-19q" hg-Os. Similarities o r differences in the 
incidence of PTEN alterations in " +  7/-10" hg-Os and GBMs might provide a 
better insight in whether "+7/-10" hg-Os might be GBMs with o ligodendroglia l 
differentiation rather than anaplastic o ligodendroglia l tumors. The present study 
is designed to evaluate the involvement of PTEN in Os, in particular in the two 
genetic subtypes of hg-Os, and make a comparison with GBMs. W e analyzed six 
lg-Os, five "-1p/-19q" hg-Os, seven " +  7/-10" hg-Os, and nine xenografted GBMs 
for PTEN aberrations using SSCP analysis and sequencing. These tumors were
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previously screened for a loss of chromosome 10 by comparative genomic 
hybridization (CGH)|53,86] (chapter 3 and 8).
M aterials a n d  M ethods
GBMs were obtained from xenografted tissue as described by Bernsen et 
a l.[107]. O s were obtained from surgical specimens. After surgery tumors were 
snap frozen in liquid nitrogen and stored at -80°C. Tumors were histologically 
classified and graded according to the W H O  classification system. Three 
independent neuropathologists classified the investigated m alignant tumors as 
high-grade O s instead of G BM s[53] and as we only analyzed pure 
o ligodendrogliomas, the tumors contained less than 5% astrocytic features 
indicating that the hg-Os are not ord inary G BM s[53] (chapter 3). Using C G H  
analysis, the tumors were genetically subtyped as "-1p/-19q" (tumors with a loss 
of 1p32-36 and/o r 19q13.3) o r "+7/-10" (tumors with a gain of 7 and/or a loss 
of 10 and w ithout a loss of 1 p32-36 and w ithout a loss of 19q 13.3) as 
described in chapter 3. Tum or characteristics are summarized in table 4-1.
For mutation analysis tum or D N A  was extracted from frozen tissue and 
reference D N A  was extracted from peripheral blood lymphocytes as described in 
chapter 2. Mutation analysis of the PTEN gene was performed as described by 
Nelen et a l.[109]. Briefly, fo r SSCP analysis D N A  fragments containing the exons of 
the PTEN gene were amplified using the primers described by Steck et a l.[110]. 
[a-32P]dCTP was incorporated and the PCR products were denatured and 
separated on a non-denaturing 5% polyacrylam ide gel containing 1 1.5% 
glycerol at 7 W att at room temperature and 4°C. PCR products were visualized 
by autoradiography. Sequence analysis was performed using the same primers. 
Exons of the PTEN gene were amplified and purified using spin columns (ROCHE 
diagnostics). Sequence analysis was performed on an ABI 377  automated 
sequencer using the ABI dye term inators rhodam ine sequencing kit. Southern 
blotting was performed to detect homozygous deletions. Contro l D N A  and tum or 
D N A  were digested with PstI, blotted and hybridized with a full-length PTEN 
cD NA  probe. As a control probe PMP22 cD NA  was used which is located at 
1 7p1 1.2. The numbers of nucleotides and codons of the PTEN cD NA  are 
according to W ang et al.[99].
Results
The results of C G H  analysis on O s  and xenografted GBMs are reported in 
more detail in chapter 3 and 8 respectively. Loss of a complete chromosome 10 
was detected in none of the lg-Os o r "-1p/-19q" hg-Os, in six out of seven
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"+7/-10" hg-Os, and in eight out of nine GBMs (table 4-1). G B M  E102 was the 
only tum or with a partial loss of chromosome 10 in which the PTEN region 
(10q23.3) was not included. In one G B M  (E168) and in one " +  7/-10" hg-O 
(N151) no loss of chromosome 10 was detected. Interestingly, the heterozygous 
constitution of a commonly detected polymorphism in intron 8 [99,102,111] 
confirmed the presence of both PTEN alleles in N151 and E102.
A ll 9 exons of the PTEN gene were screened by SSCP analysis and/or 
sequencing. Since SSCP analysis does not detect all mutations[112], we sequenced 
exon 5, the most frequently mutated exon encoding the active site of the 
phosphatase[102,113]. No  additional mutations were found. SSCP analysis showed 
an aberrant m igration pattern during gelelectrophoresis of exon 5 in E168, exon 
6 in E80, exon 6 in N12, and exon 8 in E49 (figure 4-1). Sequence analysis of 
these exons revealed two missense mutations (N12 and E80), an insertion (E49), 
and a duplication of 38 nucleotides (E168). No aberrations were detected in the 
control DNAs. The mutations and the ir predicted effects are summarized in table
4-1. A lthough C G H  detected no loss on chromosome 10 in E168, sequencing 
showed no heterozygosity. This suggests that the duplication, nt303 
(ins nt226-303), is e ither present in both PTEN alleles o r that one of the 
chromosomes harbors a deletion including the PTEN a lle le which is too small to 
be detected by CG H . Since the detection lim it fo r deletions by C G H  is about 10 
M b [35] the latter explanation is the most plausible. Unfortunately this could not be 
confirmed by micro-satellite analysis because normal D N A  was not available.
C E168 C E80 C N12 C E49
Exon 5 Exon 6 Exon 6 Exon 8
Figure 4-1 . SSCP analysis of PTEN exons. Sections from autoradiographs of SSCP gels 
showing control DNA  (left) and tumor DNA  (right). PTEN aberrations were detected in exon 5 
of tum or E168, exon 6 of tumor E80 and tumor N12, and in exon 8 of tumor E49. C =  control 
DNA.
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Table 4-1.
Summary of tumor characteristics and PTEN mutation analysis.
Tumor Malignancy
grade
Genetic
subtype 1)
Loss of # 1 0  2) PTEN mutation analysis 3) :
Exon , the detected mutation , and the 
predicted effect
N7 lg-O -1p/-19q
N13 lg-O -1p/-19q
N35 lg-O -1p/-19q
N36 lg-O -1p/-19q
N47 lg-O -1p/-19q
N105 lg-O -1p/-19q
N41 hg-O -1p/-19q
N46 hg-O -1p/-19q
N107 hg-O -1p/-19q
N130 hg-O -1p/-19q
N152 hg-O -1p/-19q
N184 hg-O +  7/-10 -10
N12 hg-O +  7/-10 -10 Ex 6 , 4 94G ® A , G165E
N40 hg-O +  7/-10 -10
N132 hg-O +  7/-10 -10
N150 hg-O +  7/-10 -10
N151 hg-O +  7/-10
N138 hg-O +  7/-10 -10
E18 GBM +  7/-10 -10
E49 GBM +  7/-10 -10 Ex 8, 955insT, T319fs®324X
E80 GBM +  7/-10 -10 Ex 6, 517C®T, R173C
E98 GBM +  7/-10 -10q22-qter Homozygous deletion4)
E102 GBM +  7/-10 -10pter-q21
E106 GBM +  7/-10 -10
E110 GBM +  7/-10 -10 Homozygous deletion
E120 GBM +  7/-10 -10
E168 GBM +  7/-10 Ex 5, 303dupl226-303 , 102fs®  111X
1) Using CG H  analysis, the tumors were genetically subtyped as either "-1p/-19q" (tumors with 
a loss of 1p32-36 and/or 19q13.3) or " +  7/-10" (tumors with a gain of 7 and/or a loss of 10 
without a loss of 1 p32-36 and 19q 13.3) as described in chapter 3 and 8; 2) Loss of 
chromosome 10 as described in chapter 3 and 8; 3) The numbers of nucleotides and codons of 
the PTEN cDNA are according to Wang et al.[99]; 4) The deletion could not be confirmed by 
southern blotting because of lack of DNA.
SSCP analysis on E98 and E110 showed no signal fo r part of the exons, 
indicating the presence of a homozygous deletion. D N A  quality was checked by 
a positive PCR experiment. Southern blot analysis of E110 and control DNA  
using a PTEN cD NA  probe revealed that 3 fragments were clearly absent in 
E110 (figure 4-2) confirm ing the presence of a homozygous deletion. The 
fragments detected by southern blot hybridization orig inate from remaining parts 
of the PTEN gene and from the PTEN pseudogene located at 9 p 21 [114]. Southern 
blot analysis of E98 was not successful due to the small amount of DNA
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available. However, this tum or is likely to contain a homozygous deletion of 
PTEN since the results of SSCP analysis are comparable to those of E110. SSCP 
analysis of the o ligodendrog lia l tumors gave no indications fo r the presence of 
homozygous deletions.
C E110
Figure 4-2. Southern blot analysis of E110. 
Genom ic DNA  digested with Pst1 and was 
probed with a full length PTEN cDNA. Three 
fragments are clearly absent in E110. 
C =  control DNA.
DISCUSSION
W e studied the involvement of PTEN in o ligodendrog lia l tumors, especially in 
the two different genetic subtypes of hg-Os, "-1p/-19q" hg-Os and "+7/-10" 
hg-Os. By comparing the incidence of PTEN mutation analysis in " +  7/-10" 
hg-Os and GBMs, we elucidated whether "+7/-10" hg-Os are GBMs rather than 
anaplastic o ligodendrogliomas, as suggested by the ir genotype.
PTEN mutations
O vera ll, six PTEN aberrations were detected in 27  gliomas: two missense 
mutations (N12 and E80), a duplication (E168), an insertion (E49) and two 
homozygous deletions (E98 and E110). Both missense mutations (R173C and 
G165E) were detected in one of the three clusters with a high mutation 
frequency[113,115]. This cluster is located at the beginning of exon 6 and encodes a 
highly conserved a-helix which is required for PTEN activity, indicating that both 
missense mutations are likely to result in loss of PTEN activity by disturbance of this 
a-helix motif[115]. The R173C mutation in E80 has been previously detected in 
G B M s[89,101,104] whereas the G 165E  mutation in N12 has been detected previously 
in a patient with Cowden disease[109]. Another mutation in codon 165, G165R, 
has been reported in G BM s[99,105,106] and was shown to result in loss of PTEN 
activity [113]. The duplication in exon 5 of E168 is also predicted to cause a loss of 
phosphatase activity due to a premature stop of the protein at am ino acid 111. 
This truncated protein does not contain the catalytic site which is located at
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am ino acids 123-130[88,113,115]. The T319 fs® 324X  mutation in E49 is new in 
GBMs and is predicted to result in a truncated protein missing one of the three 
potential tyrosine phosphorylation (residue 240, 315, and 336), both potential 
serine phosphorylation sites (residue 338 and 355), and the putative PDZ 
binding domain (the last fou r CO O H -te rm ina l am ino acids)[116]. The latter was 
shown to be required fo r full growth suppression[117]. In E110 and E98 PTEN 
activity is lost due to a homozygous deletion.
Involvement of loss of 10q23 and PTEN
We, and others[89,100,102], did not detect any PTEN alterations in lg-Os 
suggesting that the occurrence of PTEN mutations in g lioma oncogenesis is a 
late event[89,99-101]. The presence of PTEN mutations in the lg-Os as detected by 
D uerr et a l.[101] might be considered as an early m arker fo r malignant 
progression. In contrast to "—1p/-19q" hg-Os, in which loss of chromosome 10 
and PTEN mutations were not detected, a loss of chromosome 10q23 was 
detected in 88% (7/8) of the "+7/-10" hg-Os whereas a PTEN mutation was 
detected in only one of the " +  7/-10" hg-Os tumors (1/8). A lthough the number 
of tumors analyzed is small and homozygous deletions of the PTEN gene in 
tum or biopsies might be underestimated due to the presence of normal DNA, 
these results suggest that PTEN is not involved in the oncogenesis of "-1p/-19q" 
hg-Os and only occasionally in the oncogenesis of " +  7/-10" hg-Os. Previous 
reports did not describe PTEN mutations in hg-Os[89,102,103]. However, as it was 
not reported whether these tumors harbored -1p, -19q, -10q o r + 7 ,  they might 
have been mainly "—1p/-19q" hg-Os. In addition, the number of hg-Os analyzed 
in these studies was small.
In accordance with previous reports[87'89,99,101'105], we detected a loss of 10q23 
in seven GBMs (7/9) and PTEN alterations in five GBMs (5/9). This confirms our 
previous findings that G B M  xenograft lines are valid models to study GBMs from a 
genetic point of view[86]. A lthough the incidence of a loss of 10q23 in "+7/-10" 
hg-Os (6/7) and GBMs (7/9) is comparable, PTEN alterations were detected 
frequently in the GBMs (5/9) and only occasionally in "+7/-10" hg-Os (1/7). 
This suggests that these "+7/-10" hg-Os are not o rd inary GBMs but represent a 
distinct tum or type. This is supported by the previous observation that patients 
with a " +  7/-10" hg-O show a tendency towards longer post-operative survival 
than patients with a G B M [53] (chapter 3). A  la rger sample number is necessary to 
further substantiate o u r observations.
The observation that loss of 10q occurs in a h igher frequency than PTEN 
alterations indicates that other genes on this chromosome are involved in glioma 
oncogenesis. A  candidate gene to be considered is DMBT1 which was recently 
isolated from chromosome 1 0q25.3-26.1 [118]. Loss of the DMBT1 locus was 
detected in both high and low-grade gliomas indicating that this gene is involved 
early in the oncogenesis of g liom as[100,119,120]. It would be interesting to elucidate 
whether DMBT1, rather than PTEN, is involved in both subtypes of hg-Os.
60
PTEN in o ligodendroglia l tumors
IN CONCLUSION
In accordance with previous reports, PTEN aberrations were detected in none 
of the lg-Os, occasionally in hg-Os and frequently in GBMs indicating that PTEN 
is involved as a late event in glioma oncogenesis. O n ly  one PTEN mutation was 
detected in the eight "+7/-10" hg-Os suggesting that PTEN is occasionally 
involved in the oncogenesis of this genetic subtype of hg-Os. The genotype of 
"+7/-10" hg-Os suggests that these tumors are GBMs rather than pure 
anaplastic o ligodendrogliomas. However, the observation that PTEN is only 
occasionally involved in "+7/-10" hg-Os (14%) and frequently in GBMs (55%) 
supports the hypothesis that these "+7/-10" hg-Os are not just o rd inary GBMs 
but represent a distinct tum or type. This is supported by the previous finding that 
"+7/-10" hg-Os show a tendency fo r longer post-operative survival than 
G B M s[53] (chapter 3).
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A bstract
Oligo-astrocytic tumors (OAs) histologically show both o ligodendroglia l and 
astrocytic differentiation. Unequivocal criteria fo r delineation of O As from pure 
o ligodendrog lia l (Os) and astrocytic (As) tumors and fo r grading of O As are 
lacking. M o lecu la r genetic analysis may allow  fo r a better characterization of 
O As and thereby guide prognostic and therapeutic decisions. W e performed 
comparative genomic hybridization (CGH) on 39 gliomas with variab le 
phenotypic expression of both astrocytic and o ligodendrog lia l differentiation. 
O u r  results show that O As are genetically more heterogeneous than Os. In 
addition to the "-1p/-19q" and "+7/-10" subtypes that have been previously 
recognized, two additional genetic subtypes, "intermediate" and "other", were 
identified. "Intermediate" O As likely represent progression from "-1p/-19q" 
tumors. The "other" subtype appears to represent one o r more additional, 
heretofore unrecognized, genetic pathway(s). Application of rigorously "strict" 
histopathological criteria as opposed to "relaxed" criteria fo r the selection of 
oligo-astrocytic tumors resulted in a h igher percentage of "-1p/-19q" tumors, 
however some "-1p/-19q" tumors m ight be missed. O u r  results suggest that 
molecular genetic analysis is a useful and valid additional tool fo r classification 
of gliomas, particularly fo r the significant subset of tumors in which subjective 
histopathological criteria are insufficient for unequivocal distinction between Os, 
As and mixed OAs.
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INTRODUCTION
Oligo-astrocytic tumors (OAs), the most frequent type of mixed glioma, 
m icroscopically show both o ligodendrog lia l and astrocytic differentiation'2,27!. 
A lthough OAs are considered to be a distinctive tum or category in the current 
W H O  classification'27,28!, unequivocal criteria fo r identification and grading of 
these tumors are lacking'13,29]. Thus, a significant diagnostic problem exists in the 
delineation of O As from pure astrocytic tumors (As) on the one hand and pure 
o ligodendrog lia l tumors (Os) on the other, resulting in a high interobserver 
va riab ility[29]. The presence of both an o ligodendrog lia l and an astrocytic 
phenotype might suggest that O As develop from different precursor cells. 
Identification of sim ila r genetic aberrations in both components, however, 
indicates that O As are clonal tumors orig inating from a single cell[18]. 
M icroenvirom ental factors causing tum or cells to differentiate into cells with 
astrocytic o r o ligodendroglia l phenotype'18,121,122] may then explain the mixed 
pattern of OAs.
In several studies, sim ilarities have been described between O As and Os: 
molecular genetic analysis using loss of heterozygosity (LOH) analysis revealed 
LOH 1p and LOH 19q to be the most frequently detected aberration in both 
tumors'5,18,21], and both tumors have been reported to show a s im ila r response to 
radiotherapy and chemotherapy'16,27]. Consequently, in many studies O As and 
O s are included together in the group of o ligodendroglia l tumors (OTs). The few 
studies that specifically addressed the genetics of O As have employed LOH 
analysis directed only at very limited regions of interest'18,21,22]. Com parative 
genomic hybridization (CGH) is a molecular cytogenetic method that allows 
screening of chromosomal imbalances th roughout the entire tum or genome in a 
single experiment. A lthough C G H  analyses have been performed on gliomas 
before (As:'86] and references therein,'78,79'; Os: chapter 3'53] and [123]), to ou r 
knowledge a large C G H  study of O As has not been reported.
Recently, we analyzed pure O s  by C G H  and showed that high-grade O s 
(hg-Os) could be subdivided into two genetic subtypes: "-1p/-19q" tumors and 
"+7/-10" tumors'53] (chapter 3). There is evidence that genetic subtyping of 
hg-Os has prognostic and therapeutic relevance'16,53]. To determ ine whether 
sim ila r patterns can be detected in O As and to identify chromosomal imbalances 
involved in the oncogenesis of OAs, we performed C G H  on a group of gliomas 
containing both unequivocal astrocytic differentiation plus more o r less 
prom inent o ligodendrog lia l features. In o rder to address the current controversy 
concerning the histopathological delineation of OAs from O s and As, we 
applied both a "strict" and a "relaxed" set of criteria fo r identification of 
o ligodendrog lia l differentiation and studied the interrelationship between the 
histopathological criteria and the genotype of the selected tumors.
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Table 5-1 (1).
Chromosomal imbalances detected by CGH  in oligo-astrocytic tumors and corresponding clinical characteristics.
Tumor Histopathological
diagnosis
CGH  losses CG H  gains CGH-subtype Sex Age Survival
relaxed strict
N 84c lg-OA a-A 12q, 13q, 18q, X other F 47 >1.5
N159 lg-OA a-A 2p22-pter, 2q35-qter, 9p21-pter, 22 other M 44 >2.8
N 163c lg-OA lg-OA 7q21-qter, 10p +  7/-10 M 72 t2 .0
N 172c lg-OA lg-A 8q, 10p other M 45 >0.9
N 174c lg-OA lg-A 4q, 10q24-qter, 11p, 13q, 22 +  7/-10 M 38 >0.7
N185 lg-OA lg-A 1p11-31, 19q13.2-qter -1p/-19q F 23 >3.0
B264 lg-OA lg-OA 4q, 9p, 19q 7, 9q, 12p intermediate
B484 lg-OA lg-OA 1p, 19q -1p/-19q
B2018 lg-OA lg-OA 6q23-qter, 8p 8q, X other
B2864 lg-OA lg-OA 8 3, 6, 7 +  7/-10
B3922 lg-OA lg-OA 1p, 19q -1p/-19q
N3 hg-OA GBM 10, 16, 17, 20, 22 1p, 7, 12q14-21c +  7/-10 F 59 t0 .7
N4 hg-OA GBM 1q31, 1q41-qter, 10, 16p, 22 1q11-25, 1q32, 5, 7c, 18, 20 +  7/-10 M 62 t2 .0
N 44c hg-OA GBM 10, 16 7 +  7/-10 F 69 t0 .0 4
N 51c hg-OA GBM 10, 13q, 17p 1q31-32c, 3q24-qterc, 7 +  7/-10 F 68 10.1
N65 hg-OA hg-OA 5p, 9p, 10 7qc, 7p, 7p11-13*, +  7/-10 F 49 t0 .4
N88 hg-OA GBM 9p, 10 7, 19, 20, X +  7/-10 M 67 t0 .0 4
N 96c hg-OA GBM 1p, 10, 11p, 11q13, 14q, 16, 17, 19 2q21-24, 4p14-qter, 6q, 7 intermediate F 78 t0 .4
N101 hg-OA hg-OA 9p, 10, 14q, 16q, 22 3q24-qter, 7, 7p11-13* +  7/-10 M 59 t0 .5
N 113c hg-OA GBM 4q, 5, 9p, 10q22-qter, 11p, 12q 12pc +  7/-10 M 48 t0 .5
N116 hg-OA GBM 9, 10, 16, 17 7p11-13*, 7c, 19, Xc +  7/-10 F 64 t0 .3
N124 hg-OA GBM 4q, 7p, 8pter-q21 10p other M 72 t0 .7
N127 hg-OA hg-OA 1pter-q25, 2p, 3, 6, 7p, 8p, 9p, 10p, 
10q24-qter, 11p14-pter, 12p, 13q, 
14q24-qter, 16, 21
4q, 7q, 8q, 9q, 11q14-qter, 
12q13-15, X
intermediate M 54 >0.7
Table 5-1 (2).
Chromosomal imbalances detected by CGH  in oligo-astrocytic tumors and corresponding clinical characteristics.
Tumor Histopathological 
diagnosis 
relaxed strict
CG H  losses CG H  gains CGH-subtype Sex Age Survival
N128 hg-OA hg-OA 4p, 5q, 7p, 12q21-qter, 13q, 14q, 3, 4q, 5p14-pter, 9p*, 10p, 16, other F 67 >6.2
17p, 18p, 19p, 20p, X 17q, 18q11-12
N158 hg-OA GBM 2, 8, 10, 13q14-31, 14q, 15q 7, 12q13-15, 19, X +  7/-10 M 55 f  1.0
N161 hg-OA GBM 6q, 9p, 10 7, 7pc, 7p11-14* +  7/-10 F 58 f  1.5
N167 hg-OA hg-OA 1p, 6q16-qter, 11p13-pter, 17p, 18 
19q
, 11q14-qter -1p/-19q M 48 >0.6
N182 hg-OA GBM
l9q
1p11-31, 10q24-qter, 14q, 7, 11, 17q22-qterc, 19q11-13.1 intermediate F 26 >0.5
19q13.2-qter
B108 hg-OA hg-OA 1p, 19q X -1p/-19q
B220 hg-OA hg-OA 1p, 15q, 19q -1p/-19q
B232 hg-OA hg-OA 1p31-pter, 19q 11 -1p/-19q
B294 hg-OA hg-OA 10, 15q 7, 12q13-22* +  7/-10
B520 hg-OA hg-OA 13q 1q21-24, Xc other
B552 hg-OA hg-OA 4q13-21, 9p, 13q14-21, other
14q22-qter, Xp
B560 hg-OA hg-OA 1p, 4, 9p, 19q 5, 11p, 11qc -1p/-19q
B562 hg-OA hg-OA 4q 10p* other
B572c hg-OA hg-OA 4p14-q21, 9p, 13q13-31, 18 16p, 17p, 19q other
B606 hg-OA hg-OA 1p, 4, 19q 5, 7q22-qter, 11 intermediate
B3786 hg-OA hg-OA 3p21-pter, 6p, 8, 9p, 10, 11, 1q31-41, 1q32c, 7, 7p11-13*, +  7/-10
12q21-qter, 13q, 15q 19p, X
O A  =  ■oligo-astrocytoma; lg- = low-grade; hg- =  high-grade. To avoid controversy about the delineation of OAs from As and Os, both a 1relaxed" and
a "strict" histopathological approach was used as described in Materials and Methods; c =  clear copy number changes, ratio more than 1.4 or less than
*
.6;0. =  high copy gain, ratio > 1.6; c =  X-chromosome not analyzable due to sex-mismatch during CGH  experiment; Sex: M =  male, F= female; Age
ega= at surgery; Survival: >  = still alive, y =  years, f  =  dead. Tumors were genetically subtyped as either "-1p/-19q" (loss of 1p (-1p) and/or -19q
without -10 and +7), " +  7/-10" 1[-10 and/or a gain of 7 (+7) without -1 p and -19q), "intermediate" (combination of -1p or -1 9q and -10 or +7 ) or as
"other" (absence of -1p, -19q, +7 , and -10).
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M aterials a n d  M ethods
Surgical specimens of the tumors selected fo r the present study were obtained 
from patients treated at the Department of Neurosurgery at the U M C  St Radboud 
in N ijmegen and the St. Elizabeth Hospital in Tilburg(N-numbers), and the 
University Hospital in Bonn, (B-numbers) (table 5-1). During surgery part of the 
tum or was snap-frozen in liquid nitrogen and stored at -80°C.
Hematoxylin and eosin-stained paraffin sections of the tumors were examined 
by two experienced neuropathologists (AvD, PW). The tumors showed both 
unambiguous astrocytic differentiation and more o r less prom inent 
o ligodendrog lia l features. Both a "strict" and a "relaxed" approach were used for 
recognition of o ligodendrog lia l differentiation. In the "strict" approach, the 
diagnosis of mixed oligo-astrocytoma required that at least 25%  of the tum or is 
composed of monotonous cells with small round nuclei surrounded by prom inent 
c lear perinuc lear halo's and an associated "chickenwire" pattern of delicate 
capilla ry blood vessels. For the "relaxed" approach, the diagnosis of 
o ligodendrog lia l differentiation was based on the presence of a substantial 
number of tum or cells showing a relatively monotonous, small, round nucleus, 
no eosinophilic perinuc lear cytoplasm o r eosinophilic cell processes, and with at 
least some perinuc lear halos. In analogy with the O s in ou r previous study as 
described in chapter 3 [53], tumors were divided into low-grade and high-grade 
oligo-astrocytic tumors (lg-OAs, and hg-OAs respectively). Tumors were 
designated as hg-OA when three o r more of the fo llow ing five criteria were 
present: high cellularity; nuclear pleomorphism; brisk mitotic activity 
(>10 /2m m 2); florid m icrovascular proliferation; necrosis. Some tumors 
considered as lg-OA in the relaxed approach were diagnosed as anaplastic 
astrocytoma (a-A) in the strict approach, because fo r astrocytic tumors the 
presence of nuclear pleomorphism and mitotic figures (even if they are rare) 
requires a diagnosis of a-A rather than low-grade astrocytoma (lg-A)[27]. Oligo- 
astrocytic tumors with histopathological signs of high-grade malignancy 
including necrosis are sometimes designated as glioblastoma multiforme with 
o ligodendroglia l differentiation (GBM-O). Such tumors were included in the 
present study and are classified as hg-OAs. A ll tumors diagnosed as lg-OA 
(n =  11) o r hg-OA (n=28) according to the "relaxed" approach were included for 
analysis in the current study.
Com parative genom ic hybridization (CGH) was performed as described in 
chapter 2. Briefly, tum or and reference D N A  were differentially labeled with 
biotin and digoxigenin, respectively. The CGH-probe and metaphase spreads 
were denatured simultaneously and hybridization was performed for 3 days. 
Streptavidin-FITC and sheep-anti-digoxigenin-TRITC were used fo r detection. 
Standard thresholds fo r gains (1.2) and losses (0.8) were used. Aberrations with 
a ratio less than 0.6 o r la rger than 1.4 were called clear copy number changes 
whereas a ratio la rger than 1.6 was called a high copy number gain.
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Table 5-2.
Frequency of chromosomal imbalances and different genetic subtypes in oligo-astrocytomas
as detected by CGH.
lg-OAs
relaxed
n=11
strict 
n =  6
hg-OAs 
relaxed 
n =  28
strict 
n =  16
OAs 
relaxed 
n =  39
strict
n = 2 2
Chromosomal aberrati
loss 1p
on
27% 33% 32% 44% 31% 41%
gain 7p 18% 33% 50% 25% 41% 27%
gain 7q 27% 50% 57% 31% 49% 36%
loss 9p 18% 17% 39% 44% 36% 36%
loss 10p 0% 0% 50% 31% 41% 23%
loss 10q 9% 0% 57% 31% 41% 23%
loss 13q 18% 0% 29% 37% 26% 27%
loss 19q 36% 50% 28% 37% 31% 41%
Genetic subtype
"-1p/-19q" 27% 33% 18% 31% 20% 32%
"intermediate" 9% 17% 14% 13% 13% 14%
" +  7/-10" 27% 33% 46% 25% 41% 27%
"other" 36% 17% 21% 31% 26% 27%
O n ly  chromosomal imbalances detected in 35% or more of the oligo-astrocytomas in at least 
one specific category are shown. Tumors were histopathologically classified by a "strict" and a 
"relaxed" approach as described in Materials and Methods. Abbreviations: OAs =  oligo- 
astrocytomas; lg-OAs =  low-grade oligo-astrocytomas; hg-OAs =  high-grade oligo- 
astrocytomas; n =  number of tumors.
Results
The presence of o ligodendroglia l differentiation in this group of tumors was 
assessed by both "relaxed" and "strict" approaches (table 5-1). A ll tumors 
diagnosed as O As according to the "relaxed" approach (1 1 lg-OAs and 28 
hg-OAs) are included in the study. Using the "strict" approach, 6 tumors were 
classified as lg-OA and 16 as hg-OA. The chromosomal imbalances detected by 
C G H  are summarized in table 5-1 and visualized in figure 5-1. O f  all patients 
biopsied in N ijmegen and Tilburg, information about sex, age, and survival was 
ava ilab le; this information is included in table 5-1.
Chromosomal imbalances that were relatively frequently detected are 
summarized in table 5-2. Loss of 1p and 19q are detected in one third of both 
lg-OAs and hg-OAs. Loss of 9p, 10, 13q and a gain of 7 were detected more 
frequently in hg-OAs than in lg-OAs. The mean number of aberrations was 
h igher in hg-OAs than in lg-OAs (7.4 versus 3.4 , respectively) but the difference 
was not significant (SD =  4.6 versus SD =  1.4, respectively), and a wide range in 
the number of detected imbalances was found (2 to 6 for lg-OAs and 2 to 19 for
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hg-OAs). The frequencies of the detected chromosomal imbalances using either 
the "strict" o r the "relaxed" approach fo r the classification of OAs were compared 
(table 5-2). The OAs examined in this study were subtyped on the basis of the 
C G H  results as "-1p/-19q" (characterized by a loss of chromosome 1p and/or a 
loss of 19q) o r as " +  7/-10" (characterized by a gain of chromosome 7 and/or a 
loss of chromosome 10 w ithout a loss of 1p and w ithout a loss of 19q). Two 
additional genetic subtypes were also detected. Tumors containing a 
combination of -1p o r -19q and + 7  o r -10 were classified as "intermediate" and 
tumors lacking any of these aberrations were classified as "other". In table 5-1 
the different genetic subtypes are given for the individual tumors and in figure 5 ­
1 the subtypes are indicated. Table 5-2 shows the distribution of genetic subtypes 
among lg-OAs, hg-OAs, and O As overall, using either the "relaxed" o r "strict" 
approach for classification of OAs.
D isc u ss io n
From a clinical point of view, the distinction between O s  and OAs is probably 
not as important as the distinction between As and OTs (including both O s  and 
OAs), because O As have been reported to show a sim ila r responsiveness to 
radiotherapy and chemotherapy to that of pure O s [27,124]. Some investigators 
believe that O As are frequently misclassified as As[29]. It has also been noted that 
patient survival worsens with increasing astrocytic component[22]. In o rder to 
examine the question of whether O As comprise a genetically heterogeneous 
group of tumors with sim ilarities to Os, As, o r both, we screened the genome of 
O As fo r chromosomal imbalances using CGH.
The purpose of this study was to define the genetic alterations associated with 
O As and then compare them to those previously detected by us in O s [53] (chapter 
3). In the present study, both a "strict" and a "relaxed" histopathological approach 
were used fo r the recognition of o ligodendrog lia l differentiation, the rationale for 
the latter being the desire not to miss patients that could benefit from 
chemotherapy.
Chromosomal imbalances in OAs
M ultip le LOH studies analyzing chromosome 1p and 19q in O As have been 
performed[17'22,30,31]. In these studies the frequency of LOH 1p ranged from 
19%[21] to 100% [20], whereas LOH  19q ranged from 14%[30] to 75%[18'22]. O n  
average, LOH  1p and 19q were detected in approximately half of the tumors. In 
the present study -1p and -19q were each detected in about 30% of the OAs 
selected according to the "relaxed" criteria; the percentage increased to 
approximately 40% when "strict" criteria fo r selection were applied. Problems with 
unequivocal histopathological delineation of O As m ight account fo r the wide 
range in genetic aberrations discussed above. In addition, C G H  only detects 
copy number changes of chromosomal regions la rger than 2-5 M b  (chapter 2).
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LO H 17p  has been reported to  be present in approx im ate ly  30%  o f both lg -O A s 
and h g -O A s [21,22]. W e detected loss o f 17p  in none o f the lg -O A s and in 21%  o f 
the hg-O As. The low er incidences o f -1 7 p  detected by C G H  com pared  to  LOH 
17p  may be exp la ined by dup lica tion  o f the rem ain ing  a lle le  due to  m ito tic 
re com b ina tion [125], o r losses m igh t be to  sm all to  be detected by C G H [43]. LOH 
9p  has been reported to  be involved in the transition  o f low -g rade  astrocytom as 
(lg-As) to  anap lastic  astrocytom as (a-As)[2,7]. W e detected -9 p  m ore frequently in 
hg -O A s than in lg -O A s. As discussed in o u r study o f O s [53](chapter 3 ), it rem ains 
to  be de term ined if -9p  in lg -O A s can be considered as an early m arker fo r 
m a lignan t progression. A lthough  no differences were detected fo r  the 
frequencies o f -9p  and -1 3 q  using e ither the "strict" o r  "relaxed" h is topa tho log ica l 
app roach  fo r  d iagnosis o f O A s, a h igher percentage o f tum ors w ith -1p  o r  -19q  
(both 41%  versus 31%) and a low er percentage o f tum ors w ith + 7  (7p: 27%  
versus 41%) o r -1 0  (23% versus 41% ) were identified by the "strict" approach .
Genetic subtyping of OAs
W e recently reported tha t pure o lig o d e n d ro g lia l tum ors can be subtyped in 
tw o categories on the basis o f C G H : "-1 p /-1 9 q " (all low -g rade  and 50%  o f the 
h igh -g rade  tum ors) and "+ 7 / -1 0 "  (50% o f the h igh -g rade  tum ors)[53] (chapter 3). 
O A s show a m ore heterogeneous pattern. A p a rt from  the " -1 p /-1 9 q " and 
"+ 7 / -1 0 "  g roups, tw o ad d ition a l genetic subtypes were identified: "in term ediate" 
(conta in ing  a com b ina tion  o f -1 p /-1 9 q  and + 7 / -1 0 )  and "other" (w ithout -1p , 
-1 9 q , + 7 ,  o r -10). As -1p  and -1 9 q  are reported to  be early events whereas + 7  
and -1 0  are late events in g lio m a  oncogenesis[2,7,53] this suggests tha t 
"in term ediate" tum ors represent progression o f " -1 p /-1 9 q " tum ors th a t acqu ire  
+  7 a n d /o r  -1 0  during  m a lignan t progression (further analyzed in chap te r 6). 
O ve ra ll, 36%  o f the lg -O A s and 32%  o f the hg-O As selected by the "relaxed" 
h is topa tho log ica l app roach  are tum ors con ta in ing  -1 p  a n d /o r  -1 9q .
The genetic subtype " -1 p /-1 9 q " was previously defined as a tu m o r tha t exhibits 
a loss o f 1 p 3 2 -3 6  a n d /o r  19q 13 .3 -q te r[53] (chapter 3) based on previously 
reported LO H analysis and tw o tum ors, N 1 3 2  (hg -O : -1 p 1 3 -3 1 , -1 0 , and + 7 ) 
and E168 (xenografted G B M : + 7  and -1 9 q 1 1 -1 3 .2 ) [53,86]. The la tter tw o  tum ors 
were classified as "+ 7 / -1 0 " .  However, since the "interm ediate" subtype was 
identified in the present study, N 1 3 2  and E168 m ight m ore accurate ly be 
classified as "in term ediate" tum ors, and "-1 p /-1 9 q " tum ors m ight be better 
defined as tum ors sim ply characterized by losses invo lv ing 1p a n d /o r  19q. The 
"+ 7 / -1 0 "  subtype was detected in 27%  o f the lg -O A s and 46%  o f the hg-O As. 
For hg-O A s, and O A s in genera l, the frequency o f "-1 p /-1 9 q " increases and the 
frequency o f " +  7 /-1 0 "  tum ors decreases when the "strict" h is topa tho log ica l 
criteria  are used. Even in the O As selected by ap p lica tio n  o f "strict" 
h is topa tho log ica l crite ria , " -1 p /-1 9 q " was detected at a low er frequency than fo r 
the O s  exam ined in o u r previous study[53] (50%  o f the lg -O A s versus 100%  
lg -O s , and 44%  hg -O A s versus 50%  hg-O s) (chapter 3).
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Figure 5 -1 . Summary o f all chrom osom al im balances detected by C G H  in low -grade o ligo - 
astrocytic tum ors (lg-OAs) and h igh-grade o ligo-astrocytic tum ors (hg-OAs). Lines on the left 
and right o f the chrom osom e indicate losses and gains o f these chrom osom al regions, 
respectively. C hrom osom al aberrations crossing the 0 .8  o r 1.2 threshold are indicated by a 
thin line, while  c lear copy num ber changes crossing the ratios 0 .6  and 1.4 are ind icated by a 
heavy lin e . H igh copy gains, w ith a ratio  la rge r than 1.6, are indicated by an add itio na l spot 
on a bar. Tumors are genetically subtyped as either "-1 p /-1 9 q " (harboring a loss involving 1p 
a n d /o r 19q w ithout a loss on 10 and w ithout a gain on 7), " +  7 /-1 0 " (harboring a loss on 10 
a n d /o r a gain on 7 w ithout a loss o f 1p and w ithout a loss o f 19q), "intermediate" (harboring 
a loss o f 1p a n d /o r  a loss o f 19q in com bina tion  w ith a loss on 10 a n d /o r a gain on 7) o r as 
"other" (tumors not harboring loss o f 1p, loss of 19q, loss o f 10 o r a gain on 7). For co lo r 
im age see page 188 and the orig ina l pub lica tion.
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The rem a inder o f the O A s (36% o f the lg -O A s and 21%  o f the hg-O As) 
exhib ited none o f these aberra tions and was classified as "other", suggesting tha t 
one o r  m ore a d d ition a l genetic pathway(s) m ight exist fo r  O As. W e were unable  
to  detect a com m on abe rra tion  present in all "other" tum ors, but loss o f the 
ch rom osom a l regions 4 q 1 3 -2 1 , and 1 3 q 1 4 -1 5 , and a ga in  o f 10p  (includ ing a 
h igh copy o f 10p) were detected most frequently. Loss o f chrom osom e 4 has 
previously been reported to  be involved in a sm all frac tion  o f o lig o d e n d ro g lia l 
tum ors [83]. In a d d ition , gains involv ing chrom osom e 16 were only detected in 
"other" O A s but not in any o f the "-1 p /-1 9 q ", "in term ediate", o r " +  7 /-1 0 "  O A s, 
n o r in o u r previously analyzed O s [53] (chapter 3). A lternative ly , ra ther than 
representing an ad d ition a l genetic pathw ay, these "other" tum ors m igh t ha rbo r 
aberra tions invo lv ing 1p, 19q , 7, o r  10  which are to  sm all to  be detected by 
C G H  (<  2 -5  M b  (chapter 2)).
G ene tic  heterogeneity o f O A s has been previously repo rted [11,22]. A t least 2 
d iffe ren t genetic pathways have been proposed: 1) O A s presum ed to  be 
genetica lly  related to  O s and characterized by LO H 1p and 19q (50%  O A s), and 
2) O A s presum ed to  be genetica lly  related to  As and characterized by LO H 17p 
o r  TP53 m utations (25% O A s)[11,22]. Tum ors con ta in ing  a com b ina tion  o f these 
a lte ra tions were in frequently de tected [22,32]. W e detected a loss o f 17p  by C G H  in 
15%  o f the "-1 p /-1 9 q " o r  "in term ediate" O A s, in 19%  o f the " +  7 /-1 0 "  O A s, and 
in 10%  o f the "other" O As . As discussed above, C G H  and LOH data fo r 
ch rom osom e 17 analysis are not d irectly com pa rab le  due to  m ito tic 
re com b ina tion [125]. It is therefore not c lea r if o u r subtyping is ove rlapp ing  w ith the 
one previously reported.
Prognostic relevance and interrelationship between histology 
and genetic subtyping
G enetic  subtyping may have p rognostic  and therapeu tic  im p lica tions [16,53]. For 
hg -O s  it has been reported tha t " + 7 / -1 0 "  tum ors show a tendency fo r  shorter 
survival com pared  to  " -1 p /-1 9 q " tum ors, and some o f them  show a survival 
w hich is much longer than reported fo r  G B M s[53] (chapter 3). In o u r g roup  o f 
O A s, "+ 7 / -1 0 "  hg -O A s also show a tendency fo r shorte r survival com pared  to  
" -1 p /-1 9 q " hg-O A s, and the survival o f the " +  7 /-1 0 "  hg-O As is com parab le  to  
th a t reported fo r  G B M s[13]. Due to  the re latively sm all num ber o f patients, no firm  
conclusions can be draw n a b o u t the survival o f patients w ith "in term ediate" O A s; 
however, if it is true tha t "in term ediate" O A s progress from  "-1 p /-1 9 q " tum ors, a 
shorte r survival it is to  be expected com pared  to  "-1 p /-1 9 q " OAs.
Recently, C airncross et al. reported LO H 1p to  be a s ign ifican t p red ic to r o f 
chem osensitiv ity in O s , whereas the com b ina tion  o f LO H 1p and LO H 19q was 
strongly associated w ith longer overa ll surviva l[16]. Such in fo rm ation  cou ld  be 
useful fo r  trea tm ent o f patients w ith O As. If LO H 1 p is also predictive fo r 
chem osensitiv ity in O A s, both the " -1 p /-1 9 q " and "in term ediate" subtypes m ight 
be chem osensitive. Since C a irncross[16] reported chem osensitivity in 5 o f the 8
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tum ors con ta in ing  LO H 10q it is unlike ly tha t -1 0q disrupts the expected 
chem osensitiv ity as ind icated by -1p . C airncross et al. reported no data on the 
chem osensitivity o f tum ors con ta in ing  + 7 [16].
As was to  be expected, som e o f the O A s identified by the "relaxed" 
h is topa tho log ica l app roach  were reclassified as astrocytic tum ors when the "strict" 
app roach  was app lied  and app lica tion  o f the "strict" app roach  results in a h igher 
frequency o f tum ors con ta in ing  -1 p a n d /o r  19q com pared  to  the "relaxed" 
app roach . However, som e tum ors con ta in ing  -1 p a n d /o r  -1 9q are excluded 
from  the g roup  o f o lig o d e n d ro g lia l tum ors under the "strict" h is topa tho log ica l 
criteria  and may there fore  not be included in chem otherapy pro toco ls fo r 
o lig o d e n d ro g lia l tum ors. It w ou ld  be interesting to  know w hether As and G BM s 
w ith a loss o f 1p detected by C G H  ([78,79,84]and references therein) w ou ld  be 
classified as O A s using m ore "relaxed" h is topa tho log ica l criteria  fo r  recogn ition  
o f o lig o d e n d ro g lia l d iffe ren tia tion .
In c o n c l u s io n
O u r  results show tha t O As are genetica lly  m ore heterogeneous than O s ; apa rt 
from  the " -1 p /-1 9 q " and "+ 7 / -1 0 "  subtypes previously detected in O s, 
"in term ediate" and "other" subtypes were identified. Since "in term ediate" O As 
p robab ly  progress from  "-1 p /-1 9 q " tum ors, both genetic subtype represent the 
same genetic pathw ay as opposed to  " + 7 / -1 0 "  tum ors. The "other" subtype 
appears to  represent an ad d ition a l genetic  pathway(s) fo r  O As. Using "strict" as 
opposed to  "relaxed" h is topa tho log ica l crite ria  fo r  the recogn ition  o f O A s results 
in the selection o f a h igher percentage o f tum ors con ta in ing  -1p  a n d /o r  -1 9 q , 
but som e o f these tum ors are not recognized as (partly) o lig o d e n d ro g lia l by the 
"strict" criteria . These results serve to  underscore the increasingly prevalent 
sentim ent tha t m o lecu la r genetic analysis is a pow erfu l too l fo r  the classification 
o f g liom as th a t com plem ents the tra d itio n a l h is topa tho log ica l app roach  and may 
provide essential in fo rm a tion  fo r  the op tim a l c lin ica l m anagem ent o f patients 
w ith these tum ors.
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A bstract
W hile  know ledge a b o u t the genetic basis o f m a lignan t progression in 
astrocytic tum ors (As) is rap id ly  increasing, progression o f o lig o d e n d ro g lia l 
tum ors (OTs), inc lud ing  both pure o lig o d e n d ro g lio m a s  (Os) and mixed o ligo - 
astrocytom as (OAs), is still poorly  understood. The present study aim s at 
e luc ida tion  o f the ch rom osom al im balances involved in (m alignant) progression 
in OTs. Using com para tive  genom ic hybrid ization (C G H ) on snap frozen tu m o r 
tissue, the tu m o r genom e o f 5 O Ts and th e ir recurrences was screened fo r 
ch rom osom al im balances. This in fo rm a tion  was corre la ted  w ith c lin ica l data 
(includ ing fo llo w  up) and h is topa tho log ica l m a lignancy grade. In a ll cases an 
increase in ch rom osom al im balances was detected in the recurrent tum or, 
ind ica ting  progression from  a genetic po in t o f view. In 3 o f the 5 cases this 
corre la ted  w ith m a lignan t progression at the h is topa tho log ica l level. O u r  results 
strongly ind ica te  tha t, like in As, ch rom osom al im balances ha rboring  genes 
involved in the cell p ro life ra tion  con tro l m echanism  at the G1 -S bo rde r are 
involved in progression o f OTs. A dd itio n a lly , w hile  + 7  and -1 0  are most 
frequently detected in the course o f m a lignan t progression o f As, + 7  a n d /o r  - 1 0  
can also o ccu r du ring  m a lignan t progression o f typ ica l OTs con ta in ing  losses 
invo lv ing 1p a n d /o r  19q. In sum m ary, C G H  on op tim a lly  preserved m ateria l o f 
a sm all set o f prim ary OTs and the ir recurrences indicates ch rom osom al 
aberra tions tha t po ten tia lly  p lay a m echanistic role in m a lignan t progression o f 
these tum ors.
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In t r o d u c t io n
Based on the ir h is topa tho log ica l appearance , the m ajority  o f g liom as can be 
classified as astrocytic tum ors (As) o r o lig o d e n d ro g lia l tum ors (OTs), the la tter 
inc lud ing  both pure o lig o d e n d ro g lia l (Os) and mixed o ligo -astrocytic  tum ors 
(OAs). Because o f th e ir tendency to  d iffusely in filtra te  the preexistent bra in  tissue 
and th e ir resistance to  rad ia tion  and chem otherapy, these tum ors genera lly  recur 
a fte r surg ica l trea tm ent and ad d ition a l therapy. The recurrent tu m o r often shows 
m a lignan t progression from  a h is topa tho log ica l and c lin ica l po in t o f v iew [2,126]. 
There is increasing evidence th a t this phenom enon reflects the sequentia l 
accum u la tion  o f genetic a lte ra tions (for review see|127]). Identifica tion  o f these 
events and o f th e ir role in m a lignan t progression is essential fo r  understanding 
the evo lu tion  o f g liom as and is im portan t fo r  ra tiona l the rapeu tic  approaches at 
the m o lecu la r level. M ost studies o f this phenom enon in g liom as focussed on As 
and genetic m odels fo r  tu m o r progression have been suggested (for reviews 
seel1'7'10'128' 130!). M a lig n a n t progression in OTs, however, is still poorly 
understood, partly because techniques were used revealing only in fo rm ation  
a bou t the reg ion o r  gene o f interest. Loss o f heterozygosity analysis (LOH) 
revealed tha t LO H 1p and LOH 19q are early events in the oncogenesis o f these 
tum ors (for reviews see11,8,10,128'). A dd itiona lly , it was proposed tha t m a lignan t 
progression in OTs m ight be accom pan ied  by losses on chrom osom e 9 p  and 
10, and EGFR a m p lif ica tio n 121,33'. In a previous study com para tive  genom ic 
hybrid ization (C G H ), a m o lecu la r cytogenetic techn ique th a t a llow s screening o f 
the entire tu m o r genom e fo r  ch rom osom al im balances in a s ingle experim ent, 
detected loss on 1p a n d /o r  19q in all pure low -g rade  O s  (lg-O s) and in ha lf o f 
the pure h igh -g rade  O s  (hg-O s) whereas the o the r ha lf o f the hg -O s con ta ined  a 
loss on 10 and a ga in  on 7 |53] (chapter 3). A  com b ina tion  o f these aberra tions 
was occas iona lly  detected in O T s126,32,83,123,131'. To ge t a better insight in the 
aberra tions involved in m a lignan t progression o f O Ts, we perfo rm ed C G H  on 5 
OTs and the ir recurrent tum ors.
M aterials a n d  M ethods
Tum ors specimens were ob ta ined  from  patients treated at the D epartm ents o f 
N eurosurgery o f the University M ed ica l C en te r St R adboud, and o f the C anisius 
W ilhe lm ina  H osp ita l, N ijm egen , The N etherlands. D uring surgery, part o f the 
tu m o r was snap-frozen in liqu id  n itrogen and stored a t -8 0 ° C . Patient 5 
underw ent surgery fo r an O A  fo u r tim es but snap-frozen tissue was on ly ava ilab le  
from  the 3 rd  (lg -O A) and 4 th  biopsy (hg-O A ). In this paper, we w ill regard these 
samples as prim ary and recurrent tum or. H em atoxylin  and eosin-sta ined (H&E) 
paraffin  sections o f the tu m o r were exam ined by an experienced 
neu ropa tho log is t and classified acco rd ing  to  the W H O -2 0 0 0 127'. O Ts w ithou t 
p rom inen t astrocytic d iffe ren tia tion  (less than 5% o f the tu m o r cells) were
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d iagnosed  as pure O s, whereas tum ors con ta in ing  m ore p rom inen t astrocytic 
features were classified as O As. Tum ors were d iagnosed as a h igh -g rade  tu m o r 
if a t least three o f the fo llo w in g  criteria  were present; high ce llu la rity , nuclear 
po lym orph ism , m arked m ito tic  activity (> 1 0 /2 m m 2), necrosis, and flo rid  
m icrovascu la r p ro life ra tion .
C om para tive  G e n o m ic  H ybrid ization (CG H) was perfo rm ed as described in 
chap te r 2.
The tum ors were subtyped as " -1 p /-1 9 q " (conta in ing  a loss on 1p a n d /o r  
19q), " +  7 "/-1 0 " (characterized by a ga in  on 7 a n d /o r  a loss on 10 but w ithou t a 
loss on 1p o r 19q), "in term ediate" (conta in ing  a loss on 1p a n d /o r  19q in 
com b ina tion  w ith a ga in  on 7 a n d /o r  a loss on 10), o r  "other" (tumors w ithou t 
the previously m entioned aberrations) based on o u r previous C G H  studies on 2 9  
pure O s |53] (chapter 3) and 39  mixed O A s |131] (chapter 5).
RESULTS
The c lin ica l and h is topa tho log ica l da ta  are sum m arized in tab le  6 -1 . Since 
astrocytic features were not p rom inen t in 1a, 1b, 3 a , and 3 b , these tum ors were 
classified as O s  whereas tum ors 2 a , 2 b , 4 a , 4 b , 5 a , and 5 b , were classified as 
O As. A ll p rim ary tum ors and the recurrent tum ors o f patien t 1 and 2 were 
d iagnosed as low -g rade  tum or. The o the r three recurrences were classified as a 
h igh -g rade  tu m o r because (in contrast to  the prim ary tum or) they showed 
m arked nuc lear po lym orph ism  (3b), m ore than 10 m itoses /2m m 2 (3b and 4b), 
necrosis (4b and 5b), a n d /o r  flo rid  m icrovascu la r p ro life ra tion  (4b and 5b). 
Representative areas o f the H&E stained para ffin  sections o f a ll p rim ary and 
recurrent tum ors are shown in figu re  6-1 . A dd itio n a lly , the ch rom osom al 
im balances fo r  chrom osom e 1, 7, 10 , and 19 as detected by C G H  are 
visualized in this figure . The ch rom osom al im balances detected by C G H  are 
sum m arized in tab le  6-1 and visualized per case in figu re  6 -2 . The genetic 
subtyping o f the tum ors is a lso ind icated in tab le  6 -1 .
Figure 6 -1 . H istology and chrom osom al im balances fo r chrom osom e 1, 7, 10, and 19 o f all 
prim ary and recurrent tum ors. Hematoxylin and eosin stainings are shown. Num bers in the 
circles indicate the case num ber. H isto logica l features indicated by arrows: 1a : calcium  
deposition ; 2a  :  m icrocystic change; 3 b  :  mitoses; 4a  :  entrapped neuron; 4b  :  necrosis; 5b :  
flo rid  m icrovascular pro life ra tion . C hrom osom al im balances fo r chrom osom e 1, 7, 10, and 
19 are shown. The chrom osom e num ber is shown under the ideogram  o f the chrom osom e. 
Imbalances are ind icated by lines on the left and right o f the chrom osom e ideogram  ind icating 
losses and gains o f these chrom osom al regions respectively.
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O ve ra ll, C G H  detected 2 3  aberra tions (17 losses and 6 gains) in the prim ary 
tum ors and 54 aberra tions (36 losses and 18 gains) in the recurrent tum ors. 
A lthough  the m ajority  o f the aberra tions detected in the prim ary tum ors was also 
detected in the recurrent tum ors, som e aberra tions (ind icated in italics in tab le  6 ­
1) were no t present in the correspond ing  recurrent tum or. In a d d ition , all 
recurrent tum ors harbored newly acqu ired  ch rom osom al im balances. In the 
prim ary tum ors, some o f these aberra tions (underlined in the table) were a lready 
ind ica ted , but fo r  these aberra tions the thresholds were not crossed. In figure  
6 -3 , fo r  one coup le  o f p rim ary and recurrent tum or, representative exam ples o f 
ra tio -p ro files o f such aberra tions and the correspond ing  standard devia tion  
(1 2 -1 5  exam ples o f each chrom osom e were analyzed) are shown.
Figure 6 -2 . Summary o f all 
chrom osom al im balances detected 
by C G H . Lines on the left and right of 
the chrom osom e indicate losses and 
gains o f these chrom osom al regions 
respectively. A  thin line indicates 
aberrations crossing the 0 .8  o r 1 .2  
threshold, whereas a heavy line 
indicates clear copy num ber changes 
crossing the ratios 0 .6  and 1 .4. 
Aberrations in the prim ary tum ors are 
shown in discontinuous lines whereas 
those detected in the recurrent 
tum ors are shown in continuous lines. 
Primary tum ors and recirrences are 
ind icated by an a and b respectively.
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Table 6 -1 .
C lin ica l characteristics and chrom osom al im balances as detected by C G H  in prim ary o ligodendrog lia l tum ors and the ir recurrence.
Patient
(sex)
Nr.. Age Kar­
nof.
Post-
O K
Survi­
val
In te r­
val
W H O -
grade
C G H  losses C G H  gains num ber o f C G H - 
changes subtype
N-N R
1 (F) 1 a 3 7 .9 1 0 0 RT >  10.3 7.5 lg -O 1p, 15q, 19p, 19qc, 22 11, 1 7 q 21 -2 4 7 -1 p /-1 9 q N 2 1 0
1 b 4 5 .4 90 Chem >  2 .8 lg -O 1o, 2 a 34-a te r, 4o , 12o, 11, 1 7 q 21 -2 4 11 -1 p /-1 9 q N 78
14a24-a te r, 15q, 18,
19q, 22
2 (F) 2 a 4 8 .7 1 0 0 - t  6 .4 5 .8 lg -O A 3q11-24 7q31-q te r, 12p 3 +  7 /-1 0 N 260
2 b 5 4 .4 70 - t  0 .6 lg -O A 4 q 1 3 -2 4 , 5 q 3 1 , 9p, 10, 5p te r-q23 , 7 p 1 1 -1 5 , 15 +  7 /-1 0 N 123
1 3 q 1 1 -3 1 , 1 4 q 11 -2 4 , 7q31-q te r, 8 q, 12p,
18p, 13q31-q te r, 14q24-q te r,
17q22 -q te r
3  (F) 3a 4 6 .5 1 0 0 - >  5.1 1 .6 lg -O 1p, 9p, 19q 3 -1 p /-1 9 q N 43
3b 48.1 90 Chem
RT
>  3 .5 hg -O 1p, 9p, 19q, 2 2 , X 5 -1 p /-1 9 q N 46
4 (M) 4a 2 5 .5 1 0 0 t  3 .0 2 .3 lg -O A 3 p 2 1 -q 2 1 , 11p14-p te r, 8p22-qfer, 9 8 -1 p /-1 9 q N 263
1 1 q 1 4 -2 4 , 1 2 q 21 -2 3 ,
19q13 , 2 2 q 1 3
4b 2 7 .8 70 RT t  0. 7 h g -O A 3 p 2 1 -q 2 1 , 10, 11p14 - 1, 8 q, 9p, X 14 interm ediate N 162
pter, 11q14-q te r, 12p, -1 p /-1 9 q
1 2 q 2 1 -2 3 , 13q11 -
3 1 ,1 9 q 1 3 , 2 1 , 2 2 q
5 (F) 5a 23.1 90 - >  3 .6 2 .5 lg -O A 1 p 1 1 -3 1 , 19q13 .2 -q te r 2 -1 p /-1 9 q N 185
5b 2 5 .6 60 RT >  1.1 h g -O A 1 p 1 1 -3 1 , 10q24-q te r, 7 , 1 1 , 17q22 - 9 interm ediate N 182
14q, 1 9 q 13 .2 -q te r qterc,19q11 -13 .1 -1 p /-1 9 q
Sex : F =  fem ale; M =  male ; Age = age at surgery in years; Karnof. =  karnofsky score p rio r to  surgery, 1 0 0  = norm al , no com pla ints, 90 =  able to
carry on norm al activities, m inor signs or symptoms o f disease, 70  =  cares fo r self, unable to  carry on norm al activities o r to  do active w ork, 6 0  =  
am bula tory, requires some assistance in activities o f da ily living and self-care; Post-OK =  Post-operative therapy : RT =  radiotherapy, Chem  =  
chem otherapy using PCV, - =  no ad juvant therapy; Survival: survival after surgery in years, >  =  still alive, f  =  dead, Interval : interval in years, 
M alignancy grade : lg- =  low -grade, hg- =  h igh-grade, O  =  pure o ligodend rog lia l tum or, O A  =  mixed o ligo-astrocytic tum or; c =  clear copy num ber 
changes, ratio  is 1.4 o r 0 .6 . Italics : aberrations only detected in the prim ary tum or. Underlined : ind ication o f this aberra tion  in the prim ary tum or 
w ithout crossing the threshold; N -N R  =  the orig ina l numbers o f the samples in the N ijm egen brain tum or co llection.
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Figure 6 -3 . Representative ratio-profiles 
in a prim ary (1 a) and the corresponding 
recurrent (1b) tum or. Lines on the left and 
right o f the chrom osom e ideogram  
indicate losses and gains respectively. A  
thin line indicates aberrations crossing the 
0 .8  o r 1 .2  threshold whereas a heavy line 
indicates c lear copy num ber changes 
crossing the ratios 0 .6  and 1 .4. 
Thresholds were set at 0 .8  and 1 .2 . The 
average ra tiopro file  o f 1 2 -15  analzed 
chrom osom es is shown. Note  that the loss 
o f 2 q 3 4 -q te r is a lready indicated in the 
prim ary tum or. Also note that w h ile  in the 
prim ary tum or loss o f both 19p and 19q 
was found, the recurrent tum or only shows 
a loss of 19q.
D isc u ssio n  
G enetic and histopathological progression in OTs
In o rd e r to  investigate ch rom osom al im balances involved in tu m o r progression 
o f OTs we analyzed 5 pairs o f p rim ary tum ors and th e ir recurrences by C G H . 
Because D N A  isolated from  para ffin  em bedded tissue is degraded  and cross­
linked du ring  fixa tion  (depending on the fixa tion  tim e and fixative used), we only 
used snap-frozen tu m o r sam ples to  exclude artifacts due to  differences in the 
processing o f para ffin  em bedded tissue between both biopsies o f a patient. In all 
cases an increase in ch rom osom al im balances was detected in the recurrent 
tum or, ind ica ting  progression from  a genetic po in t o f view  (genetic progression). 
Interestingly, some o f these aberra tions were a lready ind icated in the prim ary 
tu m o r but d id  not cross the thresholds, im ply ing th a t these aberra tions were 
present in only a lim ited percentage o f the cells o f the prim ary tum ors. Few 
aberra tions detected in the prim ary tu m o r were absent in the recurrent tum or. 
This may be caused by c lona l expansion o f a cell popu la tion  w ithou t this 
abe rra tion  o r  by sam p ling , as only a sm all portion  o f the tu m o r is analyzed by 
C G H . In 3 o f the 5 patients (3, 4 , 5) the recurrent tum ors showed 
h is topa tho log ica l features o f increased m alignancy com pared  to  the prim ary 
tum ors (h is topa tho log ica l progression). In pa tien t 1 an increase o f ch rom osom al 
im balances was found , however, no aberra tions reported to  be involved in the 
m a lignan t progression o f g liom as such as -9 p , + 1 2 q , - 13q , + 7 ,  o r -1 0 [84] (see 
a lso below) were acqu ired  in the recurrent tum or. C lin ica lly , this patien t is still 
a live  and well 2 .8  years a fte r the biopsy o f the recurrent tum or. So, 
h is topa tho log ica l, genetic, and c lin ica l investigation agree in d iagnos ing  the 
recurrent tu m o r o f this pa tien t as lg -O . In pa tien t 2 , on the o the r hand, 
h is topa tho log ica l progression was absent, but C G H  detected the accum u la tion  
o f aberra tions known to  be involved in m a lignan t progression o f g liom as (-9p, 
-1 3 q 1 1 -3 1 , + 7 p 1 1 -1 5 ) . Since this pa tien t d ied because o f tu m o r grow th 0 .6
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years a fte r the biopsy o f the recurrent tum or, this tu m o r may indeed have been 
m ore m a lignan t than expected by the h is topa tho log ica l d iagnosis. A dd itiona l 
genetic  analysis next to  h is topa tho log ica l exam ination  m ight have been useful in 
pred icting  m a lignan t progression, im ply ing shorte r survival.
Oncogenesis and genetic subtypes of OTs
In a previous C G H  study we found  th a t the 2 9  analyzed pure O s  cou ld  be 
subtyped as e ithe r " -1 p /-1 9 q " tum ors o r as " +  7 /-1 0 "  tum ors '53' (chapter 3). 
Recent C G H  analysis on 3 9  O A s revealed tw o ad d ition a l genetic subtypes, i.e. 
"in term ediate" (conta in ing  -1 p , a n d /o r  -1 9 q  in com b ina tion  w ith + 7  a n d /o r  -10) 
and "other" (tumors w ithou t -1 p , + 7 ,  -1 0 , o r  -1 9 q ) '131' (chapter 5). The OTs 
reported in o the r C G H  studies can a lso be subclassified acco rd ing  to  these 4 
genetic subtypes'26,32,83,123'. Because -1 p  and -1 9q are early events in the 
oncogenesis o f these tum ors, whereas + 7  and -1 0  are regarded as late events 
in g lio m a  oncogenesis '1'7'8'10'21'33'128' 130', we hypothesize tha t "in term ediate" 
o lig o d e n d ro g lia l tum ors progressed from  "-1 p /-1 9 q " tum ors. In the current study, 
we show th a t "in term ediate" tum ors indeed can progress from  "-1 p /-1 9 q " tum ors, 
therefore it is m ore a p p rop ria te  to  designate them  as "in term ediate  -1 p /-1 9 q "  
tum ors. To o u r know ledge it has no t been described before tha t "-1 p / -1 9q" 
o lig o d e n d ro g lia l tum ors can acqu ire  a ga in  o f 7 a n d /o r  a loss o f 10 during 
m a lignan t progression, a phenom enon th a t is well known from  As.
H is topa tho log ica l de linea tion  o f G BM s w ith o r  w ithou t o lig o d e n d ro g lia l 
d iffe ren tia tion  and hg -O A s is d ifficu lt. The previously reported 10%  o f G BM s 
con ta in ing  -1p  a n d /o r  -1 9 q [21] may very well represent tum ors th a t are classified 
as "-1 p /-1 9 q " o r  "in term ediate  -1 p /-1 9 q "  hg -O A s in the present study. Simply 
d iagnos ing  these tum ors as G BM s im plies th a t they w ill not be inc luded in 
chem otherapy p ro toco ls fo r  o lig o d e n d ro g lia l tum ors a lthough  they ha rb o r the 
positive p red ic to r fo r  chem osensitivity, LOH 1 p '16'. A lthough  o u r results show tha t 
+  7 and - 1 0  are late events in the oncogenesis o f o lig o d e n d ro g lia l tum ors, the 
"in term ediate  -1 p /-1 9 q "  subtype has also been identified in 5 o f the 33  
lg -O Ts '32,83,123'. W he the r iden tifica tion  o f this genetic subtype in these tum ors is 
im portan t fo r  prognosis should  be fu rthe r analyzed.
Other chromosomal imbalances involved in OT progression
Loss o f heterozygosity (LOH) invo lv ing chrom osom e 9 p  is reported to  be 
associated w ith h igh -g rade  g |iom as l1'2'7'8'10'21'26'53'129'130l. W e previously 
hypothesized th a t -9 p  in lg -O s should there fore  be considered as an early 
m arker fo r  m a lignan t progression '53' (chapter 3). O u r  current results support this 
hypothesis; the lg -O  con ta in ing  a -9 p , progressed to  a h g -O  (patient 3), 
whereas both low -g rade  tum ors w ithou t -9 p  d id not show m a lignan t 
h is topa tho log ica l progression (patient 1 and 2). A  loss o f 9 p , however, appears 
no t to  be essential fo r  m a lignan t progression o f o lig o d e n d ro g lia l tum ors since it 
was detected in only part o f the (recurring) h igh -g rade  tum ors by C G H  o r LOH 
(current results a n d 132,53,83,1231). Tum ors w ithou t -9p  o r LO H 9p  can ha rbo r
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aberra tions undetectab le  by C G H  o r LO H , however, a lternatives fo r  this 
abe rra tion  in m a lignan t progression o f As have been suggested (for reviews 
see'1,126,130'). The As w ithou t a loss o f C D K N 2 A  (located a t 9p 2 1 ) may show 
am p lifica tions  o f C D K4 (located a t 12q 1 3 .3 -q 14), o r inactiva tion  o f RB1 
(located at 1 3 q 1 4 .3 ) [132-135]. The products o f these genes are involved in the cell 
p ro life ra tion  contro l m echanism  a t the G 1-S  border. A lthough  C G H  analysis 
only reveals im balances o f ch rom osom al regions w ithou t gene specific 
in fo rm a tion , the same m echanism  was detected by C G H  in G BM s show ing 
+  12q (C DK4), -9 p  (C D K N 2A ), and —13q (RB1) to  be com plem enta ry '84'. O u r  
C G H  results ind icate  tha t this m echanism  is a lso involved in m a lignan t 
progression o f O Ts; one o f the tw o  hg-O Ts w ithou t -9 p , con ta ined  -1 3 q 1 1 -3 1  
inc lud ing  the RB1 region (4b).
Previously, it was suggested th a t progression o f lg -O s to  hg -O A s is associated 
w ith de le tions on 3 p , 1 4q , and 1 5 q '83'. In the present study, -1 4 q  was acqu ired  
in the recurrent h g -O A  o f pa tien t 5 , however, -14q  was also acqu ired  in the 
recurrent low -grade  tum ors o f pa tien t 1 and 2. A d d itio n a lly  it was suggested tha t 
a ga in  o f 7q is an early event in the in itia tion  o f As'79' whereas a ga in  o f 7p is 
predictive fo r  short survival in As'136'. In pa tien t 2 , + 7 p 1 1 -1 5  m ight indeed be 
considered as an ind ica to r fo r short survival (0 .6  years a fte r detection), in 
contrast to  + 7 q 3 1 -q te r  (survival a fte r de tection 6 .3  years) w hich was a lready 
detected in the prim ary tu m o r o f this patient.
In  c o n c l u s io n
O u r  results show accum u la tion  o f ch rom osom al im balances in OTs ove r tim e. 
In 3 o u t o f 5 cases this is accom pan ied  by h is topa tho log ica l progression. 
A lthough  w ith in  the context o f g liom as, the occurrence o f —1p and —19q are 
characteristic early events in the oncogenesis o f O Ts, we detected sim ilarities in 
m a lignan t progression between these tum ors and As; A lthough  + 7  and -1 0  are 
most frequently detected in G B M s, they are also involved in the oncogenesis o f 
O Ts, e ither in tum ors w ithou t -1p  o r -1 9 q  ( "+ 7 /-1 0 "  tum ors) o r in com b ina tion  
w ith -1p  o r  -1 9 q  ("in term ediate -1 p /-1 9 q "  tum ors). A dd itiona lly , ch rom osom al 
im balances ha rboring  genes involved in the cell p ro life ra tion  contro l m echanism  
a t the G 1-S  bo rde r (C D K N 2A  (-9p21 ), C D K 4 ( + 1 2q 13 .3 -q 1 4), RB1 
(-13 q 1 4 .3 )) can be involved in progression o f OTs and can be regarded as an 
early sign fo r  progression in low -g rade  tum ors. In sum m ary, C G H  on op tim a lly  
preserved m ateria l o f a sm all set o f prim ary OTs and the ir recurrences revealed 
ch rom osom al aberra tions th a t are involved in m a lignan t progression o f these 
tum ors. Investigation o f a la rge r g roup  o f O Ts is necessary to  fu rthe r analyze the 
ch rom osom al im balances and th e ir po ten tia l ta rge t genes involved in m a lignan t 
progression and to  establish the a d d ition a l va lue o f genetic  analysis o f these 
aberra tions in pred ic ting  m a lignan t progression, which may be helpful to  gu ide 
the rapeu tic  decisions.
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-------------------------------------------------------------------------------- Recurrent o ligodendrog lia l tum ors
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Editor:
Your m anuscript has been reviewed 
and a lthough there was considerable 
difference in op in ion , I th ink if you 
respond to  the comm ents o f the 
reviewers, we w ou ld  be happy to  re­
review a revision.
# 2  W hile  the observations are not 
particu larly surprising nor very orig ina l, 
I do  th ink that the w ork has been 
carefully done. Some parts are d ifficu lt 
fo r the readers to  fo llow , w ith all the 
coding it is a lm ost hopeless. O vera ll, I 
th ink this is a sound m anuscript and 
worthy o f pub lica tion.
# 1  The authors have extended their 
studies using C G H  on this occasion 
to  analyze ... This is an interesting 
study with some potentia l va luable 
in fo rm ation , and I w ou ld  like to  see 
it published. The fundam ental 
weakness o f the paper is the variab le 
h istological groups and few 
numbers.
# 4  The -1 p /-1 9 q  subtype is confusing. 
Subclassification o f interm ediate does not 
hold m eaning because o f the small 
numbers. The chrom osom e ideogram  is 
not well understood by this reviewer. 
C o lo r cod ing is required fo r figure 2
# 3  Stylistic revision is needed. This 
is a place where o rig ina lity  of 
presentation by the authors can 
change this from  an obscure tum or 
genetics paper to  one that is 
appreciated by most o f our 
readers. I encourage the authors to  
consider this problem  carefully.
# 5  Small num ber o f cases, 
which is even less significant 
since the five include both Os 
and O As. I'm not in favor of 
pub lica tion.
Editor:
Your m anuscript has been re-reviewed and felt to  be interesting and cceptable 
fo r pub lica tion. Com ments o f the reviewers are as fo llows :
# 1  They have 
attempted in the ir 
revision to  incorporate 
the suggestions o f all 
the reviewers and I 
th ink they have done a 
very good job.
# 2  I'm satisfied that 
they have answered 
my questions
appropria te ly. I believe 
the m anuscript is now 
acceptable fo r
pub lica tion.
# 3  The paper is 
im proved and adds 
va luab le  insight into 
the changes in genetic 
material associated 
w ith progression of 
o ligodendrog liom as.
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A bstract
The goa l o f the current study was to  e luc ida te  the p rognostic  and therapeutic  
im p lica tions o f genetic subtyping o f g liom as into fo u r d iffe ren t groups as 
previously identified in o lig o d e n d ro g lia l tum ors. Rather than d istinguish ing 
between tum ors w ith o r w ithou t loss o f 1p, tum ors con ta in ing  a loss o f 1p were 
designated as a " -1 p /-1 9 q " tu m o r o r  as an "in term ediate  —1 p /-1 9 q " tum or, the 
la tter being genetica lly  fu rthe r progressed. Tum ors w ithou t loss o f 1p were 
designated as "+ 7 / -1 0 "  o r "other". W e analyzed 54 tum ors (36 h igh -g rade  and 
18 low -grade  diffuse g liom as) w ith C G H  to  identify the genetic subtype o f the 
tu m o r and these results were com b ined  w ith the h is topa tho log ica l and c lin ica l 
data . W ith in  a h is topa tho log ica l g roup  o f g liom as, d iffe ren t genetic subtypes 
cou ld  be identified. Because survival data  o f up to  3 0  months is to o  short fo r 
low -g rade  g liom as, no conclusions can be draw n a b o u t the prognostic 
im p lica tions in this g roup . For h igh -g rade  g liom as, however, o u r results suggest 
tha t the " +  7 /-1 0 "  subtype is ind icative fo r  shorte r survival, whereas "-1 p /-1 9 q " is 
ind icative fo r  longer survival, independent o f h is topa tho log ica l d iagnosis. 
Patients w ith an "in term ediate  -1 p /-1 9 q "  tu m o r tend to  show a longer survival 
than those w ith a "+ 7 / -1 0 "  tu m o r but a shorte r survival than those w ith a 
"-1 p /-1 9 q " tum or. O u r  results fu rthe r suggest tha t " -1 p /-1 9 q " and "in term ediate 
-1 p /-1 9 q "  tum ors m ight be chem osensitive to  PCV in contrast to  " + 7 / -1 0 "  
tum ors. This study indicates th a t next to  the h is topa tho log ica l d iagnosis, genetic 
subtyping o f g liom as is im portan t fo r  the c lin ica l m anagem ent o f patients with 
these tum ors.
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In t r o d u c t io n
The g roup  o f d iffusely in filtra ting  g liom as is a h is to log ica lly  heterogeneous 
g ro u p  o f tum ors th a t are classified as astrocytic tum ors (As), pure 
o lig o d e n d ro g lia l tum ors (Os), o r mixed o ligo -as trocy tic  tum ors (OAs). 
A dd itio n a lly , these tum ors are g raded on the basis o f h is topa tho log ica l criteria  
inc lud ing  nuc lear a typ ia , m ito tic  activity, h igh ce llu la rity , necrosis, and flo rid  
m icrovascu la r p ro life ra tion . A lthough , As, O s, and O A s are separate tu m o r 
categories in the W H O -2 0 0 0  c lass ifica tion '3', unequ ivoca l criteria  fo r 
iden tifica tion  and g rad ing  are still m issing, resulting in a s ign ifican t interobserver 
va riab ility '29'. Especially the d is tinction o f O A s from  pure As on the one hand and 
pure O s on the o ther is d ifficu lt. This is illustrated by o u r previous observation 
(chapter 5 '136') th a t some o f the tum ors tha t were in itia lly  classified as O A s, were 
la te r on d iagnosed  as g liob las tom a  m u ltifo rm e (GBM ) o r  anap lastic  
astrocytom as using a m ore "strict" h is topa tho log ica l app roach . A lthough  g liom as 
are often g rouped  toge the r (especially O s  and O A s), differences in c lin ica l 
b ehav io r and response to  therapy w arran t separation. This is exem plified by the 
often rem arkab le  chem osensitiv ity o f a subset o f anap lastic  O s  w ith as many as 
tw o -th ird  o f the tum ors responding to  chem otherapeu tic  trea tm ent, particu la rly  to  
the com b ina tion  o f p rocarbazine , lom ustine and vincristine (PCV)('16,142' and 
references therein).
An im portan t observation was m ade by C airncross et al in 1 9 9 8 '16' reporting 
th a t loss o f chrom osom e 1p and 19q is associated w ith both chem otherapeu tic  
response and p ro longed  overa ll survival in anap lastic  o lig o d e n d ro g lio m a s  
treated w ith PCV. C onsequently, a lo t o f studies have focussed on this subgroup 
o f O s  and th e ir c lin ica l behavior. O th e r ch rom osom al im balances frequently 
detected in O s, like loss o f 9 p , loss o f 10 , and ga in  o f 7 '3' may have add itiona l 
prognostic  o r the rapeu tic  value. Perform ing C G H  on O s '53' (chapter 3) and 
O A s '136' (chapter 5) to  identify ch rom osom al im balances involved in the 
oncogenesis o f these tum ors, we identified fo u r d iffe ren t genetic subtypes; 
in itia lly , based on m utua lly  exclusive im balances tw o genetic subtypes o f pure O s 
were identified " -1 p /-1 9 q " and "+ 7 /-1 0 " .  In m ixed O A s tw o ad d ition a l subtypes 
were identified i.e. "in term ediate  -1 p /-1 9 q "  (conta in ing  both -1 p /-1 9 q  and + 7 / ­
10) and "other" (tumors w ithou t — 1 p, -1 9 q , + 7  o r -10). Studying prim ary 
o lig o d e n d ro g lia l tum ors and the ir recurrences we showed th a t the "in term ediate  - 
1 p /-1 9 q " tum ors can arise from  "-1 p /-1 9 q " tum ors during  genetic progression 
(chapter 6).
The goa l o f the current study was to  e luc ida te  the p rognostic  and therapeu tic  
im p lica tions o f genetic subtyping. Rather than d istinguish ing tum ors w ith o r 
w ithou t loss o f 1p as done by others based on the study o f C a irncross '16', we 
subdiv ided tum ors con ta in ing  a loss o f 1p in " -1 p /-1 9 q " o r "in term ediate 
-1 p /-1 9 q "  tum ors, whereas tum ors w ithou t loss o f 1p are subtyped as " +  7 /-1 0 "  
o r "other". W e analyzed 54 tum ors (36 h igh -g rade  (hg-) and 18 low -grade  (lg-) 
diffuse g liom as) w ith C G H  to  identify the genetic subtype and com b ined  these 
results w ith the h is topa tho log ica l c lassification and c lin ica l data o f the patients
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regard ing  age, survival and therapy. Because o f the interobserver va riab ility , we 
ad d ition a lly  analyzed the im pact o f a "relaxed" versus a m ore "strict" 
h is topa tho log ica l c lassification o f the hg-O As on the associa tion between 
h is topa tho log ica l c lass ifica tion , genetic subtype and patien t survival.
M aterials a n d  M ethods
Surgical specimens o f d iffusely in filtra ting  g liom as (11 lg -O s , 7 lg -O A s, 10 
hg -O s, 16 hg-O A s, and 10 GBMs) selected fo r  the present study were ob ta ined  
from  54 patients treated in the D epartm ent o f N eurosurgery o f the University 
M ed ica l C enter St R adboud, N ijm egen, The N etherlands. The ethics com m ittee 
o f o u r hospita l has approved  this study and in form ed consent was given by the 
patients. D uring surgery, part o f the tu m o r was snap-frozen in liqu id  n itrogen and 
stored a t -8 0 °C . C lin ica l da ta  o f a ll patients were stud ied, inc lud ing  age a t tim e 
o f surgery, sex, post-opera tive  survival and post-operative therapy.
Hem atoxylin  and eosin-sta ined (H&E) para ffin  sections o f the tum ors were 
classified and g raded  acco rd ing  to  criteria  o f the W H O -2 0 0 0 '3'. The H&E 
sections o f the hg-O As were exam ined by tw o neuropatho log is ts  as previously 
described in chap te r 5 using both a "relaxed" and a m ore "strict" app roach  fo r 
the recogn ition  o f o lig o d e n d ro g lia l d iffe ren tia tion '136'. In the "strict" a pp roach , the 
d iagnosis o f m ixed O A  required th a t a t least 25%  o f the tu m o r was com posed o f 
m onotonous cells w ith sm all round nuclei surrounded by p rom inen t c lear 
perinuc lea r halos and an associated 'ch ickenw ire ' pattern o f de lica te  cap illa ry  
b lood  vessels. For the "relaxed" a pp roach , the d iagnosis o f o lig o d e n d ro g lia l 
d iffe ren tia tion  was based on the presence o f a substantia l num ber o f tu m o r cells 
show ing a re latively m onotonous, sm all, round nucleus, no eos inoph ilic  cell 
processes, and a t least som e perinuc lea r halos.
C G H  was perform ed as previously described in chap te r 2 , and based on these 
results tum ors were genetica lly  subtyped as " -1 p /-1 9 q " (conta in ing  a loss o f 1p 
a n d /o r  a loss o f 19q), " +  7 /-1 0 "  (conta in ing  + 7  a n d /o r  -1 0  w ithou t -1p  o r 
-19q ), "in term ediate  -1 p /-1 9 q "  (conta in ing  both -1 p /-1 9 q  and + 7 / -1 0 )  and 
"o th e r1 (w ithout -1 p , -1 9 q , + 7 ,  o r  -10).
To study the associa tion between h is topa tho log ica l c lass ifica tion, genetic 
subtyping and patien t survival, figures were created show ing the percentages o f 
patients a live , o f e ither a specific  h is topa tho log ica l o r  genetic subtype, at 
d iffe ren t points in tim e ( t= 0 , 6 , 12 , 18 , 2 4 , 3 0  months).
RESULTS
The c lin ica l da ta  regard ing  pa tien t age and post-operative therapy fo r the 
d iffe ren t h is topa tho log ica l subtypes are sum m arized in tab le  7-1 . Based on C G H  
analysis, the tum ors were genetica lly  subtyped as "-1 p /-1 9 q " (1 6 /5 4 ), " + 7 / -1 0 "  
(2 4 /5 4 ), "in term ediate  —1 p /-1 9 q " (7 /5 4 ) and "other" (7 /5 4 ).
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-----------------  C lin ica l im plications o f genetic subtyping
O verview  o f clin ica l data w ith in each h istopatho log ica l subtype in ou r patient population .
lg -O lg -O A hg -O h g -O A G BM
G ro u p  size 11 7 1 0 16 (6 ) 1 0  (16)
M :F ratio 1 .8:1 1.3:1 4:1 1.3:1 1:1
M ean age 45 42 51 54 (45) 59  (59)
Therapy
None 5 1 1 4 4
C hem o 0 0 0 1 0
RT 4 5 5 9 4
C hem o +  RT 2 1 4 2 2
() mean age and g roup size o f patients diagnosed with a hg-O A s using a more "strict" 
h is topatho log ica l approach fo r the classification o f O As. M:F ratio  =  m ale to  female ratio ; 
C hem o =  num ber o f patients w ho received chem otherapy; RT =  num ber o f patients w ho 
received radiotherapy;
In the g roup  o f lg -O s  (n =  11) ten patients were o f the " -1 p /-1 9 q "  subtype 
whereas one was o f the "other" subtype (still a live  3 0  months a fte r surgery). O n e  
o f the patients w ith a "-1 p / -1 9q" tu m o r d ied tw o  m onths a fte r surgery. This 
pa tien t ad d ition a lly  suffered from  hyperch lo lestero laem ia , obesity, ep ilep tic  
seizures, and ch ron ic  obstructive pu lm onary disease. O f  three patients fo llo w -u p  
was no longer than 14 , 2 4 , and 2 6  months whereas the o the r six patients were 
still a live  3 0  months a fte r surgery. In the g ro u p  o f lg -O A s (n =  7), fo u r were o f the 
"other" subtype, tw o o f the " +  7 /-1 0 "  subtype, and one o f the "-1 p /-1 9 q " subtype. 
The tw o patients w ith the " +  7 /-1 0 "  subtype only had a fo llo w -u p  o f 24  and 2 8  
months. The rest o f the patients w ith a lg -O A  is still a live at 3 0  months.
For hg -O s, hg-O A s, and G BM s figures were created to  illustrate the 
associa tion between genetic subtype, pa tien t survival and h is topa tho log ica l 
d iagnosis. Figure 7-1 shows the percentages o f patients o f specific 
h is topa tho log ica l o r  genetic subtype 18 m onths a fte r surgery ( t= 1 8 ). The 
m ajority  o f patients w ith a hg -O s  o r  a " -1 p /-1 9 q " hg -tu m o r are still a live, 
whereas the m ajority  o f patients w ith a G BM s o r a "+ 7 / -1 0 "  hg -tu m o r are dead 
18 m onths a fte r surgery. Figure 7 -2  shows fo r  each h is topa tho log ica l subtype 
the percentages o f patients still a live over tim e and the d is tribu tion  o f the 
d iffe ren t genetic subtypes. The m ajority  o f patients w ith a hg -O s (6 /1 0 ) are still 
a live , whereas all the patients w ith a G B M  (n =  10) are dead 3 0  m onths a fte r 
surgery. Figure 7 -3  shows fo r  each genetic subtype the percentage o f patients 
still a live  over tim e and the d is tribu tion  o f the d iffe ren t h is topa tho log ica l 
subtypes. A ll patients w ith a "-1 p /-1 9 q " h igh-g rade  tu m o r are still a live , whereas 
a ll patients w ith a " +  7 /-1 0 "  h igh -g rade  tu m o r are dead 3 0  months a fte r surgery. 
In this la tter figu re , the differences in app lica tion  o f "strict" and "relaxed" criteria  
fo r  the c lassification o f hg -O A s are ind ica ted ; tum ors classified as hg -O A s in the 
"relaxed" app roach  but as G B M  in the "strict" app roach  are ind icated by a 
hatched area. Part o f the " +  7 /-1 0 "  (75%) and "in term ediate  -1 p /-1 9 q "  (50%) hg- 
O A s are classified as a G B M  when the "strict" app roach  is used.
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hg-O hg-OA G BM  -1p-19q intermediate +7-10 other
Figure 7 -1 . The percentage o f patients still alive 18 months after surgery o f either a 
h is topatho log ica l or genetic subtype. Tumors are classified accord ing to  the relaxed 
h is topatho log ica l approach as described in the M ateria ls  and M ethods. Tumors are genetically 
subtyped as "-1 p /-1 9 q " (tumors conta in ing a loss of 1p (-1p) a n d /o r  -19q), " +  7 /-1 0 " (tumors 
conta in ing + 7  a n d /o r -10  w ithout -1p  o r -19q), "interm ediate -1 p /-1 9 q " (containing both 
-1 p /-1 9 q  and + 7 /-1 0 ) ,  and "other" (tumors w ithou t -1 p, + 7 ,  -10 , o r -19q).
D isc u ssio n
The age d is tribu tion  o f o u r patients am ong the d iffe ren t h is topa tho log ica l 
subtypes is, in genera l, as described in W H O -2 0 0 0 [3]. Interestingly, in o u r study 
the mean age o f patients w ith a h g -O A  is 54  o r  4 5  years depend ing  on the 
h is topa tho log ica l criteria  used fo r  the c lassifica tion o f these tum ors ("relaxed" o r 
"strict", respectively). Based on a series o f patients o f H e inrich -H e ine  University, 
D usseldorf, G erm any, the m ean age fo r  hg -O As m entioned in the W H O -2 0 0 0  
is 4 5 ,5  w hich m ight ind icate  th a t these tum ors were classified acco rd ing  to  a 
m ore "strict" app roach . The trea tm ent o f the patients inc luded in this study was 
very diverse, depend ing  on patien t cond ition  (karnofsky score), type o f surgery 
(biopsy, partia l resection, gross to ta l resection) and pro toco ls fo llow ed  in ou r 
hospita l a t tim e  o f surgery.
The goa l o f this study was to  investigate the associa tion between 
h is topa tho log ica l c lass ifica tion , genetic subtype, and patien t survival. W ith 
respect to  survival, o u r g roup  o f low -grade  g liom as is no t yet in fo rm ative  since a 
survival analysis up to  3 0  months is to o  short (only one o f the eighteen patients 
d ied w ith in  3 0  months a fte r surgery). O f  all patients w ith a h igh -g rade  g liom a , 
fo llo w -u p  data were com p le te  fo r  3 0  m onths and associations between 
h is topa tho log ica l c lass ifica tion , genetic subtype, and patien t survival becam e 
evident. Because the num bers o f patients fo r each h is topa tho log ica l and genetic 
subtype are still sm all, we decided not to  use the standard  K ap lan -M e ie r 
estimates o f the survival d is tribu tion , but to  use figures based on the same 
princ ip le .
First we com pared  the percentages o f patients which were still a live 18 months 
a fte r surgery fo r e ither the h is topa tho log ica l o r  genetic subtypes (Figure 7 -1). As 
was to  be expected, the m ajority  o f G B M  patients d ied (9 /1 0 ) whereas most 
h g -O  patients are still a live  (8 /1 0 ). From a genetic po in t o f view  all " -1 p /-1 9 q "
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patients are still a live  (5 /5 ) whereas the m ajority  o f patients in the " + 7 / -1 0 "  
g ro u p  d ied (1 8 /2 2 ). Five o f the seven patients w ith a "in term ediate  -1 p /-1 9 q "  
tu m o r were still alive. These results m ight suggest tha t the h is topa tho log ica l 
g ro u p  o f G BM s and hg -O s overlap  w ith the genetic subtypes o f " + 7 / -1 0 "  and 
" -1 p /-1 9 q ", respectively. Especially, since it was previously reported th a t a ga in  o f 
7 and a loss o f 10  are the most frequently detected aberra tions in G B M s'80' 
84,88,143], whereas a loss o f 1p and 19q are the most frequently detected 
aberra tions in O s [17-25]. However, if we include the d is tribu tion  o f the d iffe ren t 
genetic  subtypes in o u r figures on survival fo r  the d iffe ren t h is topa tho log ica l 
subtypes (Figure 7 -2 ), it appears tha t w ith in  a h is topa tho log ica l subtype d iffe ren t 
genetic  subtypes can be identified.
= 10 h g - O s n = 1 6  h g - O A s n = 1 0  G B M s
0 6 12 18 24 30
□  : " - 1 p / - 1 9 q "  □
0 6 12 18 24 30
" i n t e r m e d  i a t e "  □  :
0 6 12 18 24 30
- 7 / - 1 0 "  : " o t h e r "
Figure 7 -2 . Survival analysis o f patients with different h istopatho log ica l subtypes o f g liom as. 
Tumors are genetica lly subtyped as described fo r figure 7 -1 . D ifferent genetic subtypes are 
indicated in a specific co lor. The X-axis shows the survival after surgery in months and the 
Y-axis shows the percentage o f patients still alive.
D epicting  the survival da ta  fo r  each genetic subtype in com b ina tion  w ith the 
d is tribu tion  o f the h is topa tho log ica l c lassifica tion (figure 7-3) shows tha t 
independent o f the h is topa tho logy, a ll patients w ith " -1 p /-1 9 q " tum ors are still 
a live , whereas patients w ith a " +  7 /-1 0 "  tu m o r have a g rim  prognosis. Patients 
w ith an "in term ediate  -1 p /-1 9 q "  tu m o r have a better prognosis than  those w ith a 
" + 7 / -1 0 "  tu m o r but worse than those w ith a "-1 p /-1 9 q " tum or. This la tter 
observation is in line w ith o u r previous study on ch rom osom al im balances in 
prim ary o lig o d e n d ro g lia l tum ors and the ir recurrences, show ing tha t 
"in term ediate  -1 p /-1 9 q "  tum ors can o rig ina te  from  "—1 p /-1 9 q " tum ors during 
genetic p rogression '144 (chapter 6). The g roup  o f "other" hg -O A s exists o f only 
tw o patients: one died w ith in 8 m onths a fte r surgery whereas the o the r is still 
a live 3 0  m onths a fte r surgery. Interestingly, the tu m o r o f the pa tien t which is still 
a live d id no t conta in  im balances detectab le  by C G H , whereas the tu m o r o f the 
pa tien t th a t d ied con ta ined  aberra tions on 7 and 10 , but instead o f the 
com m on ly  detected ga in  on 7 a n d /o r  loss on 10 this tu m o r had a loss on 7p 
and a ga in  on 10.
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Figure 7 -3 . Survival analysis o f patients w ith different genetic subtypes o f g liom as. Tumors are 
genetica lly subtyped as described fo r figure  7 -1 . The im pact o f a "strict" and a m ore "relaxed" 
h is topatho log ica l approach fo r the recognition o f o ligo-astrocytic  tum ors is shown and the 
different h is topatho log ica l subtypes are indicated in a specific co lor. The X-axis shows the 
survival after surgery in months and the Y-axis shows the percentage o f patients still alive.
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In o u r previous study on O A s [136] (chapter 5 ), both a "strict" and "relaxed" 
h is topa tho log ica l app roach  were used fo r  the c lassifica tion o f these tum ors (see 
figu re  7-3). The m ajority  (7 /9 ) o f the "+ 7 / -1 0 "  and ha lf (2 /4 ) o f the 
"in term ediate  —1 p /-1 9 q " hg -O A s are classified as a G B M  when the "strict" 
app roach  was used. The only "—1 p /-1 9 q " h g -O A  rem ains a h g -O A  using the 
"strict" app roach . It is becom ing com m on practice th a t tum ors w ith 
o lig o d e n d ro g lia l features, i.e. O s  o r  O A s, are treated w ith PCV, whereas G BM s 
are not. C airncross et a l. [16] reported tha t loss o f 1p is a positive p red ic to r fo r 
chem osensitivity to  PCV as a ll 2 4  chem osensitive hg -O s conta ined LO H 1p. O u r  
data  ind icate tha t using "strict" h is topa tho log ica l criteria  fo r  the recogn ition  o f 
hg -O A s, results in a h igher percentage o f patients responding to  PCV, since the 
num ber o f " +  7 /-1 0 "  tum ors decreases com pared  to  the "relaxed" approach . 
Patients w ith the la tter tum ors w ill be spared o f trea tm ent w ith PCV as the ir 
tum ors are now d iagnosed as G B M . However, using this "strict" a pp roach , some 
o f the patients w ith "in term ediate  -1 p /-1 9 q "  hg-O A s are d iagnosed as G BM s 
and w ill there fore  not receive PCV, a lthough  based on th e ir genetic m ake-up 
they w ou ld  p robab ly  benefit from  this treatm ent. These results show tha t genetic 
markers are useful as an ad d ition a l d iagnostic  to o l next to  the h is topa tho log ica l 
d iagnosis.
Since loss o f 1 p has been described as a positive p red ic to r fo r 
chem osensitiv ity[16], it is to  be expected th a t tum ors o f both the " -1 p /-1 9 q " and 
"in term ediate  -1 p /-1 9 q "  subtype w ill respond to  chem otherapy in contrast to  
" +  7 /-1 0 "  and "other" tum ors. U nfortunate ly , no firm  conclusions can be draw n 
from  o u r g ro u p  o f patients because the trea tm ent was very diverse and the 
ind iv idua l groups are no t large enough. Three o f the five "-1 p /-1 9 q " patients 
were treated w ith a com b ina tion  o f rad io therapy (RT) and PCV chem otherapy, 
one was treated w ith RT and one received no therapy. The three " -1 p /-1 9 q "
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patients treated w ith RT and PCV showed to  be chem osensitive (stable disease o r 
decreased tu m o r size). O f  the "in term ediate  -1 p /-1 9 q "  patients (n =  7), five 
patients received RT, one received PCV and one received a com b ina tion  o f RT 
and PCV. Both "in term ediate  —1 p /-1 9 q " pa tien t treated w ith PCV (with o r w ithou t 
RT) showed to  be chem osensitive (stable disease). O f  the " +  7 /-1 0 "  patients 
(n =  2 2 ), ten were treated w ith RT, six received no therapy, tw o  patients were 
treated w ith PCV and RT, and one patien t was treated w ith tem ozo lom ide  and 
RT, and o f one patien t the trea tm ent was unclear. The tum ors o f both " + 7 / -1 0 "  
patients w ho received PCV (in com b ina tion  w ith RT) were not chem osensitive to  
PCV as these patients showed progressive disease. Interestingly, the " + 7 / -1 0 "  
pa tien t (h is topa tho log ica l d iagnosis G BM ) treated w ith tem ozo lom ide  and RT 
was chem osensitive to  tem ozo lom ide  (stable disease).
In c o n c l u s io n
The curren t data  strongly ind icate  th a t know ledge a b o u t the genetic subtype o f 
the tu m o r is im portan t next to  the h is topa tho log ica l d iagnosis (i.e. h g -O , h g -O A  
o r  G BM ) fo r  the c lin ica l m anagem ent o f patients w ith a h igh -g rade  g liom a . 
Rather than d istinguish ing between tum ors w ith o r w ithou t loss o f 1 p, we 
subd iv ided tum ors con ta in ing  a loss o f 1p in tw o groups, "-1 p /-1 9 q " o r  in the 
genetica lly  fu rthe r progressed subtype "in term ediate  -1 p /-1 9 q " , and showed tha t 
patients w ith a "-1 p /-1 9 q " tu m o r have a better survival than those w ith a 
"in term ediate  —1 p / -1 9q" tum or. Furtherm ore, tum ors w ithou t loss o f 1p were 
designated as "+ 7 / -1 0 "  o r "other". Since o u r g roup  conta ined only tw o patients 
w ith a tu m o r o f the "other" subtype, no associations w ith c lin ica l da ta  cou ld  be 
studied in this subgroup . Patients w ith a " +  7 /-1 0 "  tu m o r have a much shorter 
survival than those w ith a " -1 p /-1 9 q " o r "in term ediate  -1 p /-1 9 q "  tum or. This 
study needs to  be continued in a la rge r g roup  o f patients w ith a longer fo llo w -u p  
period . Since C G H  is a very com plex and tim e consum ing techn ique , it needs to 
be established w hich o the r techniques (e.g. FISH o r LOH) can be used fo r  the 
genetic  subtyping o f g liom as as described above , and w hich techn ique  is the 
m ost su itab le  fo r  m anagem ent o f the ind iv idua l pa tien t in routine pa tien t care.
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A bstract
H um an tum ors im p lan ted as subcutaneous xenografts in nude m ice are w idely 
used fo r the study o f tu m o r b io logy  and therapy. V a lida tion  o f these m odels 
requires know ledge o f the genetic m akeup o f the xenografts. W e used 
com para tive  genom ic hybrid ization (CG H) to  detect ch rom osom al im balances in 
the 11 xenogra fted  g liob lastom as (x-GBMs) lines used in o u r hospita l. The C G H  
results on x-G BM s were com pared  w ith those o f G B M  biopsies reported in the 
literature (l-G BM s). Furtherm ore, fo r  3 lines, the C G H  results on x-G BM s were 
com pared  to  those detected in the o rig in a l G BM s (o-GBM s) used to  establish the 
xenografts. W e showed th a t the ch rom osom al im balances in x-G BM s are s im ila r 
to  those in o -G B M s and l-G B M s, ind ica ting  tha t the G B M  xenogra ft lines used 
were va lid  m odels from  a genetic po in t o f view. A dd itiona lly , we studied genetic 
stability  during  serial passaging o f three xenogra ft lines by analyzing tw o d iffe ren t 
passages in three xenogra ft lines w hich indicates th a t x-G BM s (like l-GBM s) show 
in tra tum ora l genetic heterogeneity and do  not acqu ire  ch rom osom al im balances 
as a result o f serial passaging.
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In t r o d u c t io n
G liom as  are the m ost frequently observed prim ary neoplasm s o f the central 
nervous system, the m ost com m on being astrocytic tum ors. From  c lin ica l 
observations it is known tha t low -g rade  astrocytic and o lig o d e n d ro g lia l tum ors 
tend to  progress to  m ore m a lignan t lesions, the most m a lignan t one being 
g liob las tom a  m ultifo rm e (G BM ), w hich represents 50%  o f a ll g lio m a s '1,12,141,142'. 
G ene tic  changes involved in g liom a  oncogenesis have been detected using 
m o lecu la r genetic techniques tha t only reveal in fo rm a tion  a b o u t specific regions 
o f interest'1,5,7'9'. The in troduction  o f C G H  by K a llion iem i et a l.'35' and du M a n o ir 
et a l.'36' p rovided the oppo rtun ity  to  screen a com ple te  tu m o r genom e fo r 
genom ic im balances. The C G H  techn ique  has been used fo r this purpose in a 
variety o f tum ors inc lud ing  G BM s. C G H  analysis o f G BM s most frequently 
reveals a ga in  on chrom osom e 7 and a loss on chrom osom e 10. O th e r 
frequently occurring  aberra tions include gains on chrom osom es 1p, 8 q , 19 , and 
2 0  and losses on chrom osom es 4 q , 6q , 9 p , 11p , 13q , and 2 2 [80-84,139].
Xenografts o f hum an tum ors are w ide ly used fo r  the study o f tu m o r b io logy 
and therapy. In o u r labo ra to ry  we study xenogra ft lines o f G BM s (x-G BM s)'143- 
151]. W hereas it has been reported in som e studies th a t xenogra fted  tum ors retain 
the ir o rig ina l h is to log ica l, cytogenetic, and b iochem ica l characteristics a fte r 
serial passag ing '152-155', others have described a ltered chem osensitiv ity '156'. To 
genetica lly  va lida te  the use o f xenogra ft lines as m odels fo r  tum ors, we 
investigated the ch rom osom al im balances in 11 x -G B M  lines by C G H , and we 
com pared  them  w ith those found  in G B M  biopsy sam ples. Because on ly three o f 
the o rig in a l sam ples used to  establish the xenogra ft lines (o-GBM s) were 
ava ilab le  fo r C G H  analysis, the profiles o f ch rom osom al im balances present in 
x-G BM s were also com pared  w ith those previously reported in G BM s in the 
literature (l-G BM s). In a d d ition , tw o d iffe ren t passages o f three xenogra ft lines 
were analyzed to  establish w hether tu m o r progression occurs a fte r serial 
passaging.
M aterials a n d  M ethods
Eleven xenogra ft lines (E2, E18, E34, E49, E80, E98, E 102, E 106, E110, 
E 120, and E168) were established from  hum an G BM s as described by Bernsen, 
et a l. '144'. Briefly, biopsy m ateria l from  1 1 d iffe ren t tum ors was im p lan ted 
subcutaneously in athym ic m ice (B a lb /c  nu /nu  mice). To prevent selection during  
cu ltu ring , the biopsy m ateria l was d irectly im p lan ted w ithou t p rio r cu ltu ring . The 
o rig ina l tum ors were h is to log ica lly  d iagnosed as G BM s acco rd ing  to  the revised 
W H O  classifica tion '4'. The xenogra ft line E34 was established from  a G B M  in 
w hich som e o lig o d e n d ro g lia l d iffe ren tia tion  was observed. For three xenogra ft 
lines tw o d iffe ren t passages were analyzed using C G H : E34 (passages 12 (p12) 
and p23), E102 (p5 and p32 ), and E106 (p9 and p12).
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O f the o rig in a l tu m o r biopsy samples used to  establish the xenogra ft lines, no 
snap-frozen tissue was ava ilab le , and o f five lines (E102, E 106, E 110, E120, 
and E168) on ly a m in im um  o f fo rm a lin -fixed , pa ra ffin -em bedded m ateria l was 
ava ilab le  fo r C G H  analysis. The m ateria l o f the o the r biopsy samples has been 
used fo r  o the r types o f research w ith the xenogra ft lines'143-151'.
C om para tive  G e n o m ic  H ybrid ization (CG H) was perfo rm ed as described in 
chap te r 2.
W e created an overview  o f the frequency o f gains and losses on each 
chrom osom e arm  in l-G B M s'12,80,82'84,139'. In this overview  we d id  not d istinguish 
between com ple te  and partia l im balances on chrom osom e arms. A  s im ila r 
overview  was created fo r  the x-G BM s.
Figure 8 -1 . An overview o f the chrom osom al im balances detected by C G H  in xenografted 
GBM s. Lines on the left and right o f the chrom osom e indicate losses and gains o f these 
chrom osom al regions, respectively. C hrom osom al im balances crossing the 0 .8  and 1 .2 
threshold are indicated by a thin lin e , whereas clear copy num ber changes crossing the ratio 
0 .6  and 1.4 are indicated by a th ick line. H igh copy num ber gains, indicated by a ratio  larger 
than 1.6, are indicated by an add itio na l spot on a bar.
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TABLE 8 -1 .
C hrom osom al im balances in xenografted g liob lastom as detected by C G H .
Line Passage C G H  losses C G H  gains
1st ana lysis
E2 p33 2 q31-q te r, 4p , 5 q 1 1 -2 3 , 8p te r-q21 , 9p, 10q23-q te r, 11p13-p te r, 1 q 1 1 -2 5 c, 2p , 2 p 1 2 -1 6 c, 4 q 1 1 -2 8 , 5p, 7p21-p te r, 7q*,
12 q 1 4 -2 2 , 16p, 17q22-q te r, 20 p 1 2 p 13 c,
1 4 q 12 -2 1 , Xp11.3-pter*
E18 p32 9p, 10, 11q23-q te r, 12q21-q te r, 13q22-q te r, 16q, 18q, Xpc, Xq 1p, 5p, 7pter-q11
E34 p 1 2  x 1p, 2 q 32-q te r, 6 q 1 4 -2 3 , 7q21-q te r, 8 p, 9p, 10q, 10q23 -q te rc, 3, 6p te r-q13 , 7p te r-q11 , 8 q, 18q, 21
14 q 22 -3 1 , 19q
E49 p14 x 3p te r-q25 , 5q, 6 , 9 p 2 1 , 10, 11q, 13q, 14q, 15q, 17p 1q25-q te r, 4 p te r-q31 , 7, 9q, 12, 17q, 18
E80 p8 6q22-q te r, 9 p 2 2 -1 3 , 10 7p te r-q11 , 7p21-15*, 19
E98 p34 2 q 1 2 -1 4 , 4 q 2 1 -2 5 , 8q23-q te r, 9p , 10q22-q te r, 1 3 q 1 1 -3 1 , 21 7, 19p
E102 p5 1 0 p -q21 , 11q14-q te r, 1 4 q 11 -2 3 7, 20
E106 p9 8p te r-q22 , 10, 11, 2 1 , X 2 , 4 q 11-13*, 7, 8q22-q te r, 8 q 2 3 -2 4 c, 9q, 12q13-15*
E110 p 1 0 6 , 9 p 2 4 -2 1 , 10, 11, 12q, 13q, 15q, 17pter-q21 1p34-p te r, 7, 7p11-13*, 8 q 2 3 -2 4 .1 *, 16, 17q22-q te r, 19,
2 0 p -q 11
E120 p2 4q , 10, 13q, 16, X 7p te r-q21 , 9q32-q te r, 17, 18, 19, 20
E168 p6 13qc, 1 5 q 1 3 -2 2 , 16q, 1 9 q 11 -1 3 .2 5p, 7, 8 q, 17q
2 nd analysis
E34 x32p 1p, 2q33-q te r, 4 , 6 q 1 5 -2 3 , 7q22-q te r, 8 pc, 9p, 10q, 10q23 -q te rc, 1q, 2p , 5p te r-q31 , 6p te r-q14 , 7p te r-q21 , 8 qc, 13q31-q te r,
14 q 22 -3 1 , 19q 18, 2 0 p, 21
E102 p32 x 10p te r-q21 , 11q13-q te r, 14q, 15q, 19 2 , 7c
E106 p 1 2  x 8p te r-q22 , 10, 11, 13q, 21 4 q 1 1 -1 3 *, 7, 8q22-q te r, 8 q 23-24*, 12q13-15*
o rig ina l biopsy :samples
o -G B M  E102# 1 0 p, 1 1 q 7
o-G B M  E110# 6 , 10, 11, 12q, 13q, 15q, 17 7, 7p11-14*, 8q23-q te r*, 16
o -G B M  E120# 4q , 10, 13q, 16, X 7p te r-q21 , 9 q 32-q te r, 17, 2 0
A bbreviations used; x =  not analyzed fo r the X-chrom osom e because o f sex m ismatch; * =  high copy am plifica tion , ratio  1.6 o r m ore; c =  c lear copy 
num ber changes, ratio  more than 1.4 o r less than 0 .6 ; # =  Chrom osom es 9p and 19 were not analyzed because o f C G H  artifacts in ULS-labeled DNA.
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Figure 8 -2 . Bar graphs showing an overview o f the frequency o f chrom osom al im balances in 
x-GBM s and g liob lastom a biopsy m ateria l (l-GBMs). A  positive percentage on the y-axis 
represents the frequency o f a gain, whereas a negative percentage represents the frequency of 
a loss. The chrom osom e arms are ind icated on the x-axis. n =  num ber o f analyzed tumors.
Results
The chrom osom al im balances detected using C G H  in 1 1 x-G BM s are 
sum m arized in tab le  8-1 and depicted in figu re  8-1 . Two passages were 
analyzed from  lines E34, E 102, and E 106 ; only the ch rom osom al im balances 
detected in the early passages (E 34p12 , E 102p5 , and E 106p9) are included in 
figu re  8 -1 . G a ins invo lv ing chrom osom e 7 were present in a ll x -G BM s, and 
losses involv ing chrom osom e 10 were present in a ll x -G BM s except E168. O th e r 
chrom osom e arms frequently involved in ch rom osom al im balances (present in 
fo u r lines o r more) were loss on 6q (4 /1 1 ), 9p  (7 /1 1 ), 11q (5 /1 1 ), and 13q 
(6 /1 1 ); and ga in  on 17q (4 /1 1 ) and 19p  (7 /1 1 ). For these chrom osom es the
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com m on regions o f overlap  were 6 q 2 2 -2 3 , 9 p 2 1 , 1 1 q 2 3 -q te r, 1 3 q 2 2 -3 1 , 
1 7 q 2 2 -q te r, and 19p. C le a r copy num ber gains (ratio >  1.4) involved 1 q 1 1 -2 5 , 
2 p 1 2 -1 6 , and 8 q 2 3 -2 4 , whereas c lea r losses involved 1 0 q 2 3 -q te r, 1 3q , and 
Xp. H igh copy num ber gains (ratio >  1.6) were detected a t 4 q 1 1 -1 3 , 7 p 1 1 -1 3 , 
7 p 2 1 -1 5 , 7q , 8 q 2 3 -2 4 .1 , 1 2 q 1 3 -1 5 , and X p te r-11 .3 .
W e isolated D N A  from  the five o -G B M  biopsy sam ples used to  establish the 
x-G BM s. The isolated D N A  was seriously degraded  (fragm ent length 1 kb o r 
sm aller), p robab ly  because unbuffered fo rm a lin  was used. The D N A  isolated 
from  o -G B M  E106 and o -G B M  E168 cou ld  not be used fo r  C G H  because the 
fragm en t length was sm a lle r than 2 0 0  bp and the a m oun t was less than 2 0 0  ng. 
However, C G H  o f o -G B M  E 102, o -G B M  E 110, and o -G B M  E120 cou ld  be 
perfo rm ed using the universal linkage system (ULS) w ith b io tin  fo r  labe ling  o f 
D N A  isolated from  pa ra ffin -em bedded  tissue. The results are included in tab le
8 -1 . In conco rdance  w ith the ea rlie r find ings o f A lers, et a l. '60', we found  tha t 
chrom osom es 19 and 9 p  d id  no t show a ra tio  o f 1 .0  in o u r contro l experim ent, 
in which we used b io tin  ULS-labeled fem a le  D N A  and n ick-transla tion  
d igox igen in -labe led  m ale DNA. Therefore, we excluded these chrom osom es 
from  analysis.
In figu re  8 -2  the percentages o f x-G BM s and l-G BM s w ith d iffe ren t 
ch rom osom al im balances are sum m arized. The observation th a t 7q showed a 
ga in  in 100%  and a loss in 9% o f the x-G BM s fo llow s from  the fac t tha t E34 
con ta ined  both a partia l ga in  and loss on this chrom osom e arm : + 7 p te r-q 1 1  
and -7 q 2 1 -q te r. In l-G BM s and x-G BM s, C G H  most frequently dem onstrates + 7  
and -1 0 , fo llow ed  by -9 p , -1 3 q , -1 1 q , and -6q  (present in 2 7 -1 0 0 %  o f the 
x-G BM s and in 1 2 -4 1 %  o f the l-GBM s).
The ch rom osom al im balances present in the tw o d iffe ren t passages o f E34, 
E 102, and E106 are sum m arized in tab le  8-1 and figu re  8 -3 . The m ajority  o f 
aberra tions are present in both passages, inc lud ing  the frequently detected 
ch rom osom al im balances + 7 ,  -1 0 , -9 p , -6 q , -1 1 q , and + 1 7 q .
D isc u ssio n  
Comparison of x-GBMs with o-GBMs and l-GBMs by CGH
To exam ine w hether x-G BM s reflect G BM s, it w ou ld  be most app rop ria te  to  
com pare  the aberra tions detected by C G H  in x-G BM s w ith those present in the 
o rig in a l biopsy m ate ria l, which was used to  establish the xenogra ft lines 
(o-G BM s). C G H  was perform ed on only 3 o f the 11 o -G B M s because e ither no 
m ateria l was a va ila b le '143'151' o r  the fragm en t size and a m oun t o f isolated D N A  
were not adequate  fo r  C G H . Therefore we decided also to  com pare  the C G H  
find ings in o u r x-G BM s w ith those in l-G BM s. The m ajority  o f aberra tions 
detected in x-G BM s were a lso present in both o -G B M s and l-G B M s, inc lud ing  
the most com m on ly  detected ch rom osom al im balances in the lite ra ture '80-84,139', 
ind ica ting  tha t the xenogra ft lines are genetica lly  va lid  models.
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The d iffe ren t ch rom osom al im balances were m ore frequen t in x-G BM s than in
0 -G B M s and l-G B M s; no t a ll aberra tions detected in the x-G BM s were detected 
in the o -G B M s and e.g. + 7 p  and -1 0 q  are both present in 100%  and 91%  o f 
the x-G BM s and in 35%  and 41%  o f the l-G B M s, respectively. The la tte r was 
a lso noticed when we com pared  a study o f xenogra fted  gastric tum ors '157' w ith a 
study o f gastric cance r biopsy sam ples '158'. Rather than resulting from  tu m o r 
progression during  serial passaging, as discussed later, this phenom enon can be 
exp la ined by the fac t tha t tu m o r biopsy m ateria l (o-G BM s and l-G BM s), in 
contrast to  xenogra fted  tu m o r m ateria l (x-GBMs), consists o f a m ixture o f 
neoplastic and non-neop lastic  hum an cells. The non-neop lastic  hum an cells 
decrease the sensitivity fo r  detecting copy num ber changes in a C G H  
experim ent'40'. In a d d ition , the differences between x-G BM s and o -G B M s m ight 
a lso be due to  decreased sensitivity o f the C G H  experim ent in which ULS-labeled 
D N A  from  pa ra ffin -em bedded  tissue is used.
Genetic stability of xenograft lines
Two d iffe ren t passages o f three xenogra ft lines each (E34, E 102, and E106) 
were analyzed (figure 8 -3  and tab le  8 -1 ) to  establish w hether accum u la tion  o f 
ch rom osom al im balances occurs a fte r seria l passaging reflecting tu m o r 
progression. The m ajority  o f ch rom osom al im balances were present in both 
passages, inc lud ing  the most com m on ly  detected ch rom osom al im balances in
1-GBMs'80-84,139'. In ana logy  w ith l-G B M s'159', the differences may be exp la ined by 
in tra tum ora l heterogeneity; in l-G BM s, basic ch rom osom al im balances were 
present in all parts, whereas others were on ly detected in som e parts o f the 
heterogeneous tum or. It is unlike ly tha t tu m o r progression during  serial 
passaging is a cause o f the differences between early and late passages 
because; 1) in xenogra ft line E106 the early passage conta ins m ore aberrations 
than the la te r one, 2) a ll early passages con ta ined  one (E34 and E102) o r  tw o 
(E1 06) aberra tions tha t were not detected in the la te r ones, 3) on ly 3 new 
aberra tions were detected in E102 a fte r seria l passaging the tu m o r fo r  2 7  times 
(passage 5 com pared  to  passage 32 ), and 4) no aberra tions were m ore 
p rom inen t w ith in the g roup  o f x-G BM s com pared  to  the l-G BM s as the 
d is tribu tion  o f ch rom osom al im balances am ong x-G BM s and l-G BM s is 
com pa rab le  (figure 8 -3 ). Therefore, if d ifferences are detected between early and 
late passages, they do  not seem to  be caused by experim enta l artifacts o r by 
accum u la tion  o f ch rom osom al im balances du ring  serial passaging. This is in 
conco rdance  w ith a cytogenetic study o f x -G B M s '152', in w hich the investigators 
showed tha t structura l abno rm alities  in the karyotypes were m ain ta ined during 
serial passaging from  passages 1 o r  2 th rough  passage 10.
Oncogenesis and genetic subtypes of GBM
The com m on reg ion o f overlap  o f frequently detected chrom osom al 
im balances and the regions w ith high copy num ber gains are prim ary candidates 
to  conta in  genes involved in G B M  oncogenesis. These regions were previously
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Figure 8 -3 . An overview o f the chrom osom al im balances present in tw o different passages of 
x -G B M  lines E34, E102, and E106. The early passages (E34p12, E102p5, and E106p9) are 
represented by a dotted line, and the late passages (E34p23, E 102p32 , and E 106p12) are 
represented by a solid line. For interpretation see also the legend to  figure  8 -1 .
discussed in reports o f C G H  perfo rm ed on G B M s'80,84,139,140', as well as in a 
review o f ch rom osom al im balances in hum an neoplasm s as detected by
C G H '46'47'.
It has been reported th a t G BM s can be subd iv ided into distinct m o lecu la r 
entities on the basis o f tw o  m utually exclusive genetic aberra tions '5'7'11'12': Type 1 
G BM s show loss o f heterozygosity o f 17p  (LOH 1 7p) and TP53 m utations 
(located a t 1 7 p 1 3 ), whereas Type 2 G BM s ha rbo r an a m p lifica tion  o f EGFR 
(ep iderm al grow th fa c to r receptor; located at 7p12 ). As analyzed w ith C G H , the 
m ost com m on type o f G B M  conta ins a + 7  a n d /o r  a -1 0  (11 o f 11 x-G BM s and 
4 3  o f 58  l-G BM s)'80'81'83'84'; we w ill refer to  these as " +  7 /-1 0 "  G BM s. The 
"+ 7 / -1 0 "  G BM s p robab ly  include Type 2 G BM s, because an am p lifica tion  o f 
EGFR was detected by southern b lo t analysis in 14 o f 15 l-G BM s w ith a + 7 ,  and 
in none o f the l-G BM s w ith a ba lanced chrom osom e 7 '84'.
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In a recent C G H  study o f o lig o d e n d ro g lia l tum ors '53' (chapter 3) we found  tha t 
a ll low -g rade  (lg-) and 50%  o f the h igh-g rade  pure o lig o d e n d ro g lia l tum ors 
(hg-O s) conta ined -1 p  a n d /o r  -1 9 q , whereas the o the r hg -O s conta ined a + 7  
a n d /o r  -1 0  (denoted as "-1 p /-1 9 q " hg -O s and " +  7 /-1 0 "  hg -O s, respectively). 
Interestingly, o u r xenogra ft line E34 conta ined both -1 p /-1 9 q  and + 7 / - 1 0  and 
was the only x -G B M  established from  a G B M  with o lig o d e n d ro g lia l features. 
Because it is known from  c lin ica l observa tion  th a t o lig o d e n d ro g lia l tum ors can 
progress to  G BM s and + 7  and -1 0  are late events in g liom a  oncogenesis, we 
hypothesize tha t E34 o rig ina ted  from  a " -1 p /-1 9 q " h g -O  tha t acqu ired  + 7  and 
-1 0  during  m a lignan t progression to  a G B M . In the literature we found  tha t five 
o f the 5 8  l-G B M s harbored a loss on 1p a n d /o r  19q , one o f these 5 tum ors 
harbored an ad d ition a l loss on chrom osom e 10 whereas none harbored  a 
a d d ition a l ga in  o f 7 '80'81'83'84'. These G BM s con ta in ing  -1 p a n d /o r  -1 9q are 
p robab ly  distinct from  Type 1 G BM s because the com b ina tion  LO H 1p and LOH 
1 7 p was only spo rad ica lly  detected by m icrosate llite  analysis in G B M s'22'. 
Furtherm ore, a loss on 17p  was never detected on C G H  in these tum ors, 
however, as discussed in chap te r 5 '131', loss o f 17p  as detected by C G H  m ight 
be less frequently detected than LOH 17p  because o f m ito tic  recom bina tion  o f 
chrom osom e 17 in g lio m a s '125'.
Identifica tion  o f tum ors ha rboring  the genetic o lig o d e n d ro g lia l features 
-1 p /-1 9 q  m igh t open new perspectives in the trea tm ent o f som e G BM s, because 
this genetic p ro file  is related to  chem osensitiv ity and post-operative survival: LOH 
1p was shown to  be a positive p red ic to r fo r  chem osensitiv ity '16' and in patients 
w ith " -1 p /-1 9 q " hg -O s a tendency was shown fo r  longer post-operative survival 
than in those w ith " +  7 /-1 0 "  tum ors '53' (chapter 3). It rem ains to  be established 
w hether the iden tifica tion  o f -1 p in G BM s has the rapeu tic  o r  p rognostic 
relevance, and the study o f x -G B M  m ight also be useful fo r  this purpose.
IN CONCLUSION
O u r  xenogra ft lines are va lid  m odels fo r  the study o f G BM s from  a genetic 
po in t o f view because the ch rom osom al im balances in x-G BM s com pared  w ith 
those in o -G B M s and l-G BM s are s im ila r. Results o f the C G H  analysis o f tw o 
passages o f three xenogra ft lines ind icated tha t x-G BM s are genetica lly  
heterogeneous (like l-GBM s) and tha t s ign ifican t accum u la tion  o f aberra tions 
during  serial passaging o f x-G BM s does not occur. O n e  xenogra ft line tha t 
showed a loss o f 1p and 19q m igh t be o f special interest because this genotype 
may have an o lig o d e n d ro g lia l o rig in , which m ight be associated with 
chemosensitivity.
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A bstract
Representational d ifference analysis o f a hum an g liob las tom a xenogra ft 
resulted in the iso la tion  o f five tum or-assoc ia ted  hom ozygously deleted D N A  
fragm ents, a ll o rig ina ting  from  chrom osom e 9 , reg ion p21 . Subsequent analysis 
o f a series o f 10 g liob las tom as using o u r newly isolated RDA fragm ents in 
con junc tion  w ith a series o f known 9p21 D N A  markers revealed hom ozygous 
de le tions in 9 o f the 10 (90%) tum ors. These de le tions encom pass the p !5 / p l6  
com plex and tw o ad d ition a l putative tu m o r suppressor loci. The RDA fragm ents 
correspond to  the la tte r tw o  loci. Taken toge ther, these results suggest the 
invo lvem ent o f m u ltip le  tu m o r suppressor genes from  the 9p21 reg ion in 
g liob las tom a tum origenesis. The novel RDA fragm ents w ill be instrum ental in the 
iso la tion  o f the re levant genes.
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INTRODUCTION
Representational d ifference analysis (RDA)|160] is a pow erfu l m ethod fo r  the 
iso la tion o f tum or-spec ific  genetic rearrangem ents. Basically, RDA allow s the 
iso la tion o f d ifferences between tw o closely related genom es th rough  subtractive 
hybrid ization and polym erase cha in  reaction (PCR) a m p lifica tion . The 
subtractions are carried o u t w ith representations o f tw o  D N A  popu la tions (tester 
and driver) o f which the d ifferences are the targets (present in the tester) to  be 
isolated. Representations are m ade by restriction enzyme c leavage o f genom ic 
D N A, fo llow ed  by a d a p to r liga tion  and a d a p to r-p rim ed  PCR a m p lifica tion . Both 
tum or-assoc ia ted  am p lified  sequences and hom o-zygously deleted sequences 
have been isolated from  various tu m o r types using RDA187,160-162'. H om ozygously 
deleted D N A  fragm ents turned o u t to  be particu la rly  useful fo r the m app ing  and 
positiona l c lon ing  o f genes th a t are inactivated in tum ors as was e.g. 
dem onstra ted fo r  BRCA2|161] and PTEN1871.
G liom as  are the most frequently occurring  prim ary tum ors o f the adu lt bra in , 
the most com m on o f w hich are the astrocytic tum ors. From c lin ica l observations 
it is known tha t low -g rade  astrocytic and o lig o d e n d ro g lia l tum ors tend to  
progress into m ore m a lignan t lesions, the most m a lignan t one being 
g liob las tom a  m u ltifo rm e (G B M )|28,163]. G ene tic  events underly ing g liom a  
tum origenesis have been studied extensively and m ultip le  genetic pathways 
lead ing to  G B M  have been identified. G enetic  a lte ra tions reported include a lle lic  
losses o r rearrangem ents o f 9 p , 10 , 13q , 17p , 19q and 2 2 q |5'163' 165]. Several 
genetic changes are shared am ong d iffe ren t g liom as, whereas others a p p e a r to  
be m ore characteristic fo r  a certa in subtype. Furtherm ore, it is th o u g h t tha t 
pa rticu la r genetic  aberra tions act as early events in g lia l tu m o r deve lopm ent, 
whereas others are th o u g h t to  play a role(s) in la ter stages. In 
o lig o d e n d ro g lio m a s  a lle lic  losses o f 1p and 19q are preferentia lly  
observed121,120'. H igher-g rade  anap lastic  o lig o d e n d ro g lio m a s  and G BM s show 
increasing num bers o f ch rom osom al abnorm alities  inc lud ing  a lle lic  losses o f 9p  
and 1 0 15,163-165'.
Here, we have app lied  the RDA techn ique to  isolate G B M -associa ted  
hom ozygously deleted D N A  fragm ents using a xenogra ft o f a G B M  (x-GBM) w ith 
o lig o d e n d ro g lia l d iffe ren tia tion  (E34). Subsequent m o lecu la r characterization  o f 
five isolated fragm ents revealed the ir 9p21 o rig in . F ine-m app ing  o f this 
ch rom osom al reg ion in E34 and the a d d ition a l characterization  o f a series o f 9 
a d d ition a l x-G BM s suggest th a t m u ltip le  tu m o r suppressor genes (TSGs) from  the 
9p21 reg ion , inc lud ing  the p !5 /p !6  com p lex1166', may be involved in the 
deve lopm ent o f GBM s.
M aterials a n d  M ethods
Tumor samples, DNA preparation and Southern blot. T um or xenogra ft samples 
used in this study were a ll h is topa tho log ica lly  d iagnosed as G BM s (grade IV
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tum ors). O n e  G B M  (E34) showed som e o lig o d e n d ro g lia l d iffe ren tia tion  and loss 
o f 1p and 19q , the o the r G BM s (E18, E49, E80, E 102, E 106, E 110, E120, 
E 168, E98) showed astrocytic d iffe ren tia tion , w hile  unequ ivoca l o lig o d e n d ro g lia l 
features and loss o f 1p and 19q were absent. The presence o r absence o f 1p 
loss and 19q loss was determ ined by C G H  (chapter 2 and 8). H igh m o lecu la r 
w e igh t genom ic D N A  from  tu m o r tissues and from  periphera l b lood  cells o f 2 
unre lated hum an contro ls was isolated using m ethods described by M ille r |66] and 
S am brook |167]. Southern b lo t experim ents and hybrid ization o f the hum an PAC 
lib rary (RPC15; BAC-PAC Resources, Roswell Park C ance r Institute, Buffa lo, NY, 
USA) were perform ed as described by W ete rm an |168].
Representational difference analysis, cloning and sequencing of RDA 
fragments. RDA was perform ed essentially as described by Lisitsyn|160,1691. D N A  
bands from  RDA d ifference p roduct 3 (DP3) were isolated from  agarose gels and 
cloned into pB luescript KS + II p lasm id vectors (Stratagene). N uc leo tide  
sequencing was perfo rm ed as described by W ete rm an |168]. D atabase searches 
were perfo rm ed using the G e n b a n k  and European M o le cu la r B io logy Laboratory 
(EMBL) databases.
Fluorescence in situ hybridization (FISH). FISH analysis was perform ed as 
described before |170]. Briefly, 1 5 0  ng d igox igen in -11 -dU TP  labe led PAC D N A  
was, p rio r to  overn igh t hybrid ization a t 3 7  °C , p re-annea led  w ith a 4 0 -fo ld  
excess o f Cot-1 D N A  (Invitrogen). Target slides con ta in ing  norm al ch rom osom al 
m etaphase spreads were pre-treated acco rd ing  to  standard protocols. 
Im m unocytochem ica l detection was perform ed using sheep-an ti-d igox igen in - 
FITC (ROCHE D iagnostics) and donkey-anti-sheep-FITC  (Jackson Im m uno 
Research Laboratories). A fterwards, slides were analyzed using the O n co r-im a g e  
software (G a ithersburgh M D).
Primers, genetic markers, probes and clones. Based on the nucleotide 
sequences o f RDA clones DO1 to  D O 5 , p rim er sets were designed fo r  PCR 
analysis: D O 1 -F O R  (=  U O K 1 3 2 -1 2 .1  |Lisitsyn et a l., 1 9 9 5 ]; 5 '-G C C C C T C T - 
A AA A G A T A A G G T C T T G G T -3 ') and D O  1 -REV (5 '-G A T C T G A G C C T C T G G A A - 
G A A G T T A G -3 '); D O 2 -F O R  (5 '-G A G C C T T G A G A G A A T C C A A C -3 ') and D O 2 - 
REV (5 '-C C T T A T G TG TA T A G C TC A C G -3 '); D O 3 -F O R  (5 '-A TC A TC C A G - 
A C C A A T G C G A C -3 ') and D O 3-R EV (5 '-G A C T G T G G A A G T G A T G A T A G -3 '); 
D O 4 -F O R  (5 '-T A A C T TA G G G C A TC C T T T C C -3 ') and D O 4-R EV (5 '-A G A T G - 
CT G  CT ATT ACT G  A C C  - 3 ') ; D O 5 -F O R  (5 ' - CT G  A G  AT C A A G  C A G T  CTTT G  - 3 ') 
and DO 5-R EV (5 '-C T A T G A G A G T T C C A G C T A C C -3 '). G ene tic  markers used 
were IFNA (G enom e D atabase |GDB] accession num ber 1 0 4 6 3 0 0 ), D 9S 1749  
(GDB 5 9 5 8 7 6 ) D 9S 1748  (GDB 5 9 5 5 8 9 ), D 9S 1752  (GDB 5 9 5 9 9 3 ), D9S171 
(g D B  1 8 8 2 1 8 ), D 9S259 (GDB 1 9 9 1 3 0 ), D 9S 270 (G DB 1 9 9 4 6 7 ), and 
D 9S104 (G DB 1 8 0 7 0 1 ). A  p rim er set from  exon 2 o f the von H ippe l-L indau 
gene (VHL), G 7 1 2 F 2 /G 7 1 3 R 1 , was used as an internal co n tro l|171]. A  p !6  cD N A  
probe and the p !5 /p !6  com plex con ta in ing  P1 (1 0 6 2  and 1063 ) and cosm id 
(c5) c lones|166] were generously provided by Dr. A. de Klein (Erasmus University 
Rotterdam , The Netherlands).
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Somatic cell hybrid panel and radiation hybrid panel. The m onochrom osom al 
h u m a n /ro d e n t som atic  cell hybrid panel used was partia lly  ob ta ined  from  the 
C orie ll Institute fo r  M ed ica l Research (C am den, NJ, USA) and partia lly  prepared 
in o u r departm ent o f H um an G enetics (N ijm egen, The Netherlands). The 
rad ia tion  hybrid panel used was the S tanford G 3  panel (Stanford H um an 
G enom e  C enter, C A, USA).
PCR analysis. PCR analyses were carried ou t under standard cond itions using 
1 00  ng tem p la te  D N A , 5 0  ng FO R -prim er and 5 0  ng REV-primer in 2 5  U  
reaction vo lum e and acco rd ing  to  the p ro toco l: 3 0 -3 5  cycles o f 3 0  sec a t 94  °C, 
4 5  sec a t annea ling  tem pera ture  (61 °C fo r  D O 1 , 55  °C fo r  D O 2  to  D O 5 ), and 
4 5  o r  60  sec a t 72 °C , fo llow ed  by a fina l extension o f 5 m in a t 72 °C. Duplex- 
PCR reactions were perfo rm ed under the same cond itions except fo r  a d d ition  o f 
5 0  ng o f the G 7 1 2 F 2  p rim er and 5 0  ng o f the G 713R 1 p rim er and fo r  the 
annea ling  tem pera ture  o f 55  °C. R adiation hybrid panel m app ing  was perform ed 
under standard  cond itions using 1 0 0  ng tem p la te  D N A  and 2 5  ng o f each 
p rim er in a 10 u l reaction vo lum e ; PCR: p re -dena tu ra tion  fo r  5 m in a t 94  °C , 35  
cycles o f 1 m in a t 94  °C , 1 m in a t 55  °C and 1 .5  min a t 72  °C , perfo rm ed in a 
m icro tite rp la te  PCR appara tus (MJ Research). A fte r PCR, 10 u l o f each reaction 
mixture was loaded  on a 2%  agarose gel and subjected to  e lectrophoresis.
Results 
Isolation of GBM-associated homozygously deleted DNA 
fragments
Bglll representations o f D N A  from  x -G B M  E34 (D; driver) and a pool o f 2 
norm al unrelated DNAs (Ta and Tb; tester) were used fo r the iso la tion o f G B M - 
associated hom ozygously deleted D N A  fragm ents via RDA. D ifference products 
(DP) ob ta ined  a fte r one, tw o and three rounds o f subtractive hybrid ization and 
PCR a m p lifica tion  are shown in figu re  9 -1A . A t least 8 c lea r bands, varying in 
size from  3 5 0  bp to  7 0 0  bp, cou ld  be observed in the round 3 d ifference 
p roduct (DP3) w h ile  background  levels were reduced considerab ly. These bands 
were c loned  into p lasm id vectors and c lone inserts were used as probes on 
Southern blots con ta in ing  tester and driver, both representation and to ta l 
genom ic, DNAs. Five clones, DO1 (deleted in G B M  w ith o lig o d e n d ro g lia l 
features), D O 2 , D O 3 , D O 4 , and D O 5 , derived from  bands 1, 2 , 3 , 4 , and 5, 
respectively, showed hybrid ization s ignals in the tester lanes (T; norm al) and not 
in the d rive r lanes (D; tum or), ind ica ting  tha t these fragm ents represent 
hom ozygously deleted sequences in the o rig in a l xenog ra ft sam ple (figure 9-1B). 
Two ad d ition a l clones, derived from  band 4 , turned ou t to  represent D N A  
polym orphism s (not shown). N o  in form ative clones were ob ta ined  from  bands 3, 
6 , 7, and 8.
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Identification of isolated RDA fragments
The 5 D O -c lones were sequenced and , subsequently, com pared  w ith known 
sequences in databases. N o  hom olog ies were found  except fo r  c lone DO1 
w hich showed a 100  % identity over 2 6  bp to  p rim er U O K 1 32 -1 2 .1  (GDB 
5 6 7 1 7 1 ) and 96%  identity over 2 5  bp to  p rim er U O K 1 3 2 -1 2 .2  (GDB 5 6 7 1 7 1 ). 
These prim ers were derived from  a BglII restriction fragm ent, ca lled  c lone 
U O K 1 3 2 -1 2 , which was previously found  to  be hom ozygously deleted in the 
hum an renal cell ca rc inom a cell line U O K 1 3 2 |169]. In o u r DO1 sequence 221 nt 
are present between the 2 6  bp and 2 5  bp regions o f identity, y ie ld ing  a 2 7 2  bp 
PCR fragm en t which was a lso ob ta ined  by Lisitsyn et a l. |169] when using the 
UOK1 3 2 -1 2 .1 /2  p rim er set. A lthough  the com ple te  U O K 1 3 2 -1 2  nucleotide 
sequence is no t ava ilab le  to  us, we assume th a t c lone DO1 is identica l to  
U O K 1 3 2 -1 2 . N o  overlaps o r s im ilarities between the sequences o f the 5 D O - 
clones cou ld  be found . D O -de rived  nucleotide  sequences are ava ilab le  a t the 
G enB ank database under the accession num bers: DO1 : A F 0 7 8 6 7 2 ; D O 2 : 
A F 0 7 8 6 7 3 ; D O 3 : A F 0 7 8 6 7 4 ; D O 4 : A F 0 7 8 6 7 6  and A F 0 7 8 6 7 7 ; D O 5 : 
A F 0 7 8 6 7 5 .
Figure 9 -1 . (A) RDA results o f a pool o f 2 norm al DNAs as tester (T, BglII representation) and 
g liob lastom a xenograft E34 as driver (D, BglII representation). DP1, DP2, and DP3: difference 
products after first, second, and th ird round o f hybrid iza tion /am p lifica tion . In DP3 at least 8 
bands are present (1 to  8 ) which represent target sequences enriched from  the tester. m: 1 0 0  
bp marker. (B) Hybrid ization of clone D O 4  to  Southern blots conta in ing BglII-representations 
(left panel) and EcoRI-cleaved tota l genom ic (right panel) DNAs o f driver (D, tum or) and tester 
(T, norm al). D O 4  sequences are present in the norm al and deleted in the tum or DNA. 
Fragment sizes are deduced from  co-e lectrophoresed 100 bp and 1 kb markers (not shown).
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Assignment of the isolated RDA fragments to chromosomal 
region 9p21
To establish the ch rom osom al loca liza tion  o f the isolated RDA fragm ents a 
panel o f m onoch rom osom a l h u m a n /ro d e n t som atic  cell hybrids was used fo r 
PCR analysis w ith D O -c lo n e  derived p rim er sets (figure 9 -2A ). In a ll cases PCR 
products o f expected sizes were observed in the chrom osom e 9 con ta in ing  
som atic  cell hybrid only, ind ica ting  th a t all isolated D O -c lones m ap to  this 
chrom osom e. The hom ozygously deleted status o f the five D O -c lones  in E34, as 
previously de term ined by Southern b lo t analysis, cou ld  a lso be con firm ed (figure 
9-2A ). These la tter PCR analyses were perfo rm ed in a duplex-PCR fo rm a t in 
w hich the V H L-prim er set (G 712F 2  and G 713R 1) was added  as an internal 
con tro l fo r PCR-able qua lity  o f the tem p la te  DNA. D O -spec ific  fragm ents o f 
expected sizes were on ly seen in the tester (T; norm al) but not in de d rive r (D; 
tum or) D N A , whereas the 241 bp internal VHL contro l fragm en t was consistently 
seen in both DNAs (table 9 -1 ).
To fine -m ap  the isolated clones by FISH, a PAC lib rary was screened with 
clones DO1 to  D O 5 . Three positive PACs were iso lated: 9 7 3 N 2 0  and 1054F 14  
w hich were both positive fo r  c lone D O 1 , and 1026F 9  w hich was positive fo r 
c lone D O 5  (table 9 -1 ). FISH analysis w ith the three PACs on norm al hum an 
m etaphase spreads revealed positive signals on 9p21 only (figure 9 -2B ), thereby 
con firm ing  the loca liza tion  o f the correspond ing  D N A  fragm ents (DO1 and 
D O 5 ) on chrom osom e 9 and, in a d d ition , re fin ing th e ir assignm ent to  region 
9 p 2 1 . N o  PACs were isolated w ith the clones D O 2 , D O 3  and D O 4 . C lones 
D O 2  and D O 3  cou ld  be m apped via PCR analysis o f a rad ia tion  hybrid panel. 
S ign ifican t linkage was found  w ith markers D 9S 263 (lod score 4 .7 ) and D 9S270 
(lod score 10), respectively (not shown), a lso m app ing  w ith in reg ion 9p21 (table
9 -1 ). C lones DO1 and D O 4  cou ld  not be fine -m apped  using e ithe r m ethod.
Homozygously deleted 9p21 region includes p15/p16 and 
two additional candidate tumor suppressor loci
The p15/p16 tu m o r suppressor com plex is located at 9 p 2 1 |166] and since the 
p16 gene is known to  be frequently  involved (hom ozygously deleted o r mutated) 
in h igher g rade  g lio m a s |172-175], we decided to  investigate w hether this com plex is 
inc luded in the E34 de le tion  o f 9 p 2 1 . To this end, Southern b lo t analysis o f 
genom ic  tu m o r and norm al con tro l DNAs was perfo rm ed using a p16 cD N A  
probe (figure 9 -3 ). A  4 kb fragm en t was visualized in the tw o  norm al contro l 
DNAs (Ta and Tb), as expected, but not in the E34 tu m o r D N A  (D), ind ica ting  
th a t this locus is indeed hom ozygously deleted in the xenogra ft sam ple. The 
sam e p16  p robe was also tested on the 3 isolated PACs, but no hybrid izing 
s igna l was observed, dem onstra ting  tha t the three PACs do not cover the p16 
gene (table 9 -1 ). To test in reverse w hether o u r D O -c lones  (inc lud ing  a lso D O 2 , 
D O 3  and D O 4) are linked to  the p16  gene, D O -spec ific  PCR reactions were 
perfo rm ed on P1 clones 1 0 6 2  and 10 6 3  and cosm id c lone c5 , which are known 
to  conta in  the com ple te  p15/p16 com p lex|166]. N o  PCR products were ob ta ined
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from  these clones, aga in  ind ica ting  tha t DO1 and D O 5 , and a dd itiona lly , D O 2 , 
D O 3  and D O 4 , are not physically linked to  the p15 and p16 genes (table 9 -1).
Figure 9 -2 . (A) C hrom osom al localization o f clone D O 2 . Specific primers were used fo r PCR 
analysis of m onochrom osom al somatic cell hybrid lines (1 to  2 2 , x and y). Driver (D, tum or), 
tester (T, norm al), clone D O 2  and H2O  (-) were used as controls, perform ed in a duplex-PCR 
together with the VHL G 71 2F 2 /G 7 13 R 1  prim er set. A  D O 2-spec ific  PCR product o f expected 
size (342  bp) is observed only in the chrom osom e 9 conta in ing hybrid, ind icating that clone 
D O 2  maps to  this chrom osom e. Furthermore, a 3 42  bp PCR product is seen in the positive 
contro l (D O 2) and the tester (T), but not in the driver (D), thus, confirm ing the homozygously 
deleted status o f clone D O 2  in tum or E34. m: 100 bp marker.(B) C hrom osom al localization 
o f PAC clone 1054F14 by FISH on DAPI-stained norm al metaphase chrom osomes. A  specific 
hybridization signal can be seen only on chrom osom e 9, region p21 (arrow heads).
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Table 9 -1 .
M arker ana lysis o f tum or samples, PAC, P1 and cosmid clones.
STS/Marker PACs P1/cosm a N orm al G liob las tom a xenografts
O A A A A A A A A A
1054F1 4 9 7 3 N 2 0 1026F9 6 2 /6 3 /c 5 Ta/Tb E34 E49 E80 E168 E102 E106 E110 E98 E120 E18
(Tester) (Driver)
DO1 + + - - + - - - + + + + + + +
D O 2 - - - - + - + + + + + + + + +
D O 3 - - - - + - + + + + + + + + +
D O 4 - - - - + - - - + + + + - - +
D O 5 - - + - + - - + + + + + + + +
IFNA nd nd nd - + + + + + + + + + + +
D 9S1749 - - - - + - - - - + - + nd + +
p16 - - - + d + - nd nd nd nd nd nd nd nd nd
D 9S1748 - - - + + - - - - - - + - - +
p15 nd nd nd +  d nd nd nd nd nd nd nd nd nd nd nd
D 9S1752 - - - + + - - - - - - - - - +
Region 1
D9S171 + + - - + - - - + + + + + + +
D9S259 - - - - + - - + + + + + + + +
Region 2
D 9S270 - - - - + - + + + + + + + + +
D9S263 nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd
D9S104 - - - - + + + + + + + + + + +
9p21 D N A  markers are listed in the same o rder as on the genetic m ap (IFNA distal and D 9S104 proxim al). The relative positions o f the two putative 
tum or suppressor regions (1 and 2) as described byHam ada et a l.[176] are ind icated. Abbreviations used: a, p1 clones 1062  and 1063  and cosmid clone 
c5 (Kamb et a l., 1 9 9 4 [166]); O , G BM  with o ligodend rog lia l d iffe rentia tion; A, G BM  with only astrocytic d iffe rentia tion; das determ ined by Kamb et a l., 
1 9 9 4 P66]; +  , present; -, absent; nd, not determ ined.
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D  Ta Tb
Figure 9 -3 . Southern b lot con ta in ing  EcoRI-cleaved
tum or E34 (D) and norm al (Ta and Tb) genom ic DNAs 
hybridized with a p16  cD N A  probe. Hybridizing 
fragm ents are only observed in the tw o norm al lanes and 
not in the tum or lane, ind icating a homozygous deletion 
o f the p i ó  gene in tum or E34. The fragment size is 
deduced from a co-electrophoresed 1 kb marker (not 
shown) and is approximately 4 kb.
E coR I
A  recent investigation o f hum an lung carc inom as by H am ada and co- 
w orkers '17^  suggested the presence in 9p21 o f a t least tw o regions con ta in ing  
putative TSGs, o the r than p15/p16. These regions, denoted region 1 and region 
2 , were m apped between the markers D 9S 1752  and D9S171 (region 1) and 
D 9S 259 and D 9S 270 (region 2 ), and are both located centrom eric  to  p15/p16 
(table 9 -1 ). W e investigated the presence o r  absence o f these markers and 
m arker D 9 S 1 7 4 8 , w hich maps in between p ió  and p i5 ,  in E34. A dd itiona lly , 
the markers IFNA (distal m arker; from  the interferon a lpha  gene cluster a t 9 p 2 2 ), 
D 9S 1749  (just d istal to  the p ió  gene) and D 9S104 (proxim al m arker; located 
be low  reg io n -2 -fla n k in g  m arker D 9S270) were tested by duplex-PCR. 
H om ozygous deletions were observed in E34 fo r  a ll tested markers except IFNA 
and D 9S 104. The same PCR analyses were a lso carried o u t on the 3 isolated 
PACs, P1 clones 1 0 6 2  and 1 0 6 3 , and cosm id clone c5. O n ly  fo r  m arker 
D9S171 PCR products were ob ta ined  from  the D O 1-pos itive  PACs 1054F 14  
and 9 7 3 N 2 0 . P1 clones 1 0 6 2  and 1 0 6 3  and cosm id c lone c5 (p15/p16 
positive) y ie lded PCR products w ith only the markers D 9S 1748  and D 9S 1752 , as 
expected (table 9 -1 ).
In sum m ary, the p ió  gene and all 9p21 markers tested covering the p15/p16 
com plex and the regions 1 and 2 , were hom ozygously deleted in the x-G B M  
E34, whereas the most p roxim al (D 9S104) and most distal (IFNA) markers tested 
were retained. D O 1-pos itive  PACs 1054 F 1 4  and 9 7 3 N 2 0  cou ld  be m apped 
between the markers D 9S 1752  and D 9S259.
Frequent 9p21 homozygous deletions in other GBMs
To determ ine the invo lvem ent o f the D N A  sequences m entioned above in 
o the r related bra in  tum ors, a series o f 9 ad d ition a l x-G BM s was tested by PCR 
using D O - and 9p  m arker-specific  prim ers (table 9 -1 ; figu re  9 -4 ). G BM s E168, 
E 102, E 106, E 110, and E18 were all positive fo r the five D O -m arkers . Tum ors 
E49, E80, E98, and E120 were hom ozygously deleted fo r  subsets o f the D O - 
clones. The most distal and the most p roxim al genetic markers, IFNA and 
D 9S 104 , respectively, were both present in a ll tum ors. M a rke r D 9S 270 was
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present in a ll sam ples, m arker D 9S 259 was present in a ll sam ples except in E49, 
m arker D9S171 was present in a ll samples except in E49 and E80, m arker 
D 9S 1752  was present only in E18, m arker D 9S 1748  was present only in E110 
and E18, and m arker D 9S 1749  was present on ly in E 102, E 110, E 120, and 
E18. This la tter m arker was not tested on E98 due to  lack o f fu rthe r m ateria l 
from  this tum or. Through this analysis, hom ozygous de le tion  o f D O -c lones 
a n d /o r  o the r tested 9 p 2 1 markers was revealed in 8 o u t o f the 9 add itiona l 
x-G BM s tested (table 9-1 ; figu re  9-5).
Figure 9 -4 . Duplex-PCR analysis (DO1 and VHL) o f the tota l series o f g liob lastom as (E18 to 
E98, including E34 (=  D)). N orm a l D N A  (T), g liob lastom a E34 D N A  (D), clone DO1 and 
H2O  (-), were included as controls. The VHL-specific 241 bp PCR fragm ent (internal control 
fo r PCR-able quality o f the templates) is present in all tum ors tested. The tum ors E34 ( =  D), 
E49 and E80 are negative fo r DO1 (272 bp), ind icating a homozygous deletion o f this 
fragm ent in these samples. m: 1 0 0  bp marker.
Positioning of RDA clones within 9p21 genetic map
C om b in in g  a ll results from  the genetic m arker- and D O -spec ific  PCR reactions 
on the to ta l series o f 10 tum ors, PACs, P1 clones and cosm id c5 we were ab le  to 
position the D O -c lones in the 9p21 m ap as depicted in figu re  9 -5 : D O 4  and 
D O 1 w ith in  reg ion 1, where D O 4  is located distal to  D O 1 ; D O 5  w ith in region 
2 ; D O 2  and D O 3  close to  markers D 9S 270 and D 9S 263 , most likely also 
w ith in  reg ion 2.
D isc u ssio n
In this study, we successfully app lied  the techn ique o f representational 
d ifference analysis (RDA) to  a x -G B M  sam ple (E34) using tu m o r D N A  as driver 
and norm al D N A  as tester. Five distinct G B M -associa ted  hom ozygously deleted 
D N A  fragm ents (DO1 to  D O 5 ) were isolated. Two add itiona l RDA clones 
appeared  to  represent polym orphism s, which can be exp la ined by the fac t tha t 
the tu m o r and norm al D N A  samples used were ob ta ined  from  unrelated 
ind iv iduals.
The five deleted RDA fragm ents were a ll derived from  ch rom osom al region 
9 p 2 1 . Interestingly, we d id  not isolate RDA fragm ents from  the o lig o d e n d ro - 
g liom a-assoc ia ted [21,120] ch rom osom al regions 1p a n d /o r  1 9q , in spite o f the fact
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tha t we d id  observe 1p and 19q loss in this tu m o r using C G H  analysis'86 
(chapter 8). O n e  m ight speculate th a t in these la tte r cases only one a lle le  was 
lost in the tu m o r and tha t the rem ain ing  a lle le  has proh ib ited  e ffic ien t enrichm ent 
du ring  the RDA procedure.
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Figure 9 -5 . Hom ozygous deletion m ap o f chrom osom al region 9p21 -22  in g liob lastom a 
xenografts E34 to  E18. A  schematic representation o f Southern b lot and PCR results o f genetic 
markers and position ing o f D O , cosmid and P1 (c5, 1 062 , 1063) and PAC (1054F14 , 
9 7 3 N 2 0 , 1026F9) clones is shown. Solid and open circles indicate absence and presence of 
the genetic m arkers/D O -clones, respectively. Dashed circles ( p i 5 / p i ó  on cosm id and P1 
clones) represent data described elsewhere [166]. Estimated genetic distances are indicated at 
the left (K =  Kamb et a l.[166]; D =  D ib et al. [177]; H =  H am ada et a l.[176]. The tw o putative tum or 
suppressor regions 1 and 2  [176] are marked.
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Since the p15/p16  tu m o r suppressor gene com plex is located a t 9 p 2 1 [166] and 
since the p ió  gene is known to  be frequently involved in h igher-g rade  
g lio m a s '172' 175' we perform ed Southern b lo t analysis on G B M  E34 and, indeed, 
observed com ple te  absence o f the p ió  gene. Subsequently, we tested a series o f 
genetic markers flank ing  the p i5  and p ió  genes[166] and markers flank ing  tw o 
a d d ition a l putative tu m o r suppressor loci in 9 p 2 1 , denoted regions 1 and 2 [176]. 
In tu m o r E34 a ll markers tested between IFNA and D 9S104 were hom ozygously 
de le ted, ind ica ting  th a t the deleted region in tu m o r E34 is re latively large 
(estim ated to  be at least 8 .5  c M ;|166'176'177|).
To determ ine the invo lvem ent o f the D N A  sequences m entioned above in 
o the r related bra in tum ors, a series o f 9 ad d ition a l x-G BM s sam ples was tested 
by PCR. In several o f these tum ors hom ozygous de le tions fo r the clones D O 1 , 
D O 4  and D O 5  were observed, whereas D O 2  and D O 3  were never found  to  be 
deleted. The o ther genetic markers tested showed a diverse d is tribu tion  o f
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dele tions am ong the d iffe ren t x-G BM s (table 9 -1 ; figu re  9 -5 ). The invo lvem ent o f 
the putative tu m o r suppressor regions 1 a n d /o r  2 [176] can be suggested in 8 ou t 
o f 9 x-G BM s. Rem arkably, in 7 o f these 8 tum ors a com b ined  de le tion  o f p ió  
a n d /o r  p i5  w ith region 1 a n d /o r  reg ion 2 was observed, show ing tha t in these 
tum ors m ultip le  genes from  9p21 may be involved. The p ió  gene is assumed to  
play an im po rtan t role in h igh -g rade  g lia l tu m o rs [172-175]. However, in 1 tu m o r 
(E110) the p ió  gene does not seem to  be dele ted, since its closely flank ing  
markers D 9S 17 4 9  and D9S1 748  are still present. The on ly hom ozygously 
deleted m arker in this tu m o r is D 9S 1752 , p roxim ally  flank ing  reg ion 1. This may 
suggest the invo lvem ent in this tu m o r o f a putative tu m o r suppressor gene(s) 
(TSG(s)) located near o r  w ith in  region 1, a lthough  it can not be ruled ou t a t this 
stage th a t m ore subtle p ió  (point) m utations, resulting in the inactiva tion  o f the 
p ió  gene [175], are associated w ith the deve lopm ent o f tu m o r E110.
Hom ozygous de le tions o f D N A  sequences from  chrom osom e reg ion 9p21 is a 
frequently occurring  event, not only in G B M s[172-175], but a lso in breast 
cancers[178], sm all cell lung cancers[179], squam ous cell ca rc inom as[180], p itu itary 
adenom as[181], m e lanom as[182], and non-sm all cell lung ca rc inom as[176]. The 
proposed clustering o f several tu m o r suppressor loci to  this restricted 
ch rom osom al reg ion may provide a m echanistic basis fo r  this observa tion , i.e., 
the concerted loss o f m ore than one tu m o r suppressor gene via hom ozygous 
de le tion  o f re latively large ch rom osom al fragm ents may require less genetic 
m od ifica tion  steps than the subsequent m uta tion  a n d /o r  de le tion  o f a ll the 
ind iv idua l (allelic) loci involved.
A lthough  they do  not exem plify expressed sequences, the D O -c lones  represent 
novel sequence tagged  sites (STSs) from  the 9p21 region tha t may be used as 
markers fo r the analysis o f o the r tum ors. In a d d ition , the newly isolated RDA 
fragm ents and th e ir co rrespond ing  PACs w ill be instrum ental in the iso la tion o f 
cand ida te  TSG(s) from  the 9p21 region.
IN CONCLUSION
Using RDA, 5 hom ozygously deleted regions were isolated from  a xenogra fted  
G B M  (E34) and were positioned in the 9p21 reg ion. N o  fragm ents were isolated 
from  chrom osom e 1p o r  19q which are frequently deleted in o lig o d e n d ro g lia l 
tum ors and identified by C G H  in this xenogra fted  G B M  suggesting tha t 
mechanism s o the r than hom ozygous deletions are involved in the oncogenesis. 
N ine o f ten xenogra fted  G BM s conta ined a hom ozygous de le tion  o f (some) the 
isolated fragm ents in con junction  w ith o the r 9p21 D N A  markers tested which 
encom pass the p 1 5 /p 1 6  com plex and 2 putative tu m o r suppressor loci. All 
isolated fragm ents correspond to  the la tter tw o loci. E34 conta ined the largest 
deleted regions and the o the r 8 tum ors d id  not show a hom ozygous de le tion  o f 
all isolated fragm ents. These newly isolated regions may be useful fo r  the 
iso la tion o f cand ida te  genes located a t 9 p 2 1 .
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A bstract
Ependymal tum ors (Es) are g liom as tha t arise from  the ependym al lin ing o f the 
cerebra l ventricles and from  the rem nants o f the centra l cana l o f the spinal cord. 
Both c lin ica l and genetic studies suggest tha t d istinct genetic subtypes o f Es exist, 
the subtypes being corre la ted  w ith patien t age a n d /o r  tu m o r loca liza tion . In the 
current study we screened the tu m o r genom e o f 2 0  Es (15 adu lt and 5 pediatric  
cases) fo r  ch rom osom al im balances by C G H . The m ost frequently detected 
im balances are: -2 2 q  (75% ), -1 0 q  (65% ), -21 (50% ), -1 6 p  (50% ), -1p  (45% ), 
+ 4 q  (45% ), -1 0 p  (45% ), -2q  (40% ), -6  (40% ), -19  (40% ), -2p  (35%) -3 p  (35% ), 
and -1 6 q  (35%). C om parison  o f the ch rom osom al im balances detected in Es to  
those previously reported in o lig o d e n d ro g lia l and astrocytic tum ors revealed tha t 
in this respect Es show s im ilarities to  these o the r g liom as. By com b in ing  o u r 
results w ith those o f a recent study o f Zheng et al. and H irose et al. we found 
tha t, a lthough  Es from  d iffe ren t loca lizations and from  a d u lt and ped ia tric  
patients show overlap  a t the C G H  level, som e chrom osom al im balances occu r 
p redom inan tly  in a certa in category. In a d u lt patients, sp inal Es re latively often 
showed + 2 ,  + 7 ,  + 1 2 ,  and —1 4q , in fra ten to ria l Es - 2 2 ,  and supra ten toria l Es 
-9 . A dd itio n a lly , in posterio r fossa Es -6  and + 9  were much m ore frequen t in 
adults than in ch ild ren . W e conc lude  tha t the genetic background  o f Es is 
com plex and partly de term ined by tu m o r loca liza tion , h is topa tho log ica l subtype 
and age o f the patient.
126
Ependymal tum ors
INTRODUCTION
Ependymal tum ors (Es) are g liom as tha t are considered to  arise from  g lia l cells 
norm a lly  covering the w all o f the cerebra l ventricles and o f the centra l cana l in 
the spinal cord. A lthough  Es are relatively com m on in ch ild h o o d , they may occu r 
a t a ll ages'3,183'. A cco rd ing  to  the W orld  H ealth O rg a n iza tio n  (W H O ) 
classifica tion , Es are subd iv ided into 4 categories: m yxopap illa ry ependym om a 
(W H O  grade  I), subependym om a (W H O  grade  I), ependym om a (lg-E) (W H O  
grade  II), and anap lastic  ependym om a (a-E) (W H O  grade  III). A dd itiona lly , the 
m ost m a lignan t g lia l tum or, i.e. g liob las tom a m u ltifo rm e (W H O  grade  IV), 
som etim es shows foca l ependym al d iffe ren tia tion  (GBM-E). N um erous studies 
have yie lded con flic ting  results regard ing  the p rognostic  s ign ificance o f 
h is to log ica l param eters fo r  patients w ith lg-E o r a-E (for review see'184'). C lin ica l 
studies revealed th a t post-operative survival depends on age o f onset, tu m o r 
loca liza tion , and extent o f tu m o r resection'3'. Furtherm ore, it is well established 
tha t tu m o r loca liza tion  and age o f the patien t are in te rre la ted '3'.
These c lin ica l da ta  suggest tha t d istinct tu m o r entities exist am ong Es, which 
m ay be age o r  loca liza tion  related. Indeed, age related genetic pathways are 
suggested by loss o f heterozygosity (LOH) analysis, reporting LO H 2 2 q  to  be a 
com m on find ing  in a d u lt Es tha t is only rarely present in a ped ia tric  
p o p u la tio n '33'. Localization dependent genetic pathways are suggested by the 
observation tha t neuro fib rom atosis  type-2 (NF-2) patients especially deve lop  
sp ina l Es, and tha t spo rad ic  spinal Es are characterized by a high incidence o f 
loss o f 2 2 q  and N F-2 m utations'3,34'.
In the present study we screened 2 0  g lia l tum ors w ith ependym al 
d iffe ren tia tion  fo r  ch rom osom al im balances th ro u g h o u t the entire tu m o r genom e 
using com para tive  genom ic hybrid ization (C G H ). Furtherm ore, we analyzed 
w hether Es show s im ilarities to  astrocytic and o lig o d e n d ro g lia l tum ors a t the 
ch rom osom al level. Finally, the co rre la tion  between chrom osom al aberra tions, 
pa tien t age, tu m o r loca liza tion , and h is topa tho log ica l g rad ing  was analyzed by 
com b in ing  o u r results w ith those recently reported by Zheng et al. in a g roup  o f 
2 8  Es'185', and w ith those o f H irose et al in a g roup  o f 4 4  Es'186'.
M aterials a n d  M ethods
Surgical specim ens o f 15 a d u lt and 5 ped ia tric  tum ors selected fo r  the present 
study were ob ta ined  from  patients treated in the U M C  N ijm egen and the St. 
E lizabeth H ospita l T ilbu rg , The N etherlands. D uring surgery, part o f the tu m o r 
was snap-frozen in liqu id  n itrogen and stored a t -8 0 °C .
Hem atoxylin  and eosin-sta ined (H&E) para ffin  sections o f each tu m o r were 
classified acco rd ing  to  the W H O -2 0 0 0  classifica tion '3' as m yxopapilla ry 
ependym om a (myxo-E, n = 2 ) , ependym om a (lg-E, n =  12), o r  anap lastic
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ependym om a (a-E, n =  4). For g rad ing  as an a-E, the tu m o r had to  show at least 
three o f the fo llo w in g  fo u r h is topa tho log ica l features: h igh ce llu la rity , m arked 
nuclear po lym orph ism , brisk m ito tic  activity (> 1 0 /2 m m 2), and flo rid  
m icrovascu la r p ro life ra tion . A dd itiona lly , 2 cases o f g liob las tom a  m u ltifo rm e w ith 
local ependym al d iffe ren tia tion  in the fo rm  o f perivascu lar pseudorosette 
fo rm a tion  were inc luded in this study (GBM-Es). A pa rt from  these ependym al 
features (that are illustrated in figu re  10 -1 ), these 2 GBM -Es h is topa tho log ica lly  
showed astrocytic d iffe ren tia tion , necrosis and all 4 features fo r h igh -g rade  
m alignancy as m entioned above.
C om para tive  G e n o m ic  H ybrid ization (CG H) was perfo rm ed as described in 
chap te r 2.
C o m b in in g  the C G H  results o f Zheng et al. (28 Es)'185' and H irose et al. (44 
Es)'186', w ith those in o u r g roup  o f 2 0  Es, the co rre la tion  between chrom osom al 
im balances, pa tien t age, tu m o r loca liza tion , and h is topa tho log ica l g rad ing  was 
analyzed. An overview  was created o f the frequency o f gains and losses on each 
chrom osom e arm  fo r  d iffe ren t tu m o r loca lizations in a d u lt and pediatric  
(anaplastic) ependym om as.
Figure 10 -1 . Ependymal features in g liob lastom as. Illustration o f perivascular pseudorosette 
fo rm ation  that was only foca lly  present in two h igh-grade m alignant g lia l tum ors (N 91, N 213), 
included in the present study as g liob lastom as with focal ependymal d ifferentia tion (GBM-Es).
RESULTS
C lin ica l data  and h is topa tho log ica l d iagnosis o f the 2 0  analyzed tum ors are 
shown in tab le  1 0 -1 . H is topa tho log ica l analysis identified 2 myxo-Es, 12 lg-Es, 4 
a-Es, and 2 GBM -Es (table 10 -1 ). In the g ro u p  o f adu lt tum ors (n = 1 5 ), 8 
occurred  in the spinal canal (53%) whereas the o the r 7 were in tracran ia l tum ors 
(47%) (3 in the posterio r fossa and 4 supra ten toria l). In contrast, all ped ia tric  
tum ors (n =  5) were in tracran ia lly  located (3 posterio r fossa and 2 supra ten toria l). 
The C G H  results are sum m arized in tab le  10-1 and depicted in figu re  10 -2 .
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O ve ra ll, losses (151) were detected tw ice as often as gains (66) and the mean 
num ber o f aberra tions per tu m o r was 11 (range 2 to  25 ). Frequently detected 
ch rom osom al im balances (present in 7 tum ors o r  more) were -22  (1 5 /2 0 ), -10q  
(1 3 /2 0 ), -1 6 p  (1 0 /2 0 ), -21 (1 0 /2 0 ), -1 p  (9 /2 0 ), -1 0 p  (9 /2 0 ), + 4 q  (9 /2 0 ), -2q 
(8 /2 0 ), -6p  (8 /2 0 ), -6q  (8 /2 0 ), -19  (8 /2 0 ), -2 p (7 /2 0 ) -3p  (7 /2 0 ), and -16q  
(7 /2 0 ). The com m on regions o f overlap  o f these regions are -1 0 q 2 5 -q te r, 
-1 p 3 1 -p te r, + 4 q 1 1 -3 2 , -2 q 3 3 -q te r, -6 q 2 3 -q te r, 2 p 1 6 -2 4 , and -3 p 1 4 -2 4 .
In figu re  1 0 -3  an overview  is shown o f the frequency o f gains and losses 
involv ing the ind iv idua l ch rom osom e arms fo r  sp ina l, poste rio r fossa, and 
supra ten toria l Es in adu lts, and fo r  ped ia tric  poste rio r fossa and supra ten toria l 
Es. In this figu re  we com b ined  o u r C G H  results w ith those previously reported by 
Zheng et a l. '185' and H irose et a l'186'. The myxo-Es and GBM -Es were not 
inc luded in this overview.
Figure 10 -2 . Summary o f all chrom osom al im balances as detected by C G H  in adu lt and 
pediatric Es. Lines on the left and right o f the chrom osom e indicate losses and gains of these 
chrom osom al regions respectively. A  thin line indicates aberrations crossing the 0 .8  o r 1.2 
threshold, a heavy line indicates a c lear copy num ber change (crossing the ratios 0 .6  and 
1.4), and an add itiona l spot on the bar indicates a high copy ga in . Aberrations in adu lt Es are 
ind icated by a continuous line, aberrations in pediatric Es by a d iscontinuous line .
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Table 1 0-1 .
C h rom osom a l im balances detected by C G H  in ependymal tum ors and corresponding clinical characteristics.
NR Sex Age G rade Localization C G H  losses C G H  gains ab.
N 2 7 0 M 31 myxo-E spinal 1p31-p te r, 1q, 2 p 1 6 -2 4 , 2 q 33-q te r, 3 p 1 4 -2 4 , 
6q23-q te r, 6 p, 10, 11, 14q, 16p, 17, 19, 22
4 p 1 4 -q te r, 5 p 1 4 -q 3 1 , 9p te r-q31 , 1 
18
2 p 1 2 -q2 1 , 19
N 273 F 33 myxo-E spinal 1p31-p te r, 4 p15-p te r, 8 p, 10, 12p, 13q, 14q, 
16p, 19, 22
4 p 1 4 -q te r, 5 p 1 3 -q 3 1 , 7q21-31 13
N 222 M 57 lg-E spinal 16, 2 2 12 3
N221 M 49 lg-E spinal 2 1 c, 2 2  c 7, 12 4
N 226 F 57 lg-E spinal 1, 2 , 3 , 6 , 8 , 10, 11, 13q, 14q, 16, 19, 2 0 , 2 1 , 22 4 , 5, 7, 9, 18 19
N 229 M 39 lg-E spinal 2q , 6 q, 13q, 22 19 5
N231 F 45 lg-E spinal 1p, 4p , 5, 6 p, 9, 10, 19, 2 0 q , 2 1 , 22 2 , 3, 4q , 8 q 1 1 -2 3 , 1 3q, 14q 16
N 268 M 57 lg-E spinal 1p31-p te r, 9q33-q te r, 10q25-q te r, 1 1 q 12 -1 3 , 
15q, 16, 17, 19, 2 0q , 2 2 , X
1 p 1 1 -2 2 , 2 q 2 1 -3 2 , 3p14-q te r, 4 p 1 5 -q 3 2 , 
5 q 1 1 -2 3 , 6 q 1 1 -2 4 , 8 q 1 1 -2 2 , 1 1 p 11 -1 4 , 
1 1 q 1 4 -2 2 , 1 2 p 11 -1 2 , 1 2 q 1 4 -2 3 , 13 q 14 -3 1 , 
1 4 q 1 1 -2 1 , 18q
25
N 225 F 32 lg-E post.fossa 2 , 3, 6 , 10, 16, 17, 21 , 22 4 , 9, 13q, 14q 12
N 269 M 25 lg-E post.fossa 1p22-p te r, 2p , 2 q 32-q te r, 6 , 8 p, 8q23-q te r, 10, 
16q, 2 1 , 2 2 , X
4 q , 9 13
N271 F 59 lg-E post.fossa 1p31-p te r, 10q23-q te r, 14q, 16p, 19, 2 0 , 2 1 , 22 4q 9
N 267 F 25 lg-E suprat. 1 p 1 1 -3 1 , 2 , 3 , 4 , 6 , 7, 9, 10, 11, 12, 13q, 18, 21 1q, 5, 8 , 19, X 18
N 76 M 2 2 a-E suprat. 3p te r-q24 , 5q, 10q, 11, 13q, 18, 21 9q 8
N 213 F 34 GBM-E suprat. 21 12q, 1 2 q 1 1 -2 1 c, 13q22 -q te r 4
N91 M 60 GBM-E suprat. 6 q, 9p21-p te r, 12p, 14q, 1 5 q 11 -2 2 7, 1 2 q 1 3 -1 5 * 7
N 224 M 2 a-E post.fossa 17, 19, 2 0 q , 22 X 5
N 227 M 2 a-E post.fossa 1 0 q, 16p, 2 2 X 4
N 266 F 12 lg-E post.fossa 1, 2, 3 , 6 , 8 , 10, 12, 13q, 14q, 16, 17, 2 1 , 22 7, 9q, 11c, 15q, 18c, 2 0 19
N 228 F 17 lg-E suprat. 2 , 3, 6 p, 10, 11p te r-q13 , 16, 17, 19, 2 0 q , 2 1 , 22 4 12
N 87 M 6 a-E suprat. - 2 p 2 2 -p te r* , 1 1 q 14 -2 2  c 2
Abbreviations : Sex: M =  male, F =  fem ale; Age =  age at surgery; G rade  : myxo-E =  m yxopapillary ependym om a (W H O  grade I), lg-E = ependym om a
(W H O  grade II), a-E =  anaplastic ependym om a (W H O  grade III), GBM-E =  g liob lastom a m ultiform e showing focal ependym al d ifferentia tion (W H O  
grade IV); Localization : tum or loca liza tion , spinal =  spinal canal, post.fossa =  posterior fossa, suprat. =  supra tentoria l; ab =  num ber o f chrom osom al 
aberra tions; c =  clear copy num ber change, ratio  more than 1.4 o r less than 0 .6 ; * =  high copy gain, ratio  > 1 .6 .
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D isc u ssio n  
C hromosomal imbalances detected by CGH in Es
A  loss o f 2 2  was the most frequently detected abe rra tion  in o u r g roup  o f Es 
(75). O th e r ch rom osom al im balances frequently  detected are: -1 0 q  (65% ), -21 
(50% ), -1 6 p  (50% ), -1p  (45% ), + 4 q  (45% ), -1 0 p  (45% ), -2q (40% ), -6  (40%), 
-1 9  (40% ), -2 p  (35%) -3 p  (35% ), and -16q  (35%). In genera l, o u r results are in 
conco rdance  w ith those o f Zheng et a l '185' whereas the frequencies reported by 
H irose et a l. '186' are lower. In several studies, LOH 2 2 q  in Es ranged from  0% to 
100% '34,187-189'. D ifferences between ind iv idua l studies on Es are also present fo r 
the invo lvem ent o f N F-2 in Es'34'. These d iscrepancies may reflect loca liza tion - o r 
age-re la ted  genetic pathways th a t lead to  the fo rm a tion  o f d istinct subsets o f 
Es[34,190]. The com m on reg ion o f overlap  o f frequently detected aberra tions most 
likely conta ins genes involved in the oncogenesis o f Es. Since Zheng et a l. '185' 
and K nuutila  et a l.'46,47' a lready e labora ted  on this subject, we w ill not fu rthe r 
discuss this top ic .
Recently, tw o  o the r C G H  studies on Es were pub lished '183,185'. The results o f 
these studies are not inc luded in o u r overview  o f C G H  find ings in Es. In one o f 
these papers, a d ifference exists in the sensitivity o f th e ir C G H  experim ent using 
e ithe r the "standard" o r "reverse" labe ling  techn ique  (as shown by the ir figure
10 -2 ) w hich may result in an underestim ation o f the num ber o f abe rra tions '183'. 
In the o the r pape r some ch rom osom al regions were excluded from  analysis '191' 
as early C G H  papers reported tha t false positive results may occu r a t 1p 3 2 -p te r, 
16 , 19 , and 2 2 '35'. However, a fte r re fin ing C G H , such artifacts are only 
occas iona lly  detected '40' and partia lly  depend on the qua lity  o f the metaphase 
chrom osom es and o f the tw o labe led D N As'61'. Interestingly, in contrast to  
1 p 3 2 -p te r, 16, and 19 w hich were excluded from  analysis, chrom osom e 2 2  was 
analyzed in the ir study and -22  and + 2 2  were reported to  be present in less than 
10%  and 23%  o f the 2 6  Es, respectively'191'. A  + 2 2  was only detected in 2 o u t o f 
the  9 2  Es analyzed by Zheng et a l. '185', H irose et a l. '186', and o u r g roup.
Comparison of Es and other gliomas
A lthough  one study reported resem blance a t the m o lecu la r genetic level 
between Es and astrocytic and o lig o d e n d ro g lia l tum ors (As and OTs)(OTs 
inc lud ing  both pure o lig o d e n d ro g lia l and mixed o ligo -as trocy tic  tum ors (Os and 
O A s))'187', others reported th a t aberra tions involved in the oncogenesis o f As 
were rarely detected in Es'3,10,33,34'. O Ts very frequently  show loss o f 1p and 19q, 
the com m on ly  deleted reg ion being 1 p 3 2 -3 6  and 1 9 q 1 3 .3 '19'23'53'85'131'. Losses 
invo lv ing these regions were detected in 8 (40%) o f the Es analyzed by us, and 
involved a com p le te  loss o f chrom osom e 19 but only a partia l loss o f 1p. W e 
d id  no t find  a co rre la tion  between aberra tions o f chrom osom e 1 o r  19 in Es and 
the presence o f o lig o d e n d ro g lia l features in these tum ors at the h is topa tho log ica l 
level.
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G enes involved in the tw o m ain cell cycle regu la tory pathways at the G 1-S  
border, the RB1 -pathw ay and the P 53-pathw ay are reported to  be involved in 
As '132-135,192'. For the RB1-pathway it was shown th a t a loss o f C D K N 2 A  (located at 
9 p 2 1 ), am p lifica tions  o f C D K 4 (located a t 1 2 q 1 3 .3 -q 1 4 ), o r inactiva tion  o f RB1 
(located at 1 3 q 1 4 .3 ) are a lternatives fo r  escape o f grow th co n tro l'132-135'. For the 
P 53-pathw ay, TP53 (17p13) m utations o r de le tion , and am p lifica tion  o f m dm 2 
(12q13) a p p e a r to  be alternatives fo r  escape o f grow th co n tro l'192'. O u r  current 
results show tha t 13 o f the 2 0  Es ha rb o r aberra tions inc lud ing  + 1 2 q 1 3  (C D K4), - 
9p21 (C D K N 2A ), a n d /o r  -1 3 q 14 (RB1), suggesting th a t the RB1 pathway is 
involved in the oncogenesis o f pa rt o f the Es.
*
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Figure 10 -3 . An overview o f the frequency of chrom osom al im balances in ependymal tumors 
on different localizations, based on com bina tion  o f the results o f the present study and those 
of Zheng et al '185' and Hirose et al. '186'. A  positive percentage represents the frequency o f a 
gain, whereas a negative percentage represents the frequency o f a loss. The chrom osom e 
arms are indicated at the bottom  o f the figure. M axim um  differences between different tum or 
localizations in adults exceeding 35%  are ind icated by *, whereas such differences in pediatric 
tum ors are indicated by + .  Differences between adu lt and pediatric Es at the same localization 
(posterior fossa or supratentoria l) are indicated by # .  Used abbreviations: n =  num ber of 
analyzed tumors.
Furtherm ore, 12 o f the 2 0  Es showed aberra tions inc lud ing  -1 7 p 13 (TP53) 
a n d /o r  + 1 2 q 1 3  (m dm 2), ind ica ting  tha t the P53 pathway may also be involved 
in the oncogenesis o f these tum ors. N o  co rre la tion  was detected between the 
invo lvem ent o f these pathways and age, tu m o r loca liza tion , o r h is topa tho log ica l 
d iagnosis.
Histopathological classification
Two o f the Es included in the present study were d iagnosed as G B M  with foca l 
ependym al d iffe ren tia tion  in the fo rm  o f perivascu lar pseudorosettes (N 2 1 3  and 
N 91)(figu re  10-1 ). A  C G H  study o f 1 0 0  G BM s reported as most frequen t 
aberra tions -1 0q (77% ), -1 0p (59% ), + 7  (75% ), and -9p  (59% )'140'. N 2 1 3  
conta ined none o f these aberra tions, whereas N91 conta ined + 7 ,  and -9p.
+
+
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These la tter aberra tions are a lso detected in lg -Es. W h ile  -22  is the most 
frequently detected abe rra tion  in Es, this aberra tion  was not detected in the tw o 
GBM -Es. However, both GBM -Es are supra ten toria l localized and -22  was 
detected in on ly 33%  o f the supra ten toria l (anaplastic) ependym om as in adults 
analyzed by us, Zheng et a l. '185', and H irose et a l. '186' (discussed below). 
A dd itiona lly , losses sm a lle r than 2 -5  M b  (chapter 2) are undetectab le  by C G H  
and m ight still be present on 2 2 '43'. It rem ains to  be seen if such GBM -Es should 
indeed be separated from  o rd inary  G BM s and inc luded in the g roup  o f Es as a 
grade  IV tum or.
A cco rd ing  to  the W H O  classification, myxo-Es are a distinct entity w ith in  the 
g roup  o f Es. They are slow  g row ing , g rade  I tum ors w ith a genera lly  favorab le  
prognosis '3'. Since ch rom osom al im balances accum ula te  during  (m alignant) 
progression o f tum ors it was unexpected to  find  such an extensive array o f 
genom ic  aberra tions (13 in N 2 7 3 , 19 in N 2 7 0 ). Both myxo-Es included in the 
present study showed c lea r s im ilarities w ith regard to  the ch rom osom al 
aberra tions; -1 p te r-p 3 1 , + 4 p 1 4 -q te r , + 5 p 1 3 -q 3 1 , -1 0 , -1 4 q , -1 6 p , -1 9 , and 
- 2 2  were detected in both tum ors, im p lica ting  tha t these chrom osom e arms 
p robab ly  conta in  genes tha t are im po rtan t fo r  the oncogenesis o f myxo-Es in 
adults. As these aberra tions were occas iona lly  detected in the previously 
analyzed ped ia tric  myxo-Es'186', it rem ains to  be established w hether d iffe ren t 
genetic pathways exist fo r  a d u lt and ped ia tric  myxo-Es.
The lg-Es may show m a lignan t progression to  a-Es'3'. A lthough  -2 2  was 
detected in 12 o f the 13 lg-Es, on ly 2 o f the 4 a-Es conta ined this aberra tion . 
Furtherm ore, a lthough  tum ors genera lly show accum u la tion  o f genetic 
aberra tions during  m a lignan t progression, the a-Es conta ined few er aberra tions 
than the lg-Es (an average o f 5 in a-Es, and 13 in lg-Es) suggesting th a t d iffe ren t 
genetic pathways exist fo r  lg-Es and a-Es. However, since all a-Es were 
in tracran ia lly  located whereas approx im ate ly  ha lf o f the lg-Es occurred  in the 
spinal cana l, such differences between lg-Es and a-Es a t the C G H  level may also 
reflect loca liza tion  dependent pathways.
Age and localization related differences
As adu lt patients fare better than ped ia tric  patients and LO H 2 2 q  was 
reported to  be a com m on find ing  in adu lt (but not in pediatric) Es, age related 
genetic differences m ight exist'3,33'. Furtherm ore, the observations tha t patient 
age and tu m o r loca liza tion  are in te rre la ted '3', patients w ith neurofibrom atosis 
type 2 (NF-2) disease deve lop  spinal Es and tha t spo rad ic  spinal Es often show 
an a ltered N F-2 gene and LOH 2 2 q '34,189', suggest a co rre la tion  between 
m o lecu la r genetic aberra tions and tu m o r loca liza tion . To identify age o r tu m o r 
loca liza tion  dependen t genetic pathways in Es we com b ined  o u r results w ith 
those reported in the C G H  study o f Zheng et a l. '185' and H irose et a l. '186'. Since 
overa ll on ly  3 ped ia tric  spinal Es were analyzed, these tum ors were not included. 
A dd itiona lly , as myxo-Es may be a distinct entity and it is not c lea r w hether 
GBM -Es should be regarded as Es, only the lg-Es and a-Es were analyzed fo r  this 
purpose.
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The differences in the d is tribu tion  o f ch rom osom al im balances fo r  Es in the 
supra ten to ria l com partm en t, sp inal canal and poste rio r fossa are illustrated in 
figu re  1 0 -3 . In Es o f a d u lt patients the fo llo w in g  loca liza tion  related differences 
in ch rom osom al im balances as detected by C G H  exceeded 35%  : + 2  in 38%  o f 
the spinal Es; -2 p  in 40%  o f the posterio r fossa Es (which never ga ined  this 
chrom osom e); + 7  approx im ate ly  in 60%  o f the spinal Es, in 30%  o f the posterio r 
fossa Es, and occas iona lly  in supra ten to ria l Es; -9 in 50%  o f the supra ten toria l 
Es; + 1 2  in approx im ate ly  ha lf o f the spinal Es, in one th ird  o f the poste rio r fossa 
Es and occas iona lly  in spinal Es; -1 4 q  in 39%  o f the sp ina l Es and -2 2  in 81%  o f 
the spinal Es. S im ilarly, differences in d is tribu tion  o f ch rom osom al im balances fo r 
in tracran ia l ped ia tric  Es were detected: + 1 q  and -6q  are detected in 50%  o f the 
supra ten to ria l and in 6% o f the posterio r fossa Es. O ve ra ll these results suggest 
loca liza tion  dependent genetic pathways fo r  both adu lt and ped ia tric  Es.
D ifferences between adu lt and ped ia tric  Es o f the same loca liza tion  were also 
no ticed; -6  and + 9  are detected in 53%  o f the a d u lt poste rio r fossa Es and in 
on ly 6% o r less o f the ped ia tric  Es a t this loca liza tion  and -9q is detected in 50%  
o f the a d u lt supra ten to ria l Es and in 13% o f the ped ia tric  supra ten to ria l Es. Thus, 
this analysis offers evidence fo r the existence o f genetic  pathways fo r  Es tha t are 
no t on ly loca liza tion , but a lso age dependent.
In c o n c l u s io n
O u r  C G H  study shows tha t the oncogenesis o f Es is ra ther com plex and tha t 
-22  and -1 0 q  are the most frequently detected aberra tions in these tum ors. Like 
in o the r g liom as, the RB1 and the P53 pathway seem to  be involved in the 
oncogenesis o f part o f the Es. In myxo-Es we detected a large am o u n t o f 
aberra tions which is rem arkab le  fo r  a low -g rade , s low  g row ing  tum or. Since 
GBM -Es show som e differences w ith o rd inary  G BM s a t the C G H  level, it rem ains 
to  be seen if these tum ors should be regarded as grade  IV Es ra ther than as 
o rd inary  G BM s. C om b in in g  o u r results w ith those o f Zheng et a l. '185' and Hirose 
et a l. '186', we show tha t d iffe ren t ch rom osom al im balances are involved in the 
oncogenesis o f Es in adults tha t are corre la ted  w ith tu m o r loca liza tion ; -2 2  was 
most frequently detected in in fra ten to ria l Es, -9  was most frequently  detected in 
the supra ten toria l Es, whereas + 2 ,  + 7 ,  + 1 2 ,  and -1 4 q  are most frequently 
detected in spinal Es. Furtherm ore, differences between posterio r fossa o r 
supra ten toria l Es in ch ild ren  and adults suggests th a t age related chrom osom al 
im balances exist. For fu rthe r e luc ida tion  o f the genetic background  o f Es, more 
tum ors should  be analyzed w ith a large enough num ber in each subgroup  as 
de term ined by pa tien t age, tu m o r loca liza tion , and h is topa tho log ica l subtype.
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G eneral d is c u s s io n
Based on the ir h is topa tho log ica l appearance , the m ajority  o f g liom as can be 
classified as astrocytic tum ors (As), pure o lig o d e n d ro g lia l tum ors (Os), mixed 
o ligo -as trocy tic  tum ors (OAs) o r  ependym al tum ors (Es). U nfortunate ly, 
c lass ifica tion and g rad ing  o f g liom as is subject to  in terobserver va ria tion  due to 
vague defin itions and subjective in te rpre ta tion  o f the h is topa tho log ica l criteria . 
M o le c u la r genetic markers m igh t be helpfu l to  recognize m ore un ifo rm  
subgroups o f g liom as w ith regard to  prognosis and response to  chem otherapy 
and thereby to  op tim ize  the m anagem ent o f the ind iv idua l patient. The goa l o f 
this thesis was to  e luc ida te  the genetic background  o f the less com m on g liom as,
i.e. the o lig o d e n d ro g lia l tum ors (OTs), inc lud ing  both O s  and O A s, and the Es. 
In this discussion the C G H  results on a ll the OTs and Es we studied up till now 
(end o f 2 0 0 1 ) are incorpora ted .
Chromosomal imbalances and genetic subtypes in OTs
In 1 9 9 6 , when we started o u r study, it was genera lly accepted tha t LOH 1p 
and LOH 19q are detected in the m ajority  o f O Ts, but little was known a bou t 
o the r ch rom osom al aberra tions. W e perform ed C G H  on 41 pure O s, 4 7  mixed 
O A s, and 2 2  G BM s (includ ing 11 xenogra fted  G BM s (x-GBMs)), an overview  o f 
the ch rom osom al im balances in these tum ors is shown in figu re  1 1 -1 . Loss o f 
ch rom osom e 1p (-1p) and -1 9 q  were detected in the m ajority  o f pure O s  (83% 
and 78%  respectively), which is in conco rdance  w ith previous LO H studies'17-25'. 
In mixed O A s, these im balances were less frequently detected (25% and 30%  
respectively). C o m paring  h igh -g rade  (hg-) OTs to  low -grade  (lg-) O Ts, + 7 ,  -9p , 
-1 0 , -1 3q (O As), -1 4q (Os), and -1 5q (Os) were m ore frequently detected 
(present in >  25%  o f the hg-O Ts) suggesting tha t these chrom osom es conta in  
genes involved in m a lignan t progression (oncogenes fo r  gains and tu m o r 
suppressor genes fo r  losses). In the G B M s, + 7  (92%) and -1 0  (75%) were most 
frequently detected which is in line w ith previous C G H  reports'80-84,139'.
The tu m o r suppressor genes (TSGs) on chrom osom e 1p and 19q , involved in 
O T  oncogenesis, have not yet been identified. A fte r show ing tha t o u r xenogra ft- 
lines are va lid  m odels from  a genetic po in t o f view, RDA (representation 
d ifference analysis) was perfo rm ed on an x -G B M  con ta in ing  -1 p  and -19q  in an 
a ttem pt to  identify those TSGs. Fragments from  1p o r 19q were no t iso lated, 
suggesting th a t they were no t hom ozygously deleted in this tum or. However, five 
tum or-assoc ia ted  hom ozygously deleted D N A  fragm ents were iso lated, all 
o rig ina ting  from  chrom osom e reg ion 9 p 2 1 . Testing o the r markers located in this 
region showed tha t the deleted region in this tu m o r is re latively large, whereas in 
9 ad d ition a l x-G BM s (w ithout -1 p  o r  -19q) the deleted reg ion on 9p21 was 
sm a lle r and never inc luded tw o o f the five fragm ents isolated by RDA. Both 
fragm ents are located in a reg ion which was reported to  conta in  a putative TSG 
in lung ca rc inom as '176', suggesting tha t this putative TSG m ight a lso be involved 
in oncogenesis o f g liom as con ta in ing  -1 p /-1 9 q .
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Figure 1 1 -1 . An overview o f the frequency o f chrom osom al im balances in different 
h is topatho log ica l g liom a subtypes. Tumors are included in the o ligodendrog lia l category 
accord ing to  the "relaxed" approach as described in chapter 5. A  positive percentage on the 
y-axis represents the frequency o f a ga in , whereas a negative percentage represents the 
frequency o f a loss. The chrom osom e arms are indicated on the x-axis. In this figure  no 
distinction is made between com plete o r partia l im balances of the chrom osom e arms. n =  
num ber o f analyzed tumors.
In the m ajority  (75%) o f g liom as analyzed by us using C G H , -1p  a n d /o r  -19q  
were m utua lly  exclusive w ith + 7  a n d /o r  -1 0 , there fore  we proposed a genetic 
subtyping into " -1 p /-1 9 q " (conta in ing  -1p  a n d /o r  -19q) (n =  40) and " + 7 /-1 0 "  
(conta in ing  + 7  a n d /o r  -1 0  w ithou t -1 p and w ithou t -19q ) tum ors (n =  35). 
Furtherm ore, som e tum ors (n = 1 0 ) conta ined a com b ina tion  o f -1 p /-1 9 q  and 
+  7 / - 1 0 and were designated as "in term ediate  -1 p /-1 9 q " , whereas others 
(n =  15) d id  no t conta in  any o f these aberra tions and were designated as "other". 
A lthough  C G H  only detects aberra tions la rge r than 2 -5  M b  (chapter 2 ), in 90%
140
G ene ra l discussion &  Future perspectives
lg-OAs (n = 1 5)
£ 0 -
GBMs (n =  11)
'
1
m m m r i r h  rrTTi 1
1 1 1 H u  LJ L
1 1 2 2 3 3 4  4  5 5 6 6 7  7  8 8 9 9 1 0 1 0  1 1 1 1 1 2 1 2 1 3 1 4 1 5 1 6 1 6 1 7 1 7 1 8 1 8 1 9 1 9 2 0 2 0 2 1  2 2  X  X  
p q p q p q p q p q p q p q p q p q p q p q p q q q q p q p q p q p q p q q q p q
1 1 2 2 3 3 4  4  5 5 6 6 7  7  8 8 9 9 1 0 1 0  1 1 1 1 1 2 1 2 1 3 1 4 1 5 1 6 1 6 1  7  1 7  1 8 1 8 1 9 1 9 2 0 2 0 2 1  2 2  X  X  
p q p q p q p q p q p q p q p q p q p q p q p q q q q p q p q p q p q p q q q p q
o f the "-1 p /-1 9 q " and in 76%  o f the "+ 7 / -1 0 "  tum ors both aberra tions were 
found . N o  preference fo r  one o f the aberra tions was detected in the rest o f these 
g liom as. In "in term ediate  -1 p /-1 9 q "  tum ors, 70%  con ta ined  both -1 p  and -19q  
and no preference fo r  one o f these im balances was detected in the rest o f the 
g liom as. A lthough  a + 7  was detected m ore frequently (90%) than -1 0  (50%), 
suggesting tha t + 7  may o ccu r before -1 0  du ring  genetic progression, one 
"in te rm ed ia te  -1 p /-1 9 q "  tu m o r d id  not conta in  + 7 .
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Figure 11 -2 . An overview o f the frequency of chrom osom al im balances in the different genetic 
subtypes. A  positive percentage on the y-axis represents the frequency o f a ga in , whereas a 
negative percentage represents the frequency o f a loss. The chrom osom e arms are indicated 
on the x-axis. N o  distinction was made between com plete o r partial im balances o f the 
chrom osom e arms. Im balances detected in at least 25%  o f the tum ors are shown in a darker 
shade. n =  num ber o f analyzed tumors. * =  im balances which are more frequently detected 
in "interm ediate -1 p /-1 9 q " tum ors com pared to  "-1 p /-1 9 q " tum ors (difference > 15%).
Since the genetic subtypes may reflect d iffe ren t oncogen ic  pathways, an 
overview  was created show ing the invo lvem ent o f ch rom osom al im balances in 
the fo u r genetic subtypes (figure 11 -2 ). The to ta l num ber o f aberra tions detected 
varied considerab ly; "other" and " -1 p /1 9 q " g liom as conta ined less aberra tions 
com pared  to  " +  7 /-1 0 "  and "in te rm ed ia te  -1 p /-1 9 q "  g liom as (average o f 3 .9 , 
4 .5 , 6 .9 , and 9 .7 , respectively). As ch rom osom al im balances accum u la te  during  
tu m o r progression this suggests tha t g liom as o f the "+ 7 / -1 0 "  and "in term ediate  
-1 p /-1 9 q "  subtypes are m ore m a lignan t. A dd itio n a lly , these tum ors conta in  a 
relatively high frequency o f + 7 ,  -9 p , -1 0 , -1 3 q , -1 4 q, -1 5 q , ch rom osom al 
im balances previously identified to  be involved in g lio m a  progression (figure 
1 1 -1 , and reference'3'). C h rom osom a l im balances present in a t least 25%  o f the 
tum ors are ind icated in figu re  1 1 -2 . W ith  the exception o f -1 p , -1 9 q , + 7 ,  and 
-1 0 , de fin ing  the genetic subtypes, most o f these ch rom osom al im balances are 
not specific  fo r  one o f the genetic subtypes. However, + 1 0 p  is a lm ost exclusively 
detected in "other" tum ors (4 /1 5 ). Since these "other" tum ors do  not have a 
pa rticu la r genetic abe rra tion  in com m on and the m ost frequently detected 
ch rom osom al im balances (-4q , -9 p , -1 3 q , and -X) are not m utua lly exclusive in 
this category, they may develop a long  d iffe ren t genetic pathways. A lternative ly, 
some o f these g liom as may ha rbo r aberration(s) undetectab le  by C G H , am ong 
others, on the chrom osom e arms de fin ing  the genetic subtypes.
Genetic progression in OTs
The TP53 and RB1 cell cycle regu la tory pathways a t the G 1-S  bo rde r are 
frequently affected du ring  progression in a variety o f neoplasm s. For the RB1- 
pathway it was shown tha t a loss o f C D K N 2 A  (located a t 9p21 and cod ing  fo r 
p1 6), inactiva tion  o f RB1 (1 3q  1 4), and am p lifica tions  o f C D K4 (1 2q  14) are 
alternatives fo r  escape o f grow th co n tro l'132-135'. A dd itio n a lly , the RB1-pathway 
can be d isturbed by am p lifica tio n  o f C D K 6 (7 q 2 1 -2 2 ), cyclin D1 (1 1 q 1 3 ), and 
EGFR (7p 12) o r by a loss o f E2F1 (20q 11) and p21 (6p21). For the P53- 
pathway, m utations o r  de le tions o f TP53 (17p13) and am p lifica tion  o f M D M 2  
(12q 14 -15 ) are reported to  be alternatives fo r  escape o f grow th co n tro l'192'. 
Furtherm ore, p21 (6p21) and p 1 9 (1 9p1 3) are involved in this mechanism . 
A lthough  we realize th a t o the r genes may be involved in P53-RB1 cell cycle 
contro l as well and th a t C G H  does not provide gene specific in fo rm a tion , we 
eva luated the invo lvem ent o f RB1-P53 cell cycle contro l in the g liom as analyzed 
by us. C o m p a rin g  hg-O Ts and lg -O Ts, a h igher percentage o f hg-O Ts conta ins
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such aberra tions (3 7 /4 8  and 1 4 /4 0  respectively) and the affected tum ors m ore 
frequently con ta ined  2 o r  m ore o f these aberra tions (> 2 aberra tions in 2 8 /3 7  
hg-O Ts and 4 /1 4  lg-O Ts). W ith  respect to  the genotype, these chrom osom al 
aberra tions were detected in the m ajority  o f "in term ediate  -1 p /-1 9 q "  and " +  7 / ­
10" tum ors (1 0 /1 0  and 3 0 /3 2  respectively) and less frequently in "other" (7 /1 5 ) 
and " -1 p /-1 9 q " (1 2 /4 0 ) tum ors. Furtherm ore, the affected g liom as o f the latter 
tw o subtypes less frequently con ta ined  m ore than one o f these aberra tions (> 2 
aberra tions in 2 /1 2  "-1 p /-1 9 q ", 3 /1 7  "other", 8 /1 0  "in term ediate  -1 p /-1 9 q " , and 
3 0 /3 2  "+ 7 /-1 0 ) .  These results suggest tha t P53-RB1 cell cycle contro l is involved 
in progression o f O Ts and such aberra tions can accum u la te  resulting in a m ore 
m a lignan t behav io r o f the tum or. Identifica tion  o f such aberra tions in lg -O Ts, 
"-1 p /-1 9 q " o r  "other" g liom as m igh t there fore  be ind icative fo r  progression.
Six p rim ary OTs and the ir recurrences were analyzed by C G H  to  study the 
genetic background  o f O T  progression. New aberra tions were detected in all 
recurrent O Ts in add ition  to  those detected in the prim ary OTs. In 3 cases this 
genetic progression corre la ted  w ith progression a t the h is topa tho log ica l level. 
A berra tions previously identified to  be involved in O T  progression (figure 1 1 -1 : 
+  7, -9 p , -1 0 , -1 3 q , -1 4 q , and -15q) and aberra tions ha rboring  genes involved 
in P53-RB1 cell cycle con tro l appeared  du ring  progression o f these OTs. Since 
the presence o f these im balances in a h is to log ica lly  low -grade  tu m o r may 
a lready im p lica te  tu m o r progression, genetic analysis next to  h is topa tho logy may 
a lso be o f use fo r  tu m o r g rad ing . Indeed, the recurrent tu m o r o f a pa tien t w ho 
d ied 7 m onths a fte r surgery was d iagnosed  as a lg -O A , but ch rom osom al 
im balances ind ica ting  progression were detected. Interestingly, in one case an 
"in term ediate  -1 p /-1 9 q "  O T  deve loped th rough  progression from  a " -1 p /-1 9 q " 
O T . The ch rom osom al im balances m ore frequently detected in "in term ediate  
-1 p /-1 9 q "  than in "-1 p / -1 9q" tum ors (ind icated in figu re  11-2 ) are therefore 
associated w ith progression in OTs con ta in ing  -1 p /-1 9 q , however, they are not 
exclusively associated w ith the -1 p /-1 9 q  genetic pathw ay, as they are also 
detected in "+ 7 / -1 0 "  (78%) and the "other" (73%) tum ors.
Clinical implications of genetic subtyping of OTs
As described above, "+ 7 / -1 0 "  and "in term ediate  -1 p /-1 9 q "  g liom as seem to  
be m ore m a lignan t a t the genetic level com pared  to  " -1 p /-1 9 q " and "other" 
tum ors. C o rre la tion  o f the survival data  o f o u r g roup  o f hg -g liom a  patients with 
the fo u r genetic subtypes suggests tha t, independent o f the h is topa tho log ica l 
d iagnosis, the " +  7 /-1 0 "  subtype is indeed associated w ith shorter survival (within 
18 m onths a fte r surgery 90%  o f the 2 2  patients died) whereas the " -1 p /-1 9 q " 
subtype indicates longer survival (all 5 patients are still a live  3 0  months after 
surgery). Patients w ith "in term ediate  -1 p /-1 9 q "  tum ors show a longer survival 
than those w ith a "+ 7 / -1 0 "  tu m o r and a shorte r survival than patients w ith an 
"-1 p /-1 9 q " tu m o r (the la tter being in conco rdance  w ith the observation tha t these 
g liom as can progress from  " -1 p /-1 9 q " g liom as). M ore  patients w ith a tu m o r o f 
the "other" type need to  be eva luated fo r  survival analysis. A lthough  O s and O As 
are often included toge the r in the g roup  o f O Ts, we show in figu re  11 -3  th a t the
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d istribu tion  o f the genetic subtypes am ong O s and O A s varies considerab ly (in 
O A s "-1 p /-1 9 q " was detected less frequently whereas "other" and " + 7 /-1 0 "  
(lg-O As) were detected m ore frequently  com pared  to  Os). As we just showed a 
co rre la tion  between genetic subtype and prognosis, these differences in the 
genetic  background  may very well expla in the reported differences in c lin ica l 
b ehav io r between O s  and O A s; e .g. overa ll survival fo r  O s  is longer com pared  
to  O A s [3]. O n  the basis o f o u r patien t p o p u la tion , no firm  conclusions can be 
draw n w ith regard to  the co rre la tion  between therapeu tic  response and genetic 
subtype, because the trea tm en t in this popu la tion  o f patients was diverse. 
C airncross et a l. [16] previously reported tha t LOH 1p in O Ts is predictive fo r 
chem osensitivity. In conco rdance  w ith this observa tion , the fo u r patients w ith a 
g liom a  con ta in ing  -1 p / -1 9q w ho received PCV showed response to  
chem otherapy (stable disease o r  tu m o r reduction), whereas both patients w ith 
"+ 7 / -1 0 "  tum ors w ho received PCV showed progression.
G enetic  analysis thus appears to  be a va luab le  too l in the c lassification o f 
h igh -g rade  g liom as, p rov id ing  p rognostic  in fo rm a tion  and gu id ing  therapeu tic  
decisions. G enetic  subtyping into the fo u r groups m entioned above is pre ferab le  
over the eva lua tion  o f only LO H 1p since differences in survival between patients 
w ith " -1 p /-1 9 q " and those w ith "in term ediate  -1 p /-1 9 q "  tum ors were found.
Figure 11 -3 . The d istribution o f the different genetic subtypes o f o ligodend rog lia l tumors. 
D ifferent o ligodendrog lia l tum ors (OTs) encompass pure o ligodendrog liom as (Os) and mixed 
o ligo-astrocytom as (OAs). A  distinction was m ade between low -grade (lg-) and h igh-grade 
(hg-) tumors. The different genetic subtypes are "-1 p /-1 9 q ", "interm ediate -1 p /-1 9 q ", 
"+ 7 /-1 0 " , and "other". The criteria fo r these subtypes are described in the text (page 140).
Histopathological classification of OTs
U nequivoca l h is topa tho log ica l criteria  fo r the de linea tion  o f O A s from  pure O s 
and As, and fo r  the g rad ing  o f O As are lack ing , resulting in s ign ifican t 
in terobserver va ria tion . Review o f the h is topa tho log ica l slides o f the six 
"-1 p /-1 9 q " and six "+ 7 / -1 0 "  hg -O s in itia lly  analyzed by C G H  d id  not identify 
d iscrim ina ting  h is topa tho log ica l features. A  PTEN /M M AC 1 (10q23)
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Figure 11 -4 . The d istribution o f the different genetic subtypes am ong mixed h igh-grade o ligo - 
astrocytic tum ors (hg-O As) and g liob lastom a m ultiform e (G BM ) classified accord ing to  a 
"relaxed" o r "strict" h istopatho log ica l approach o f O As. H istopatho log ica l criteria are described 
in the material and methods o f chapter 5. The different genetic subtypes are "-1 p /-19 q ", 
"interm ediate -1 p /-1 9 q ", " +  7 /-1 0 ", and "other" and the criteria fo r these genetic subtypes are 
described in the text (page 140).
m utation  was only occas iona lly  detected in the g liom as d iagnosed as " + 7 /-1 0 "  
hg-O Ts w h ile  they were detected in m ore than ha lf o f the G B M s, suggesting tha t 
these "+ 7 / -1 0 "  hg -O s are no t just o rd inary  G BM s (as m ight be suggested by 
the ir ch rom osom al im balances). In o u r study on O A s, by app ly ing  m ore "strict" 
h is topa tho log ica l crite ria  fo r  the recogn ition  o f o lig o d e n d ro g lia l d iffe ren tia tion , 
som e o f the tum ors in itia lly  classified as O A s were now d iagnosed as As (5/11 
lg-O As) o r G BM s (1 4 /3 2  hg-O As). Figure 11 -4  shows the d is tribu tion  o f the 4 
genetic subtypes am ong  the hg -O A s and G BM s analyzed by C G H  using e ither 
the "strict" (18 hg-O A s and 3 6  GBMs) o r the "relaxed" (32 hg-O A s and 2 2  
GBMs) h is topa tho log ica l app roach . Using the "strict" a pp roach , the percentage 
o f " -1 p /-1 9 q " hg -O A s increases whereas the percentage o f " +  7 /-1 0 "  hg-O A s 
decreases. A dd itio n a lly , the num ber o f " +  7 /-1 0 "  G BM s also slightly decreases 
due to  the inclusion o f "in term ediate  -1 p /-1 9 q "  and "other" tum ors as G B M . As 
som e believe th a t only g liom as con ta in ing  -1 p  a n d /o r  -1 9 q  are true O Ts, the 
"strict" app roach  m ight be favored over the "relaxed" app roach . However, using 
this "strict" a pp roach , som e o f the tum ors con ta in ing  -1 p  o r  19q m ight be missed 
as O Ts, and, unless genetic testing is pe rfo rm ed, patients w ith such tum ors w ill 
not be inc luded in the chem otherapy protoco ls fo r  OTs a lthough  th e ir tu m o r 
conta ins the positive p red ic to r fo r chem osensitiv ity (LOH 1p). O n  the o the r hand, 
using the "strict" app roach  part o f the patients w ith a "+ 7 / -1 0 "  w ill not be o ffered 
chem otherapy w hich is not likely to  be successful. As suggested above, genetic 
subtyping may have p rognostic  and therapeu tic  im p lica tions independent o f 
h is topa tho log ica l d iagnosis, and genetic subtyping may becom e m ore relevant 
fo r  the m anagem ent o f a pa tien t than the h is topa tho log ica l d iagnosis o f O  
versus O A  in the near future.
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Chromosomal imbalances and genetic subtypes in Es
Previous c lin ica l and genetic studies a lready suggested tha t d istinct subtypes o f 
Es exist, be ing corre la ted  w ith pa tien t age a n d /o r  tu m o r loca liza tion [3,33,34]. In o u r 
C G H  analysis o f 2 0  Es, loss o f chrom osom e 2 2  (75%) and 10q (65%) were the 
most frequently detected aberra tions in these tum ors. S im ilarities between Es and 
OTs were found  w ith regard to  the occurrence o f ch rom osom al im balances 
w hich can a ffect the P53-RB1 cell cycle contro l (present in 1 8 /2 0  Es). 
Furtherm ore, losses invo lv ing chrom osom e 1p and 19q were frequently  detected 
(six Es conta ined both, three Es showed only losses invo lv ing chrom osom e 1, tw o 
Es only -1 9 ), how ever this d id  not corre la te  w ith presence o f o lig o d e n d ro g lia l 
features a t the h is topa tho log ica l level. A lthough  the m ajority  o f Es is d iagnosed 
as low -grade  E o r  anap lastic  E, som e G BM s foca lly  show ependym al features 
and m ight be d iagnosed as G BM -E. Since the tw o  exam ined G BM -Es showed 
some differences w ith o rd inary  G BM s a t the C G H  level, it rem ains to  be seen if 
these tum ors shou ld  be regarded as highly m a lignan t (grade IV) Es ra ther than as 
o rd inary  G BM s.
By com b in ing  o u r C G H  results in Es w ith those o f Zheng et a l. [185] and Hirose 
et a l. [186](n =  92 ), we also showed tha t the d is tribu tion  o f ch rom osom al 
im balances corre lates w ith tu m o r loca liza tion  and patien t age. In adu lt patients, 
sp inal Es re latively often showed + 2 ,  + 7 ,  + 1 2 ,  and —14 q , in fra ten toria l Es 
(includ ing spinal tum ors) - 2 2 ,  and supra ten to ria l Es -9. Furtherm ore, in posterio r 
fossa Es -6  and + 9  were much m ore frequen t in adults than in ch ildren. 
However, these ch rom osom al im balances were no t m utua lly exclusive am ong  the 
d iffe ren t tu m o r groups and c lea r-cu t genetic subtypes cou ld  not yet be identified.
Future perspectives
The results discussed in this thesis e luc ida ted  part o f the genetic background  
o f g liom as, especially o f OTs. Nevertheless, m ore tum ors should be genetica lly 
characterized and fo llo w  up should be longer as described in o u r study (30 
months) fo r a de fin itive  app rec ia tion  o f the place o f genetic testing o f g liom as in 
d iagnostic  neuropa tho logy. Next to  C G H , analysis a t the gene level is w arranted 
especially to  establish the actua l invo lvem ent o f the P53/RB1 cell cycle contro l 
during  g liom a  progression. Furtherm ore, because som e O A s may be classified 
as As o r G BM s these tum ors should  also be inc luded in these fu ture studies. 
A lthough  it was a lready reported by C a irncross[16] tha t LOH 1p is predictive fo r 
chem osensitivity, genetic analysis by C G H  prov id ing  an g lo b a l overview  o f 
ch rom osom al im balances o r by analysis a t the gene level on g liom as o f patients 
treated acco rd ing  to  d iffe ren t the rapeu tic  strategies (e.g. gene-therapy, 
chem otherapy, im m unotherapy, o r therapy using onco lytic  viruses) w ill reveal 
w hich therapy is pre ferab le  fo r  tum ors ha rboring  a specific genetic defect(s). As 
large sets o f tum ors treated acco rd ing  to  a specific p ro toco l need to  be analyzed 
fo r defin ite  conclusions, inc lud ing  genetic analysis in the rapeu tic  tra ils  is 
w arran ted.
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W e showed th a t genetic subtyping o f g liom as acco rd ing  to  the fo u r genetic 
subtypes described in this thesis has c lin ica l im p lica tions. Due to  the com plexity 
o f the C G H  techn ique , w idespread im p lem enta tion  o f this techn ique in 
d iagnostic  neu ropa tho logy  is unlike ly and o the r techniques need to  be 
considered to  perfo rm  genetic analysis o f bra in tum ors in rou tine  pa tien t care. 
Examples o f such alternatives are: in situ hybrid ization (ISH), LO H -analysis, and 
southern b lo t analysis. In fact, these techniques are a lready app lied  on OTs by 
som e institutions, each using the ir own set o f markers. It rem ains to  be seen 
w hich o f these techniques and markers are the most su itab le  to  detect the 
re levant genetic subtypes in both paraffin  em bedded tissue and (snap) frozen 
tissue. A  d isadvantage o f ISH, LO H , and southern b lo tting  is th a t on ly one region 
o f interest can be analyzed in one experim ent. Analysis o f m u ltip le  regions, as 
m igh t be necessary fo r  op tim a l genetic subtyp ing, w ill be tim e consum ing. 
Recently, C G H  based m icro -a rray analysis has been described which is very 
prom ising fo r  genetic  subtyping in a routine setting. In such m icro -a rray 
experim ent, a large a m oun t o f d iffe ren t D N A  fragm ents con ta in ing  (un)known 
genes can be spotted a t a designated position on a glass slide. S im ila r to  the 
C G H  experim ents as described in this thesis, tu m o r and test D N A  are 
d iffe ren tia lly  labe led and com petitive ly  hybridized to  the array-slide. A  m a jo r 
advan tage  o f such a rray -C G H  experim ents is tha t gene specific  in fo rm ation  can 
be genera ted , and th a t sm all aberra tions can be detected. D ependent on the 
d iagnostic  question, d iffe ren t arrays can be established con ta in ing  the D N A  
fragm ents o f interest. Based on the studies described in this thesis, fo r g liom as 
such an array should  conta in  D N A  fragm ents prov id ing  in fo rm ation  on the 
genetic subtype (involving chrom osom e 1 p, 19q , 7, and 10), and D N A  
fragm ents prov id ing  in fo rm a tion  on progression (e.g. genes involved in the P53- 
RB1 cell cycle contro l). W ith  such a g liom a-a rray , D N A  isolated from  tu m o r 
tissue cou ld  prov ide in fo rm ation  on both the genetic subtype and m alignancy 
grade  o f the tum or. Based on these results a m ore accurate  estim ation o f 
prognosis can be provided and m ore op tim a l and "ta ilo r made" therapy 
pro toco ls can be established.
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Based on th e ir h is topa tho log ica l appearances, g liom as can be classified as 
astrocytic tum ors (As), o lig o d e n d ro g lia l tum ors (OTs), inc lud ing  both pure 
o lig o d e n d ro g lia l tum ors (Os) and mixed o ligo -as trocy tic  tum ors, o r ependym al 
tum ors (Es). The goa l o f the studies described in this thesis was to  fu rthe r 
e luc ida te  the genetics o f the less com m on g lia l tum ors, OTs and Es, in o rd e r to  
identify markers w ith p rognostic  o r the rapeu tic  im p lica tions .
To e luc ida te  the genetic background  o f O T  oncogenesis we in itia lly  screened 
2 9  pure O s  (chapter 3) and 39  mixed O A s (chapter 5) fo r  ch rom osom al 
im balances using C G H  (chapter 2). A  loss o f 1p and 19q were most frequently 
detected and 4 d iffe ren t genetic subtypes were identified: (1) " -1 p /-1 9 q " tum ors 
(conta in ing  a -1p  a n d /o r  -19q ), (2) "+ 7 / -1 0 "  tum ors (conta in ing  + 7  a n d /o r  -1 0  
w ithou t -1p  o r  -1 9 q ), (3) " -1 p /-1 9 q  in term ediate" tum ors (conta in ing  both -1 p /-  
19q and + 7 / -1 0 ) ,  and (4) "other" tum ors (w ithout -1 p, -1 9 q , + 7 ,  o r -10). 
Analyzing genetic progression in couples o f p rim ary OTs and the ir recurrences as 
described in chap te r 6, we showed tha t "-1 p / -1 9q in term ediate" OTs can 
progress from  "-1 p /-1 9 q " OTs. Because + 7  and -1 0  are detected in the m ajority 
o f g liob lastom as (GBM s), the most m a lignan t type o f As, we subsequently 
studied w hether the "+ 7 / -1 0 "  h igh -g rade  O s  (hg-OTs) m ight be G BM s w ith a 
p rom inen t o lig o d e n d ro g lia l phenotype (chapter 4). A berra tions in the PTEN gene 
(located a t 10q23 ) were frequently  detected in G BM s but on ly occas iona lly  in 
" +  7 /-1 0 "  hg -O s, suggesting tha t "+ 7 / -1 0 "  hg -O s are not just o rd inary  G BM s.
C o m p a rin g  h is topatho logy, genetic subtyping and c lin ica l da ta , we showed in 
chap te r 7 th a t the genetic subtype o f " +  7 /-1 0 "  is ind icative fo r  shorte r survival 
whereas " -1 p /-1 9 q " is ind icative fo r  longer survival, independent o f 
h is topa tho log ica l d iagnosis. Patients w ith "in term ediate  -1 p /-1 9 q "  tum ors tend to  
show a shorter survival than those w ith an " -1 p /-1 9 q " tum or, which is in 
conco rdance  w ith the hypothesis tha t these tum ors can progress from  "-1 p /-1 9 q " 
tum ors. Furtherm ore, the survival o f these patients is longer com pared  to  patients 
w ith an " +  7 /-1 0 "  tum or. A lthough  we can not d raw  firm  conclusions regard ing 
the rapeu tic  response, we con firm  the previous observation o f C airncross et a l. 
tha t loss o f 1p is predictive fo r  chemosensitivity.
U nequivoca l criteria  fo r  the de linea tion  o f O A s from  pure O s and As are 
lack ing , resulting in a high interobserver va ria tion  in the d iagnosis o f these 
tum ors. A pp lica tion  o f both a "strict" and a m ore "relaxed" h is topa tho log ica l 
a pp roach , as described in chap te r 5 , showed th a t som e hg-O A s were classified 
as G BM s using the "strict" app roach . The frequency o f "-1 p /-1 9 q " tum ors 
increases am ong  the hg -O A s when the "strict" app roach  is used, however, w ith 
this app roach  som e tum ors con ta in ing  -1 p are not classified as OAs. 
C onsequently, these patients w ill not be inc luded in the chem otherapy protoco ls 
fo r  O Ts a lthough  th e ir tu m o r conta ins the positive p red ic to r fo r  chem osensitivity 
(i.e. loss o f 1 p). As genetic subtyping was shown to  have p rognostic  and 
the rapeu tic  im p lica tions, genetic analysis may becom e m ore re levant fo r the
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m anagem ent o f a patien t than the h is topa tho log ica l d iagnosis o f O  versus O A  in 
the near future.
The actua l tu m o r suppressor genes on chrom osom e 1p and 19q involved in 
the oncogenesis o f OTs have not yet been identified. A fte r show ing tha t 
xenogra fted  G BM s are va lid  m odels to  study tu m o r-b io lo g y  from  a genetic po in t 
o f view  (chapter 8 ), we isolated d iffe ren t hom ozygously deleted fragm ents (by 
RDA) in a xenogra fted  tu m o r con ta in ing  -1 p  and -1 9 q  (chapter 9). A ll isolated 
fragm ents o rig ina ted  from  the 9p21 reg ion. O th e r xenogra fted  G BM s (w ithout - 
1 p /-1 9 q ) d id  not conta in  a hom ozygous de le tion  o f a ll the isolated fragm ents, 
suggesting specific ity o f som e o f the isolated fragm ents fo r  g liom as con ta in ing  - 
1 p /-1 9 q .
A  loss o f chrom osom e 2 2  (-22) was the most frequently detected im ba lance 
using C G H  on 2 0  Es (chapter 10). C om b in in g  o u r C G H  results w ith those 
previously reported by others (58 tum ors), we showed tha t som e aberra tions 
o ccu r p redom inan tly  in a specific  category suggesting age a n d /o r  loca liza tion  
suggesting d iffe ren t genetic  subtypes.
O ve ra ll, o u r results show  th a t d iffe ren t genetic subtypes can be identified 
am ong  OTs and Es w hich can provide in fo rm a tion  a b o u t the tu m o r type, g rade 
o f m a lignancy, and chemosensitivity. G ene tic  analysis appears to  be a va luab le  
d iagnostic  to o l, on the basis o f w hich a m ore accurate  estim ation o f prognosis 
can be provided and a m ore op tim a l and "ta ilo r made" the rapeu tic  app roach  
can be chosen fo r  the ind iv idua l patient.
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O p  basis van h is topatho log ische kenm erken kunnen g liom en w orden 
onderverdee ld  in o .a . astrocyta ire tum oren  (As), o lig o d e n d ro g lia le  tum oren 
(OTs), en ependym ale tum oren  (Es). O n d e r de OTs vallen zowel de pure 
o lig o d e n d ro g lia le  tum oren  (Os) als de gem engde o ligo -astrocyta ire  tum oren 
(O As). Het d oe l van de studies beschreven in d it proefschrift was de genetische 
ach te rg rond  van de m inder frequente g liom en , de OTs en de Es, verder op  te 
helderen en markers te identificeren d ie prognostische o f therapeutische w aarde 
kunnen hebben.
O p  het geb ied  van OTs werden de chrom osom a le  a fw ijk ingen in 2 9  O s 
(hoofdstuk 3) en 39  O A s (hoofdstuk 5) in kaart geb rach t m et behulp van C G H  
(hoofdstuk 2). Verlies van ch rom osoom  1p (-1 p) en -1 9q werden het meest 
frequent gevonden en er werden vie r versch illende genetische subtypes 
geïdentificeerd: (1) " -1 p /-1 9 q " (tum oren m et een -1 p  e n /o f -19q ), (2) " + 7 /-1 0 "  
(tum oren met een + 7  e n /o f een -1 0 , m aar zonder een -1p  o f een -19q ), (3) 
"in term ediate  -1 p /-1 9 q "  (tum oren met zowel -1 p  e n /o f -1 9 q  en + 7  e n /o f -10) 
en (4) "other" (tum oren zonder -1 p, -1 9 q , + 7 ,  o f -10 ). In onze studie naar 
genetische tu m o r progressie in p rim a ire  O Ts en hun recidieven hebben we 
gezien d a t deze "in term ediate  -1 p /-1 9 q "  OTs kunnen ontstaan uit " -1 p /-1 9 q " 
tum oren  (hoofdstuk 6). In het m erendeel van de G BM s (de meest kw aadaard ige  
vorm  van As) w o rd t vaak  een + 7  en -1 0  aange tro ffen  hetgeen suggereert da t de 
" +  7 /-1 0 "  hoogg rad ige  (hg-) O Ts wel eens G BM s m et o lig o d e n d ro g lia le  
kenm erken zouden kunnen zijn. Echter o m d a t a fw ijk ingen in het PTEN gen 
(genlocatie : 10q 2 3 ) frequen t w orden gevonden in G BM s m aar slechts 
sporadisch in " +  7 /-1 0 "  hg -O s zijn derge lijke  " +  7 /-1 0 "  hg -O s w aarsch ijn lijk  
geen "gewone" G BM s (hoofdstuk 4).
D o o r de h is to log ie , genetische en klinische data te com bineren hebben we in 
hoofdstuk 7 aange toond  dat, ona fh a n ke lijk  van de h is to log ie , " + 7 / -1 0 "  een 
ind ica tie  is v o o r een kortere overleving in ve rge lijk ing  met de overleving van 
patiënten met een "-1 p /-1 9 q " tum or. Bovendien is de gem idde lde  overleving van 
patiënten met een "in term ediate  -1 p /-1 9 q "  tu m o r korte r dan die van patiënten 
met een "-1 p /-1 9 q " tu m o r (hetgeen aans lu it bij de bevinding da t deze tum oren 
d o o r progressie ontstaan uit " -1 p /-1 9 q " tum oren), en langer dan die van 
patiënten m et een " +  7 /-1 0 "  tum or. Hoewel in onze g roep  slechts een klein 
a a n ta l patiënten werd behande ld  met chem otherap ie , ondersteunen de 
resultaten hiervan de bevinding van C airncross d a t verlies van 1 p 
chem osensitiv ite it voorspelt.
Eenduid ige h is topatho log ische kenm erken om  onderscheid te m aken tussen 
O A s en O s o f As zijn niet beschreven h ie rdoo r kan gem akke lijk  d iscrepantie  
ontstaan tussen verschillende p a th o logen . De toepassing van een "strikte" in 
plaats van een m eer "relaxed" h is topatho log ische benadering , zoals beschreven 
in hoofdstuk 5 , heeft to t gevo lg  da t een deel van de hg-O A s als G B M  w ord t 
ged iagnosticeerd . De frequentie  van " -1 p /-1 9 q " O As neem t toe als een "strikte"
Sam envatting  -------------------------------------------------------------------------
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benadering  w o rd t toegepast, m aa r e r zijn o o k  enkele tum oren met -1 p  die nu 
niet m eer als O A  w orden beschouw d. Patiënten m et een de rge lijk  tu m o r zullen 
d a a rd o o r op  basis van de h is topatho log ische d iagnose niet in aanm erk ing  
kom en vo o r de chem otherap ie  p ro toco llen  vo o r O Ts, te rw ijl deze tum oren toch 
de chem osensitiv ite it voorspe llende a fw ijk ing  -1 p  hebben. O nze  resultaten laten 
zien da t genetische subtypering prognostische en therapeutische im plicaties kan 
hebben . D erge lijke  genetische analyse zal naa r verw achting in de toekom st 
be lang rijke r w orden vo o r het kiezen van de behandelings strategie van de 
patiën t dan het h is topatho log ische onderscheid  tussen O  o f O A .
De tu m o r suppressor genen op ch rom osoom  1p en 19q d ie betrokken zijn bij 
de oncogenese van OTs zijn nog niet ge ïdentificeerd. N a d a t we hebben 
aange toond  da t xenogra ft lijnen van G BM s vanu it genetisch o o g p u n t va lide 
m ode llen  zijn (hoofdstuk 8), hebben we de G B M  xenogra ft lijn die on d e r andere 
-1 p  en -1 9 q  bevat, geb ru ik t om  hom ozygoot gedeleteerde ch rom osoom reg io 's  
op  te sporen (hoofdstuk 9 ). De geïsoleerde fragm enten zijn a lle m a a l a fkom stig 
u it de 9p21 regio. Aangezien niet a lle  fragm enten hom ozygoo t gedele teerd zijn 
in de andere G B M  xenografts zonder -1 p /-1 9 q , zouden enkele fragm enten 
specifiek kunnen zijn vo o r g liom en met -1 p /-1 9 q .
In 2 0  Es was het verlies van ch rom osoom  2 2  (-22) de meest frequen t 
gevonden a fw ijk ing  d ie kon w orden aange toond  m et behulp  van C G H  
(hoofdstuk 1 0 ). D o o r onze resultaten te com bineren met reeds gepub liceerde 
C G H  resultaten in 58  Es, hebben we aange toond  d a t som m ige a fw ijk ingen met 
nam e voorkom en in tum oren op een bepaa lde  loca tie  o f in een bepaa lde  
lee ftijdsca tego rie .
Kort sam engevat laten onze resultaten zien da t verschillende genetische 
subtypes kunnen w orden geïdentificeerd in de g roep  van OTs en Es, en da t deze 
genetische ach te rg rond  in fo rm atie  geeft over tu m o r type, m a lign ite itsg raad , en 
chem otherap ie  gevoe lighe id . G enetische analyse lijk t zo aanvu llende  w aarde te 
hebben in de d iagnostiek  van g liom en . O p  basis van deze d iagnostiek  kan vo o r 
een ind iv idue le  patiën t beter de prognose w orden ingeschat en the rap ie  op  m aat 
w orden gegeven.
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e igen lijk  o o k  jouw  boek je . Ik ben dan o o k  b lij da t je m ijn p a ran im f w ilt z ijn .
M ijn  (co -)p rom oto ren , D o lf Boerm an, Pieter W esseling en A ndré  G rotenhuis. 
Bedankt vo o r ju llie  bege le id ing  ! Ju llie  inzichten hebben een be langrijke  b ijd rage  
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het m isschien da t we toch onze eigen weg g a a n . D o lf, helaas b lijft het bij 
speculeren over de oorsp rong  van o lig o d e n d ro g lia le  tum oren , m aar het 
onderzoek is nog lang niet a fge lopen . N og  rege lm atig  kom  ik artike len tegen die 
ik van jou heb gekregen. Pieter, jij hebt m ij laten zien d a t e r heel veel grijs zit 
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O A . Bij jou kan ik a ltijd  even b innen lopen  en je v ind t a ltijd  de tijd  om  even te 
vragen hoe het erm ee gaa t, je interesse en m edeleven zijn prettig. André, 
bedankt v o o r je lu isterende o o r en de positieve ondersteuning. Het gem ak 
w aarm ee we a ltijd  m a te riaa l hebben gekregen van jou en je collega's is erg 
be lang rijk  geweest vo o r d it onderzoek.
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con tact !
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b ijd rage  was misschien ind irect m aar zeker zo be lang rijk ! Sandra en ik zullen 
ju llie  geze llighe id  m issen.
O o k  heb ik met veel p lezier sam engew erkt met de studenten die in het kader 
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z ijn, tijdens d it onderzoek heb ik veel p lezier sam en gew erkt m et ju llie  
a fde lingen . G reg  Fuller, th a n k  you fo r  p roo fread ing  som e o f the m anuscripts 
described in this thesis. Hans Bernsen, Hans Teepen, en M ax Kros hope lijk  
kunnen we onze prettige sam enw erking nog lang blijven voortzetten. M artina  von 
Böhl en Philip van D am m e, zonder ju llie  vakkund ighe id  en extra persoonlijke  
aandach t zou deze dag een an d e r u ite rlijk  hebben ge h a d . Jeske, Joost, en 
François, de (ex)-A IO -co llega 's van H arry en m ede lo tgenoten, het w as/is  a ltijd  
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Abbreviations
GLIAL TUMORS
As
Es
GBMs
Os
OAs
OTs
astrocytic tumors 
ependymal tumors 
glioblastom a multiforme 
pure o ligodendrog lia l tumors 
mixed oligo-astrocytic tumors 
o ligodendrog lia l tumors,
including both Os and OAs
GRADING TUMORS
a- anaplastic tumors
hg- high-grade tumors
lg- low-grade tumors
myxo-Es myxopapillary ependymomas
GBM-E GBM  with focal ependymal differentiation
G B M -O GBM  with focal o ligodendrog lia l differentiation
GENETIC SUBTYPES
"-1p /-19q " containing loss(es) o f 1p a nd /o r 19q 
"+ 7 /-1 0 "  containing a gain o f 7 a n d /o r a loss o f 10
"other" w ithout -1 p /-1 9 q  and + 7 /-1 0
"intermediate" containing a com bination o f -1 p /-1 9 q  and + 7 /-1 0  
or "intermediate -1 p /-19q "
TECHNIQUES
CG H  comparative genomic hybridization
DOP-PCR degenerated o ligonucleotide primer - PCR
LOH loss o f heterozygosity
PCR polymerase chain reaction
RDA representational difference analysis
SSCP single stranded conform ation polymorphism
ULS universal linkage system
CHAPTER 8 +  9
l-GBMs GBMs previously reported in the literature
o-GBM s orig inal tum our used to establish x-GBMs
x-GBMs xenografted GBM  line /  tum or
VARIOUS
CNS
PCV
TSGs
W H O
central nervous system 
chemotherapy with a com bination o f 
procarbazine, lomustine, and vincristine 
tum or suppressor genes 
world health organization
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Figure 2 -1 . A  schematic overview o f the com parative genom ic hybridization (CGH) technique as described in chapter 2.
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Figure 3 -1 . H istology and the corresponding ratio  profiles o f tw o pure h igh-grade 
o ligodend rog lia l tum ors, N 46  and N 12 . M itoses (^) and b lood  vessels (BV) are indicated in 
the hematoxylin and eosin stain ing. Corresponding ratio  profiles o f chrom osom e 1, 7, 10, 
and 19 are shown. The mean ratio  (blue) w ith thresholds (0.8 in red and 1.2 in green) are 
shown. Losses and gains are indicated respectively by red bars on the left and green bars on 
the right o f the chrom osom e id iogram . A dd itiona lly , representative C G H  images fo r both 
tum ors are shown. G ains are shown in green whereas losses are shown in red.
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Figure 5 -1 . Summary o f all chrom osom al im balances detected by C G H  in low -grade o ligo - 
astrocytic tum ors (lg-OAs) and h igh-grade o ligo-astrocytic tum ors (hg-OAs). Lines on the left 
and right o f the chrom osom e indicate losses and gains o f these chrom osom al regions, 
respectively. C hrom osom al aberrations crossing the 0 .8  o r 1.2 threshold are indicated by a 
thin line, while  c lear copy num ber changes crossing the ratios 0 .6  and 1.4 are ind icated by a 
heavy line. H igh copy gains, w ith a ratio  la rger than 1.6, are indicated by an add itiona l spot 
on a bar. Tumors are genetically subtyped as either "-1 p /-1 9 q " (harboring a loss involving 1p 
a n d /o r 19q w ithout a loss on 10 and w ithout a gain on 7), " +  7 /-1 0 " (harboring a loss on 10 
a n d /o r a gain on 7 w ithout a loss o f 1p and w ithout a loss o f 19q), "intermediate" (harboring 
a loss o f 1p a n d /o r  a loss o f 19q in com bina tion  w ith a loss on 10 a n d /o r a gain on 7) o r as 
"other" (tumors not harboring loss o f 1 p, loss o f 19q, loss o f 10 o r a gain on 7).
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